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 ABSTRACT 
 
      With the significant extension in human life expectancy during the last decades, the number 
of older people is increasing dramatically. As a consequence, the incidence of age-related 
diseases such as cancer, neurodegenerative and cardiovascular diseases is also increasing. Our 
ever-aging population also has considerable social and economic impact. Therefore, 
understanding the underlying molecular mechanisms of the aging process is of central 
importance to improve the quality of life and develop novel therapeutic approaches for aging-
related diseases. 
      A decline in protein homeostasis (proteostasis) in somatic cells is a hallmark of aging. On 
the other hand, pluripotent stem cells such as human embryonic stem cells (hESCs) have shown 
to be immortal in culture and do not age, correlating with higher proteostasis mechanism. Thus, 
we hypothesized that understanding the regulation of the proteostasis network in pluripotent 
stem cells may provide valuable information for the better understanding of pluripotent stem 
cell identity and the aging process. 
       In the first part of this study, we aimed to investigate how proteostasis pathways regulate 
hESC identity and function. hESCs have higher proteasome activity which is essential to 
maintain their self-renewal and pluripotency as well as their ability to differentiate. However, 
the underlying mechanisms by which enhanced proteasome activity regulates hESCs identity 
and function remain unknown. We hypothesized that increased proteasome activity could be 
essential to maintain proper concentration of many regulatory proteins. Since E3 ubiquitin 
ligases are responsible for the ubiquitin transfer to the specific substrate, we first identify which 
E3 ligases are up-regulated in hESCs compared with their differentiated counterparts. We found 
that some HECT-domain E3 enzymes such as HERC2 and UBE3A and some RING-domain 
E3 enzymes such as UBR7 and RNF181 are highly expressed in hESCs. Our interactome data 
indicates a possible link of these enzymes with hESC identity function. Interestingly, loss of 
different up-regulated E3 ligases leads to significant changes at both the transcriptome and 
proteome of hESCs. Nevertheless, these changes do not have strong effect on either 
pluripotency markers or differentiation capacity. On the contrary, by using a shot label-free 
proteomics approach, we show that global proteasome inhibition induces an alteration in key 
biological processes of hESCs identity such as protein synthesis, RNA biogenesis, telomere 
function. Therefore, our data suggests that enhanced proteasome activity is connected with 
other biological pathways of hESCs identity. 
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      In the second part of this study, we aimed to investigate how enhanced proteasome activity 
determines proteostasis of mutant HTT (mHTT) in pluripotent stem cells by specifically 
focusing on the intrinsic E3 ubiquitin ligase network. Proteostasis is essential for organismal 
development and cell function. Impairment of proteostasis leads to accumulation of damaged, 
misfolded and aggregated proteins, a process linked with the onset of age-related diseases such 
as Huntington’s disease (HD). HD is caused by abnormal expansions of polyglutamine repeats 
(polyQ) in the Huntingtin protein, leading to its aggregation and concomitant toxicity. 
Remarkably, the length of pathological polyQ does not influence survival, self-renewal and 
pluripotency of induced pluripotent stem cells (iPSCs) derived from HD patients (HD-iPSCs). 
These results suggest that iPSCs might have enhanced mechanisms to maintain proteostasis 
of mutant HTT. Here, we examined the mechanisms by which iPSCs maintain proteostasis of 
HTT. We find that proteasome activity determines HTT levels and prevents the accumulation 
of polyQ aggregates in HD-iPSCs. Notably, iPSCs have increased levels of the E3 ubiquitin 
ligase UBR5, which interacts with HTT and regulates the degradation of both mutant and wild-
type HTT protein levels. Moreover, loss of UBR5 results in accumulation of HTT protein as 
well as polyQ-expanded aggregates in HD-iPSCs. Furthermore, we find that knockdown of the 
orthologue of UBR5 hastens polyQ-expanded aggregation and neurotoxicity in a C. elegans 
model of HD. Strikingly, ectopic expression of UBR5 is sufficient to induce polyubiquitination 
and degradation of mutant HTT, decreasing polyQ aggregates in HD cell models. Moreover, 
higher UBR5 expression determines global proteostasis of iPSCs preventing the aggregation of 
misfolded proteins ensued from normal metabolism. Thus, our data put UBR5 as a novel 
modulator of super-vigilant proteostasis of iPSCs. 
 
 
 
 
 
 
 
 
 
 
   
 
9
Zusammenfassung  
 
       In den letzten Jahren hat die Lebenserwartung der Menschen stark zugenommen, wodurch 
auch die Anzahl älterer Menschen dramatisch gestiegen ist. Dementsprechend hat die Anzahl 
der altersbedingten Krankheiten wie Krebs, neurodegenarative Erkrankungen und 
Erkrankungen des Herz-Kreislauf-Systems ebenfalls stark zugenommen. Die immer weiter 
alternde Gesellschaft hat einen starken sozialen und wirtschaftlichen Effekt. Ein besseres 
Verständnis der molekularen Abläufe, die den Alterungsprozess steuern, ist von zentraler 
Bedeutung, um die allgemeine Lebensqualität zu verbessen und für die Entwicklung von neuen 
therapeutischen Behandlungen für altersassoziierte Krankheiten.  
      Ein Zeichen der Alterung ist die Abnahme der Proteinhomöostase (Proteostasis) in 
somatischen Zellen. Allerdings sind pluripotente Zellen, so wie embryonale Stammzellen 
(hESCs), unsterblich in Zellkultur und altern nicht, was man auf ihre erhöhte 
Proteinhomöostase zurückführen kann. Wir vermuten, dass ein besseres Verständnis der 
Regulierung der Proteinhomöostase in pluripotenten Stammzellen wichtige Informationen über 
die Identität pluripotenter Stammzellen und ihres Alterungsprozesses liefern wird.  
      Im ersten Teil unserer Studie untersuchten wir, wie Homöostasesignalwege die Identität 
und Funktion von hESCs regulieren. hESCs haben eine erhöhte proteasomale Aktivität, was 
ihnen die Fähigkeiten zur Selbsterneuerung, Pluripotentität und Differenzierung erlaubt. 
Allerdings ist der genaue Mechanismus, wie die erhöhte proteasomale Aktivität, Identität und 
Funktion der hESCs reguliert wird, nicht bekannt. Unserer Hypothese besagt, dass erhöhte 
proteasomale Aktivität essenziell zur Erhaltung der idealen Konzentration von 
Regulationsproteinen ist. E3 Ubiquitinligasen sind Enzyme, die Ubiquitin auf ihre spezifischen 
Substrate übertragen. Hier haben wir zuerst alle E3 Ubiquitinligasen identifiziert, die nur in 
hESCs hochreguliert sind und nicht in differenzierten Formen.  Unsere Ergebnisse haben 
gezeigt, dass bestimmte HECT E3 Ligasen wie HERC2 und UBE3A, so wie Enzyme mit 
RING-Domäne, wie UBR7 und RNF181 in HESCs stark exprimiert sind.  Unserer via 
massenspektrometrischer Analyse erstelltes Interaktom deutete eine Verbindung zwischen den 
genannten Proteinen und hESC Identität an. Bei einem Verlust von hochregulierten E3 Ligasen 
kann man signifikante Veränderungen im Transkriptom und im Proteom von hESCs feststellen. 
Allerdings haben keine dieser Veränderungen einen starken Einfluss auf Marker der Pluripotenz 
oder auf die Differenzierungsfähigkeit von Zellen. Nichtdestotrotz hat die 
massenspektrometrische Analyse gezeigt, dass die globale, proteasomale Inhibierung wichtige 
biologische Prozesse ändert und die hESC Identität mit beeinflusst. Ebenfalls beeinflusst 
werden Proteinsynthese, RNA Biogenese und die Telomerfunktion. Insgesamt zeigt unsere 
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Analyse, dass proteasomale Aktivität mit biologischen Prozessen verbunden ist, welche die 
hESC Identität beeinflussen.  
      In dem zweiten Teil dieser Arbeit wurde untersucht, wie erhöhte proteasomale Aktivität die 
Proteostase von mutiertem HTT (mHTT) in pluripotenten Stammzellen beeinflusst. Der 
besondere Fokus lag auf dem inhärenten E3 Ubiquitin-Ligasenetzwerk. Proteostase ist für 
Zellen lebensnotwendig für die Entwicklung des Organismus und für die Zellfunktion. Eine 
Störung der Proteostase führt zu einer Anreicherung von beschädigten, falsch gefalteten und 
aggregierten Proteinen. Dieser Prozess ist eng verlinkt mit altersbedingten Krankheiten wie 
Huntington-Krankheit (HD). HD entsteht durch abnormale Zunahme der Polyglutamine-
Wiederholungen (polyQ) des Huntigton Proteins, was zu seiner Aggregierung mit 
anschließender Toxizität führt. Besonders bemerkenswert ist, dass die Länge von 
pathologischem PolyQ kein Einfluss auf die Überlebensfähigkeit, Selbsterneuerung oder auf 
die Pluripotenz induzierte Stammzellen hat, die von huntington-kranken Patienten (HD-iPSCs) 
isoliert wurden, hat. Diese Beobachtung legt die Vermutung nahe, dass diese Zellen einen 
Mechanismus haben, der ihnen erlaubt, die Proteostase von mutiertem HTT zu wahren. In 
dieser Arbeit haben wir den Mechanismus untersucht, durch den iPSCs ihre Proteostase 
erhalten können. Unsere Ergebnisse zeigen, dass proteasomale Aktivität die Menge von HTT 
reguliert und die Anreicherung von PolyQ-Aggregaten verhindert. Es ist beachtenswert, dass 
iPSCs eine hohe Menge der E3 Ligase UBR5 generieren, welche direkt mit HTT interagiert 
und die Proteinmengen von sowohl Wildtyp, als auch von Mutanten reguliert. Ein Verlust des 
Proteins UBR5 führt zu einer starken Akkumulation von HTT und PolyQ-Aggregaten in HD-
iPSCs. Weiterhin haben wir herausgefunden, dass der Verlust von UBR5 Orthologen in C. 
elegans zur schnelleren Bildung von PolyQ-Aggregaten und zu Neurotoxizität führt. Auffällig 
ist, dass die ektopische Expression von UBR5 ausreichend ist, um Polyubiquitylierung zu 
induzieren und mutiertes HTT zu degradieren, was in den HD Modelzellsystemen zur Abnahme 
von PolyQ-Aggregaten führt. Ferner bestimmt eine erhöhte Expression von UBR5 die globale 
Proteostase in iPSCs. Außerdem verhindert sie Aggregatbildung von falsch gefalteten 
Proteinen, die aus dem normalen Metabolismus resultieren.  Zusammenfassend zeigt unsere 
Arbeit, dass UBR5 als ein besonderer Modulator der supervorsichtigen Proteostase in iPSCs 
dient.  
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 1.INTRODUCTION 
 
CHAPTER 1) The role of the ubiquitin-proteasome system in embryonic 
stem cell identity 
1.1) The hallmarks of aging 
 
      During the last decades, the average age of human population has increased significantly 
due to the advances in medical care, improvements in healthier food and drug development. 
This increase in older age population results in a higher incidence of age-related diseases such 
as cancer, neurodegenerative disorders, diabetes, cardiovascular disorders, which have social 
and economic impacts (Carmona and Michan 2016).  Therefore, understanding the underlying 
molecular and cellular mechanisms of aging and the susceptibility to age-related disease is 
necessary to identify novel interventions that can improve the quality of life at older ages. 
      Aging is a gradual, physiological deterioration process which is associated with decline in 
molecular and cellular function, causing causes vulnerability to disease and death (Carmona 
and Michan 2016). There are many theories have been proposed to explain organismal aging  
and they are categorized into two main groups: programmed and error theories (Jin 2010). In 
the programmed theories, aging follows a biological timetable and it is regulated by changes in 
gene expression that influence biological systems responsible for repair, maintenance, and 
defense mechanisms. The error theories are based on the concept that damage 
accumulates at various levels throughout the entire lifespan due to environmental assaults and 
causes aging (Jin 2010). Among a number of theories, antagonistic pleiotropy and disposable 
soma theory stand out. In the first theory, it has been suggested that a decrease in force of natural 
selection with age results in aging (Rose, Flatt et al. 2012). The extrinsic risks such as starvation, 
infection or predators lead to limitation of organismal lifespan and decrease in the natural aging 
population. Therefore, natural selection can cause elimination of genes which are drivers for 
deleterious effects (Rose, Flatt et al. 2012). However, the genes which are important in early-
life survival cannot be eliminated and they may also drive aging in late-life, which is a concept 
known as antagonistic pleiotropy (Baig, Bhadbhade et al. 2014). According to the disposable 
soma theory, the higher energy expense used for growth and reproduction has a considerable 
cost on the somatic maintenance. The accumulation of cell damage over time limits the 
functioning of important organ systems and lifespan (Hughes, Alipaz et al. 2002). The main 
characteristic of aging is the loss of function (degeneration) at molecular, cellular and 
organismal levels. In mammalians, age-related degeneration is a hallmark of distinct 
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pathologies such as neurodegenerative diseases (Alzheimer’s (AD), Huntington’s (HD) and 
Parkinson’s diseases (PD)), atherosclerosis and diabetes (Carmona and Michan 2016). 
Moreover, in multicellular organisms, aging can also lead to a gain of function which causes 
inappropriate cell proliferation called hyperplasia (Rose, Flatt et al. 2012). 
      The aging process is characterized by nine hallmarks at the molecular and cellular level: 
instability in genome (accumulation of damage in genome throughout life), telomere attrition 
(deterioration of telomere region), epigenetic alterations (i.e., change in DNA methylation 
level, chromatin remodeling and posttranslational modification of histone) , impairment in 
proteostasis (i.e., deficiency in degradation pathways such as proteasome and autophagy and 
impairment  in folding capacity of proteins) , deregulated nutrient sensing (i.e., variation in 
insulin and IGF-1 (insulin-like growth factor type 1) signaling (IIS) pathway, mTOR pathway),  
impairment in mitochondrial fitness (i.e., decline in the efficiency of the respiratory chain) , 
cellular senescence (irreversible arrestment in cell proliferation), changed intercellular 
communication and stem cell exhaustion (Lopez-Otin, Blasco et al. 2013) (Figure I). 
      Over recent years, studies based on several organisms ranging from yeast to humans have 
suggested that dietary restriction, genetic and pharmacological interventions may promote 
protection against aging-related cellular and molecular declines by improving cellular 
homeostasis and stress resistant, resulting in longer lifespan and healthspan (Lin, Seroude et al. 
1998, Smith, Kaeberlein et al. 2008, Saraswat and Rizvi 2017). A range of signaling pathways 
such as mTOR, sirtuins, insulin/IGF-1 have been identified as having a role in the regulation of 
aging process (Tatar, Bartke et al. 2003, Longo and Kennedy 2006, Johnson, Rabinovitch et al. 
2013). 
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Figure I) The nine hallmarks of aging in molecular and cellular level. Aging is a 
gradual, physiological decline in function of multiple cells and tissues. Aging is characterized by the 
nice hallmarks including; stem cell exhaustion, altered intercellular communication, genomic instability, 
telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence. Figure reprinted from Ref. (Lopez-Otin, Blasco et al. 
2013), with permission from Elsevier. 
 
 
1.2) The Ubiquitin-Proteasome system (UPS) and loss of UPS in aging process 
1.2.1) The Ubiquitin-Proteasome System 
 
      Maintenance of protein homeostasis by the Ubiquitin-Proteasome System (UPS) is 
important for cellular function and their viability. UPS regulates intracellular protein 
degradation which is a vital process for determining the protein half-life and preventing 
damaged proteins or aggregates to accumulate (Powers, Morimoto et al. 2009). UPS is involved 
in a variety of biological functions such as regulation of gene transcription, cell cycle, 
immunological response, aging and stem cell identity (Eldridge and O'Brien 2010).  
      For targeting a protein to the UPS, first it is required the attachment of ubiquitin, a protein 
which is 76 amino acids long.  Ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, 
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K48, K63) and a N-terminal methionine (Met1) residue which can be linked to other ubiquitin 
to form multi or polyubiquitin chain. The pattern and type of ubiquitinylation determine the 
fate of a protein. Monoubiquitylation or multiubiquitylation (multiple monoubiquitylation of a 
target protein) are involved in different biological functions such as endocytosis, DNA repair, 
protein sorting. On the contrary, polyubiquitiniation signals are involved in protein degradation, 
kinase regulation and activation/inhibition of transcription factors (Jana, Zemskov et al. 2001, 
Sun and Chen 2004). For example, K63 linked polyubiquitination has a key role in the 
regulation of DNA damage response and endocytosis. On the contrary, K48 linked 
polyubiquitination targets proteins to the proteolytic complex, 26S proteasome, for degradation 
(Adams 2003). Moreover, linear types of ubiquitination chain can be formed by conjugation of 
the one of the carboxy-terminal glycine of ubiquitin to lysine residue of another ubiquitin. This 
ubiquitination plays role in nuclear factor-kappa B (NF-κB) activation (Iwai and Tokunaga 
2009). Ubiquitination of target protein is accomplished through a three-step cascade mechanism 
(Pickart and Eddins 2004). Initially, ubiquitin is activated in an ATP-dependent manner by a 
ubiquitin-activating enzyme (E1) that forms a thioester bond between a cysteine residue and 
carboxy-terminal of ubiquitin (Hochstrasser 1996). The activated ubiquitin is transferred to 
ubiquitin conjugating enzymes (E2s) via formation of E2-Ub thioester structure (Pickart 2001). 
In the final step, E3 ligase catalyze the attachment of ubiquitin to the target protein by binding 
to both the E2-Ub thioester structure and target protein (Hochstrasser 1996).  
      E3 ubiquitin ligases are essential components of the ubiquitination cascade reaction due to 
their role in both controlling the efficiency and substrate specificity. Due to the requirements 
of a specific substrate targeting, there are more than 600 human E3s encoded by the human 
genome. The E3s are classified into three different families based on their structural domains 
and mechanism for ubiquitin transfer from the E2 enzyme to the target substrate protein: the 
(RING) E3s family, the homologous to the E6AP carboxyl terminus (HECT) E3s family and 
the RING-between-RING (RBR) E3s family (Deshaies and Joazeiro 2009, Metzger, Hristova 
et al. 2012, Spratt, Walden et al. 2014). RING E3 enzymes represents the biggest E3 ligase 
family. It contains a RING or U-box domain which is required for binding both to the E2 
enzyme and the target protein. The RING domain is characterized by two zinc ions while the 
U-box domain does not contain zinc ions but adopts the same folding of the RING domain. By 
binding both to the E2-Ub thioester and the target protein, these E3s ligases transfer ubiquitin 
directly from the E2 enzymes to the target proteins (Metzger, Hristova et al. 2012). RING E3 
ligases can function in diverse ways including monomers, homodimers and heterodimers. 
Moreover, some RING E3s such as the cullin-RING ligases (CRLs) are composed by multi-
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subunits (Deshaies and Joazeiro 2009). U-box proteins are also a part of the RING E3 ligase 
family as they transfer ubiquitin through the same mechanism and resemble the structure of the 
RING domain. U box proteins can also function as monomers or homodimers such as UBE4B 
and CHIP respectively (Buetow and Huang 2016). On the other hand, HECT E3 and RBR E3s 
family catalyze ubiquitin transfer in a two-step reaction which first transfers ubiquitin from E2 
to an active site cysteine of the E3 ligase and in the second step, from the E3 ligase to the target 
protein (Metzger, Hristova et al. 2012, Spratt, Walden et al. 2014). In humans, 28 HECT E3s 
are found. HECT E3s have a HECT domain and a N-terminal substrate-binding domain (Rotin 
and Kumar 2009). The HECT domain is located at the C-terminal and is involved in catalysis 
of ubiquitin conjugation and transfer while the N-terminal substrate-binding domain interacts 
with E2-Ub. HECT E3s are divided into 3 subfamilies: the NEDD4 family, which comprises 
tryptophan-tryptophan (WW) motifs, the HERC family, which has regulators of chromosome 
condensation 1 (RCC1)-like domains (RLDs) and “other” HECTs with various protein-protein 
interactions domain (Metzger, Hristova et al. 2012). Like HECT E3s, RBR E3s catalyze the 
ubiquitin transfer in two-step reaction. In humans, 14 RBR E3s are described and they comprise 
two RING fingers, RING1 and RING2 and are separated with an in-between-RINGs zinc-
binding domain (Spratt, Walden et al. 2014). RBR E3s are defined as a hybrid of HECT and 
RING E3s. RING1 domain recruits E2-Ub and RING2 domain has a catalytic cysteine (Buetow 
and Huang 2016). In addition to E3 ligases, the UPS is also regulated by a number of 
deubiquitinating enzymes (DUBs) (Wilkinson 2000). DUBs are responsible for removal of 
ubiquitin chain from substrate before substrates enter the proteolytic core of proteasomes. 
DUBs act by direct or indirect association with the proteasome (Wilkinson 2000). The classical 
DUBs are classified into two main families according to their enzymatic cleavage mechanism: 
zinc metalloproteases and cysteine proteases (Pfoh, Lacdao et al. 2015). 
         The polyubiquitin chain is made by the addition of a C-terminal Gly residue of one 
ubiquitin to another ubiquitin’s lysine residue. This polyubiquitin chain acts like a degradation 
signal which is recognized by the 26S proteasome complex (Glickman and Ciechanover 2002). 
The proteasome is a well conserved complex composed of a central unit (20S) and a regulatory 
subunit (19S). 19S is composed of the wo subcomplexes; the base and the lid which consist of 
20 subunits. The lid consists of nine non-ATPase subunits (Rpn3, Rpns5-9, Rpn11, Rpn12, and 
Rpn15) whereas the base consists of three non-ATPases (Rpn1, Rpn2, and Rpn13) and six 
AAA-type ATPases (Rpt1-6) (Gumeni and Trougakos 2016). The 19S is responsible for the 
recognition of polyubiquitylated proteins (da Fonseca, He et al. 2012). The central unit 20S is 
composed of four rings; two central and identical heptameric rings called β-rings and two outer 
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rings called α-rings. β subunits include three catalytic subunits - β1, β2, β5- which have caspase-
like, trypsin-like activity and chymotrypsin-like activity, respectively (Groll, Ditzel et al. 1997). 
After the proteins enter into the 20S complex, they are targeted by a N-terminal threonine 
residue of the catalytic subunits of the 20S (Adams 2003). (Figure II). There is also a specialized 
form of proteasome which is called immunoproteasome. In the immunoproteasome, the 
catalytic subunits β1, β2, β5 of proteasome are replaced by the cytokine inducible β1i, β2i, β5i 
subunits. The immunoproteasome is stimulated by proinflammatory cytokines such as 
interferons as well as oxidative stress (Ferrington and Gregerson 2012). Moreover, in the 
immunoproteasomes, the regulatory subunits 19S is replaced by the PA28 activator (11S) 
(Borissenko and Groll 2007). Immunoproteasomes promote increased cleavage after 
hydrophobic residues and decreased cleavage after acidic residues. This leads to the generation 
of peptides with higher affinity to bind to the MHC class I complex, which is one of the primary 
classes of major histocompatibility complex (Ferrington and Gregerson 2012). 
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 Figure II) The ubiquitin proteasome system (UPS). UPS regulates intracellular protein 
degradation and targeting a protein to UPS, first it is needed the attachment of ubiquitin to substrate 
protein. Ubiquitination of substrate protein is achieved through a three-step cascade mechanism. Firstly, 
ubiquitin is activated in a ATP-dependent manner by E1. The activated ubiquitin is transferred to E2s 
via formation of E2-Ub thioester structure. Finally, E3 ligase catalyze the ubiquitin attachment to the 
substrate protein by binding to both the E2-Ub thioester structure and substrate protein. The same 
cascade reaction is repeated to form a ubiquitin chain. After ubiquitination, this polyubiquitin chain is 
recognized and degraded by the 26S proteasome complex. The active proteasome is formed by of a 
central unit (20S) and a regulatory subunit (19S). The 19S recognizes the polyubiquitylated substrate 
and mediates deubiquitination. The central subunit 20S is normally found as inactive form and 
require binding of 20S activators such as 19S regulatory protein. After substrate is recognized and 
enter into 20S complex, the substrate is cleaved into small peptides. The UPS is important regulator 
for several cellular functions such as stress response, signal transduction. 
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1.2.2) The Alterations of Ubiquitin-Proteasome system activity during aging 
 
      Stability of protein homeostasis is a key determinant in the regulation of aging and lifespan. 
Regulation of proteostasis englobes protein refolding capacity, regulation of protein stability, 
cellular localization of proteins, protein degradation. Impairment in proteostasis leads to the 
accumulation of damaged, misfolded and aggregated protein which compromises cell viability 
(Saez and Vilchez 2014). One of the key components in proteostasis is the UPS, which is the 
major protein clearance mechanism and is essential for removing damaged, unneeded and 
aggregated proteins as well as short lived proteins. Thus, the progressive decline in UPS 
function and activity has been correlated with aging and senescence. This impairment in activity 
and function could be due to several reasons such as structural alterations or the replacement of 
proteasome subunits, declined amount of proteasome, disassembly of proteasomes, activity 
alteration due to interaction with protein aggregates and decline in energy source (ATP) from 
malfunction of mitochondria (Grune, Jung et al. 2004, Ferrington, Husom et al. 2005, 
Chondrogianni, Petropoulos et al. 2014). An age-related decline in proteasome activity has been 
reported in different human tissues such as muscle, skin, kidney and in several other mammals, 
such as rats and mice (Bulteau, Szweda et al. 2002, Chondrogianni and Gonos 2005, Kapphahn, 
Giwa et al. 2006, Dasuri, Zhang et al. 2011, Chondrogianni, Petropoulos et al. 2014).  
Moreover, human senescent fibroblasts show a reduction in proteasome activity and expression 
of proteasome subunits compared to lower-passage counterparts (Chondrogianni, Stratford et 
al. 2003). The role of proteasome activity in senescence is also supported by the fact that 
fibroblasts treated with an inhibitor of the proteasome inhibitor show senescence-like 
phenotypes and a decreased replicative lifespan (Torres, Lewis et al. 2006). The role of 
proteasome in aging has also been supported with gain-of-function experiments. Proteasome 
activation by genetic manipulation or chemicals endorse lifespan and healthspan extension in 
organisms and cellular models and prevents the formation of aggregates, a process associated 
with distinct age-related diseases (Chondrogianni, Voutetakis et al. 2015, Krahn, Kaschani et 
al. 2017).  The treatment of human embryonic fibroblasts with chemical compounds such as 
IMP20 and WI-38, which enhance proteasome activity reduces protein carbonyl levels and 
promotes lifespan extension (Katsiki, Chondrogianni et al. 2007). In Drosophila melanogaster, 
the activation of the proteasome activity via overexpression of Rpn11 (a subunit of 19S 
regulator) promotes lifespan extension (Tonoki, Kuranaga et al. 2009). Different E2 and E3 
ligases have a role in UPS activation as well as lifespan extension. For example, RLE-1, an E3 
ligase, is responsible for ubiquitination of DAF-16, which is the ortholog of FoxO family of 
transcription factors in C. elegans, and leads to its degradation (Li, Gao et al. 2007). Moreover, 
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UPS is also involved in the regulation of insulin signaling. Insulin/ IGF-1 regulates aging in 
several organisms and inhibits the forkhead transcription factor, FoxO. Suppression of FoxO 
transcription mediates the inhibition of proteasomal degradation. Notably, activation of FoxO 
through reduced insulin/IGF-1 signaling increases lifespan (Saez and Vilchez 2014). 
      On the other hand, deficiency in proteasome activity worsens the phenotype of several 
aging-related diseases such as neurodegenerative diseases (e.g. HD, PD and AD), skin aging, 
cardiovascular diseases and cancer through a decrease in the degradation of damaged and 
oxidized proteins (Saez and Vilchez 2014). Notably, the accumulation of oxidized proteins due 
to an age- related impairment in the  proteasome activity is one of the major factor that promotes 
skin aging (Koziel, Greussing et al. 2011). A decline in proteasome activity in AD patients 
compared with controls has been shown (Keck, Nitsch et al. 2003). Furthermore, in the 
neurodegenerative disease HD, the overexpression of the proteasome subunit PSMD11/RPN6 
in a C. elegans model of HD ameliorates the pathology of the disease (Vilchez, Morantte et al. 
2012). In summary, proteasome dysfunction is tightly associated with aging and aging-
associated diseases. Therapeutic approaches for regulating the proteasome activity may 
improve cellular homeostasis and promote lifespan extension. 
1.2.3) The role of Ubiquitin-Proteasome system in stem cell identity 
 
      One of the roles of the UPS is to regulate pluripotency and self-renewal of hESC and 
induced pluripotent stem cell (iPSC), as well as cellular reprogramming (Okita and Nakayama 
2012, Vilchez, Boyer et al. 2012, Strikoudis, Guillamot et al. 2014, koyuncu 2015). ESCs are 
derived from the inner cell mass of blastocysts and are pluripotent. Therefore, they have the 
capacity to differentiate into the three different germ layers: endoderm, ectoderm and mesoderm 
(Thomson, Itskovitz-Eldor et al. 1998). Like ESCs, iPSCs are also pluripotent and can 
differentiate into the three germ layers. iPSCs are derived from somatic cells that are 
reprogrammed by a set of transcription factor into epigenetic and transcriptional state to  
embryonic-like pluripotency (Takahashi, Tanabe et al. 2007, Kaye and Finkbeiner 2013). This 
major breakthrough in stem cells area by generation of iPSC came in 2006 by generation of 
iPSC from fibroblasts cells by using combination of four transcription factor (Oct4, Sox2, Klf4, 
and, c-Myc). 
      Regulation of the levels of some pluripotency factors such as Oct-4, Nanog through 
polyubiquitylation is a key determinant of hESC/iPSC function (Strikoudis, Guillamot et al. 
2014). Furthermore, the UPS is also essential for cell reprogramming (Buckley, Aranda-
Orgilles et al. 2012). Proteomics analysis based on three different hESC lines (H2, H3, H5) 
20
have indicated that the proteins which are enriched in hESCs include components of UPS when 
compared with differentiated counterparts (Baharvand, Hajheidari et al. 2006). Moreover, 
microarray-based transcriptional network analysis based on RNAi dependent depletion of 
OCT4 function in hESCs has uncovered 18 genes related with the UPS pathway (Babaie, 
Herwig et al. 2007). Strikingly, hESCs are more sensitive to proteasome inhibition compared 
with differentiated cells (Assou, Cerecedo et al. 2009, Vilchez, Boyer et al. 2012). Pluripotent 
stem cells treated with the proteasome inhibitor MG132 exhibit strong downregulation of 
pluripotency- associated genes such as OCT4, c-MYC and SOX-2 (Assou, Cerecedo et al. 2009, 
Vilchez, Boyer et al. 2012). Furthermore, it has been reported that the non-ATPase subunit 
PSMD11/RPN6 is required for pluripotency in hESC by increasing proteasome activity 
(Vilchez, Boyer et al. 2012, Vilchez, Boyer et al. 2013). PSMD11/RPN6 is highly expressed in 
both hESCs and iPSC and this expression decreases during neuronal differentiation. Decrease 
in PSMD11/RPN6 leads to a reduction in the proteasome activity. Notably, this enhanced levels 
of PSMD11/RPN6 are regulated by FOXO4, a pro-longevity transcription factor (Vilchez, 
Boyer et al. 2013). Moreover, comparison between hESCs with either hESCs-derived cells or 
somatic cells such as fibroblasts, indicate a decline in proteasome activity with differentiation 
(Vilchez, Boyer et al. 2012, Vilchez, Boyer et al. 2013). Another way the UPS  regulates 
pluripotency is based on the immunoproteasome, which is upregulated in response to cytokines 
(Ferrington and Gregerson 2012). Inhibition of the two immunoproteasome subunits PSMB9 
and PSMB8 results in downregulation of the pluripotency markers in hESCs (Atkinson, Collin 
et al. 2012). In embryonic-body mediated differentiation of hESCs, it has been observed a 
decline in PSMD9/β1i and PSMB8/β5i expression (Atkinson, Collin et al. 2012). Similar to the 
26S/30S proteasome, the immunoproteasome is highly assembled in hESCs compared with 
differentiated counterparts (Atkinson, Collin et al. 2012). 
       Although the UPS has a specific role in maintenance of pluripotency and cell-fate decisions 
by controlling the half-life of proteins as well as removing damaged proteins, it is still not clear 
which are the underlying mechanisms for this regulation. The regulation of pluripotency by the 
proteasome might be based not only on controlling protein degradation rates both also on other 
functions such as increased global translational. As such, the proteasome also prevents the 
nonspecific assembly of the preinitiation complex by targeting cryptic promoter elements for 
degradation (Szutorisz, Georgiou et al. 2006). In summary, the UPS is key for regulating cell-
fate and pluripotency although the mechanisms underlying this regulation are yet not well-
understood. 
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CHAPTER 2) Proteostasis of Huntingtin 
 
2.1) Huntington’s Disease (HD) 
 
      Huntington’s Disease (HD) is a fatal autosomal dominant neurodegenerative disease 
characterized by motor dysfunction, cognitive decline and psychosis (Mendez 1994, Ross and 
Tabrizi 2011). HD is caused by abnormal expansion of a CAG triplet repeats in the Huntingtin 
(HTT) gene which translates into a polyglutamine (polyQ) stretch of the N-terminal domain of 
the huntingtin (HTT) protein and leads to protein aggregation and proteotoxicity (Davies, 
Turmaine et al. 1997, Scherzinger, Lurz et al. 1997, Finkbeiner 2011). In unaffected 
individuals, HTT gene encodes for HTT protein which contains 6–35 polyQ repeats, while in 
HD patients HTT protein contains more than 35 polyQ repeats (Finkbeiner 2011). Although 
HTT protein is ubiquitously expressed, expanded- polyQ mutations leads to selective 
neurodegeneration which affects preferentially neurons of the striatum essential for cognition, 
motor control and sensory pathways (Vonsattel, Myers et al. 1985). This selective 
neurodegeneration is associated with the age-dependent aggregation of mutant HTT protein in 
the striatum (Vonsattel and DiFiglia 1998). The age of onset and disease progression inversely 
correlates with the length of polyQ repeats (Ross and Tabrizi 2011).  
      HTT protein is involved in several biological processes such as embryonic development, 
transcriptional regulation, apoptosis, microtubule-based transport, ciliogenesis and  autophagy 
(Saudou and Humbert 2016). Although polyQ-expansions could also lead to a loss of normal 
HTT function and contribute to the pathology of HD, extensive experimental data and the 
dominant inheritance pattern of the disease indicate that a gain-of-function HTT is toxic. As a 
result of a gain-of-function, mutant HTT impairs cellular homeostasis by overwhelming the 
cellular proteostasis machinery and triggers neurodegeneration (Bates 2003, Kratter and 
Finkbeiner 2010, Zuccato, Valenza et al. 2010). (Figure III). The function, folding and 
clearance of HTT are regulated by different proteostatic mechanisms including chaperones, the 
UPS and autophagy-lysosome pathways (Wyttenbach, Carmichael et al. 2000, Rubinsztein 
2006, Li, Li et al. 2010, Vilchez, Saez et al. 2014). 
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 Figure III) The collapse in different proteostasis network upon accumulation of 
mHTT aggregation. The abnormal polyQ expansion in HTT protein leads its aggregation and also 
formation of toxic oligomers. The accumulation of polyQ-expanded aggregates and oligomers causes 
impairment in distinct proteostasis nodes such as the chaperome, the ubiquitin-proteasome system 
(UPS) and autophagy. Image reprinted from (Koyuncu, Fatima et al. 2017), with permission from Int J 
Mol Sci. 
 
2.2) The chaperone node in Huntington’s Disease 
 
      Protein quality control is crucial for maintaining a proper folding and conformation of 
newly- synthesized proteins. Moreover, cells must regulate the concentration and localization 
of proteins in response to cellular stimuli (Balch, Morimoto et al. 2008). Chaperones are key 
players in protein quality control system by assisting correct folding into the native 
conformation and assembly of newly synthesized proteins (Chen, Retzlaff et al. 2011). In 
addition to their folding activity, they also regulate proper translocation, aggregation and 
degradation of proteins (Hartl, Bracher et al. 2011, Cortez and Sim 2014). In humans, there are 
88 chaperones and 244 co-chaperones forming a chaperome network (Brehme, Voisine et al. 
2014). Chaperone families are classified according to their molecular weight and homology 
into several classes: 40 kilodalton heat shock proteins (HSP40s), HSP60, HSP70, HSP90, 
HSP100 and the small HSPs (sHPSs) (Li and Srivastava 2004). Each class includes multiple 
members which have equivalent functional domains and similar sequence identity. They are 
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mainly divided into two groups according to their source of energy required for their activity: 
ATP-dependent chaperones such as HSP90s and HSP100s, and ATP-independent chaperones 
such as small HSPs (Saibil 2013, Brehme, Voisine et al. 2014, Haslbeck and Vierling 2015). 
Chaperones prevent the formation of protein aggregation through preventing aberrant protein 
interactions (Balchin, Hayer-Hartl et al. 2016). Moreover, several co-chaperones such as CHIP, 
parkin, the BAG-domain-containing family (BAG1–BAG6) assist in the proteostatic roles of 
chaperones (Hartl and Hayer-Hartl 2002, Brehme, Voisine et al. 2014).  
      Recent studies have suggested that an impairment in chaperone function is associated with 
HD (Tam, Geller et al. 2006, Brehme, Voisine et al. 2014, Kakkar, Meister-Broekema et al. 
2014, Labbadia and Morimoto 2015). Proteomic analyses have shown that mutant HTT 
(mHTT) interacts with members of the HSP90, HSP70, HSP40 (DNAJ chaperones) and TCP-
1 ring complex (TRiC) chaperone families (Shirasaki, Greiner et al. 2012). Moreover, the 
reduction in HSP70 and HSP40 levels in HD mice brain tissues has also evidenced the essential 
role of chaperones in HD (Hay, Sathasivam et al. 2004, Yamanaka, Miyazaki et al. 2008). These 
data have suggested that expression of aggregate-prone mHTT may lead to impaired global 
disruption of the proteome through affecting the chaperome network. Furthermore, 
overexpression of HSP40s and HSP70s in multiple models of HD enhances suppression of 
mHTT toxicity and polyQ-mediated neurodegeneration (Warrick, Chan et al. 1999, Kazemi-
Esfarjani and Benzer 2000, Muchowski and Wacker 2005). Multiple HSP40s and HSP70S co-
chaperones are also determinant for polyQ-expanded aggregation and toxicity. The co-
chaperones BAG1 and CHIP regulate mHTT aggregation through the interaction with HSP70s 
(Jana, Dikshit et al. 2005, Jana and Nukina 2005, Katsuno, Sang et al. 2005). HSP70 is 
upregulated in cerebellar neurons in HD but not in striatal neurons. This suggests that the 
differential induction of HSP70 could also contribute to the selective neurodegeneration in 
striatal neurons (Tagawa, Marubuchi et al. 2007). In addition, a mammalian cell- based screen 
of HSP70 and DNAJ chaperones in regulating polyglutamine aggregation indicated that a 
DNAJB subclass of molecular chaperones, such as DNAJB2a, DNAJB8, have an essential role 
in suppressing mHTT aggregation (Hageman, Rujano et al. 2010). Besides, the TRiC/CCT 
complex (T-complex protein-1 ring complex, also called CCT for chaperonin containing TCP1) 
has also a key role in the regulation of mHTT aggregation. Mutation or loss of a single subunits- 
mediated loss of function leads to the acceleration of mHTT deposition and disease-associated 
changes (Kitamura, Kubota et al. 2006, Tam, Geller et al. 2006, Brehme, Voisine et al. 2014). 
Conversely, overexpression of subunits of CCT complex leads to a reduction of mHTT 
aggregates and neurotoxicity (Kitamura, Kubota et al. 2006, Noormohammadi, Khodakarami 
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et al. 2016). Altogether, the chaperome network is an essential regulator of mutant HTT 
aggregation and toxicity. mHTT could cause decrease the levels of molecular chaperones which 
could lead to a proteostasis collapse and neurodegeneration (Cummings, Mancini et al. 1998, 
Perez, Paulson et al. 1998, Suhr, Senut et al. 2001). 
2.3) The UPS in Huntington’s Disease 
 
      As previously described in section 1.2.1, the UPS is necessary to maintain the proper 
proteome composition by determining the half-life of numerous proteins and also preventing 
the accumulation of damaged, misfolded and aggregated proteins (Powers, Morimoto et al. 
2009). The importance of the UPS in the regulation of mHTT has been highlighted in several 
studies. Several mutations in components of UPS have been described in HD (van Leeuwen, 
de Kleijn et al. 1998). For example, mutant ubiquitin (UBB+1) have been detected in inclusion 
bodies (IB) formed by mHTT (van Leeuwen, de Kleijn et al. 1998). Furthermore, upregulation 
of UPS-associated proteins in the striatum of HD mice R6/2 model is another important 
indicator for the  requirement of the UPS in HD (Liu, Miller et al. 2007). Another study also 
proves that IB are disassembled in a proteasome-dependent manner in a conditional mouse 
model of HD (Yamamoto, Lucas et al. 2000). Co-staining of mutant HTT- aggregates with 
ubiquitin and proteasome subunits in human HD postmodern brains and in mouse models also 
points to a role of the proteasome in the regulation of mHTT (Mangiarini, Sathasivam et al. 
1996, Davies, Turmaine et al. 1997, DiFiglia, Sapp et al. 1997). Moreover, pharmacological 
data indicates that inhibition of the proteasome by specific inhibitors increases aggregation of 
mHTT (Waelter, Boeddrich et al. 2001, McNaught, Perl et al. 2004).  
      One of the main features of HD is an impairment of the proteasome (Ciechanover and 
Brundin 2003). In transient cells transfected with mHTT fragments the UPS was inhibited, 
suggesting that mHTT- aggregation could directly impair UPS function (Bence, Sampat et al. 
2001). Furthermore, a decline in the activity of the proteasome has been observed in both HD 
patients and HD mouse models (Finkbeiner and Mitra 2008). Incubation of ubiquitylated, 
aggregated mHtt with 26S proteasome results in the inhibition of the 26S proteasome in HD 
mouse model (Diaz-Hernandez, Valera et al. 2006).  
      Although several studies have suggested a proteasome impairment in HD, there are some 
contradictory results. In the mHtt-Q150 expressing neuronal cells, increased proteasome 
activity has been reported (Jana, Zemskov et al. 2001). Besides, one in vitro study in which 
they aimed to test whether 26S activity is affected by IBs,  indicates that there is a no clear 
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effect of IB on 26S activity (Bennett, Bence et al. 2005). However, whether proteasome 
impairment is a consequence of IB or it is rather the triggering factor is unknown. These data 
suggest that a possible reason of the proteasome impairment may be due to a general 
proteostasis collapse in HD disease (Hipp, Patel et al. 2012). Remarkably, mHTT also affects 
endoplasmic reticulum-associated degradation (ERAD) which targets misfolded proteins of the 
endoplasmic reticulum for proteasomal degradation. Impairment in ERAD is caused by the 
sequestration of p97/Npl4/Ufd1 chaperone and mHTT could cause sequestration of this 
chaperone complex (Leitman, Ulrich Hartl et al. 2013).  
     On the other hand, enhanced proteasome machinery is also beneficial in HD disease models. 
Ectopic expression of PSMD11/RPN6 in a HD nematode model helps in the amelioration of 
the disease- related symptoms (Vilchez, Morantte et al. 2012). Overexpression of ubiquilin-1 
delays Htt aggregate formation and extends lifespan in HD mice (Safren, El Ayadi et al. 2014). 
Moreover, overexpression of PA28γ activator improves survival of neurons (Seo, Sonntag et 
al. 2007). Also, the overexpression of specific E3 ligases such as Hrd1, Parkin and CHIP 
improved the clearance of mHtt and reduced cell death (Tsai, Fishman et al. 2003, Jana, Dikshit 
et al. 2005, Yang, Zhong et al. 2007). Activation of proteasome with sulforaphane equally 
enhanced the elimination of mHtt in cells (Liu, Hettinger et al. 2014). Taken together, these 
studies evidence an important role of the UPS and suggest that an activation of the UPS could 
be an effective approach for the treatment of HD.  
2.4) The Autopaghy-Lysosome system in Huntington’s Disease 
 
      Autopaghy is a catabolic process that delivers cytosolic franctions, macromolecules such as 
long-lived proteins and organelles to the lysosomes for degradation (Rubinsztein, Gestwicki et 
al. 2007). Autophagy is classified into three different types; macroautophagy, microautophagy 
and chaperone mediated autophagy (Chen and Klionsky 2011). Macroautopaghy is a clearance 
process which is characterized by the formation of a double-membrane structure vesicle called 
autophagosome. The autophagosomes fuse with lysosomes, which contain nucleotidases, 
lipases, hydrolases, glycosidases and proteases, and form autolysosomes (Rubinsztein, 
Gestwicki et al. 2007). After the degradation of the sequestered cellular material in 
autolysosomes, the degradation products are transported into the cytosol for their reuse (Chen 
and Klionsky 2011). In the chaperone-mediateted autophagy (CMA), chaperone proteins such 
as HSP70 bind to specific client proteins and promote that these proteins are located to a 
complex surrounded by a lysosomal membrane. This complex is recognized by the lysosomal 
membrane proteins LAMP-2A and the targeted proteins are unfolded and degraded (Saftig, 
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Beertsen et al. 2008). In microautopaghy, the cytosol is directly sequestered to the lysosomal 
membrane or vacuole (Li, Li et al. 2012). Although microautopaghy is generally a non-selective 
process, it has been reported that certain organelles are selectively removed by microautopaghy, 
as it is the case with micropexophagy (autophagy for peroxisomes) (Sakai, Koller et al. 1998). 
      Autophagy is involved in multiple cellular processes such as development, cell growth and 
cell death. Moreover, regulation and impairment in autophagy is associated with many 
neurodegenerative disease such as HD (Martinez-Vicente and Cuervo 2007, Glick, Barth et al. 
2010). Impairment in autophagy hastens HD-associated phenotypes such as increase in 
vulnerability to cell death due to mHTT (Bjorkoy, Lamark et al. 2005). Conversely, activation 
of autophagy ameliorates proteotoxicity in HD (Ravikumar, Vacher et al. 2004, Sarkar, 
Perlstein et al. 2007). For instance, the mTOR inhibitor rapamycin activates autophagy in 
Drosophila and mouse models of HD and consequently ameliorates mHTT toxicity 
(Ravikumar, Vacher et al. 2004). Moreover, small molecules which activate autophagy promote 
the removal of mHTT in different HD models including yeast, fly and mammals (Sarkar, 
Perlstein et al. 2007). 
       On the other hand, different studies indicate that mHTT impairs autophagy formation. For 
example, the expression of Omi/HtrA2, a mitochondrial chaperone and protease which is 
important for the regulation of autophagy and mitophagy, is decreased in human HD striatum 
and cultured striatal neurons (Inagaki, Tagawa et al. 2008). Therefore, a reduction in the 
expression of autophagy-lysosome related proteins as well as in the autophagy flux could make 
neurons more vulnerable to mHTT. Moreover, HTT has a scaffolding role in selective 
autophagy. HTT interacts with p62, which is an autophagy receptor and involved in 
sequestration of cargos into autophagosomes. HTT also interacts with ULK1, a key regulator 
of autophagy (Rui, Xu et al. 2015). In HD, the scaffolding function of HTT in autophagy is 
impaired. Evidence based on human cells from HD patients and mouse models of HD have also 
suggested that there is an impairment in the recognition of the cytosolic cargo by 
autophagosomes in HD, possibly due to an interaction of mHTT with p62 (Martinez-Vicente, 
Talloczy et al. 2010). In conclusion, these results have shown the fundamental role of autophagy 
in HD either as a mechanism to regulate degradation of mHTT or an important biological 
process regulated by HTT. 
2.5) Modeling Huntington’s Disease in Pluripotent Stem Cells 
 
      Due to the multiple function of HTT in the cellular processes, the understanding of the 
mechanisms of HD pathologies should be based on multiple levels by using different 
approaches to recapitulate the disease. The knowledge about the progress and mechanism of 
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HD is based on the studies from model systems, including cellular and animal models 
(Vonsattel 2008, Carter and Chan 2012, Pouladi, Morton et al. 2013). Until recently, murine 
neuronal cells and transgenic animals were the primary models. However, the therapies which 
are helpful in these models have been not beneficial in human patients. One of the main problem 
about the rodent transgenic model for HD is the functional differences of human and rodent 
proteins (Kaye and Finkbeiner 2013). Secondly, the human brain is more complex than rodents 
and the development of the subventricular zones and cerebral cortex are significantly different 
(Dolmetsch and Geschwind 2011). Therefore, recapitulate the physiologically same 
phenomena in rodent models is complicated. Moreover, studies in human tissue have been also 
limited with blood samples, immortalized cell lines and fixed post-mortem tissues. Although 
they promote valuable information about the disease pathology and progress, these models also 
present limitations. For example, post-mortem tissues are vulnerable to DNA and RNA 
degradation. Immortalized cells have different biological characteristics than brain cells. 
Though blood samples give valuable information about variations in gene expression which 
may be used as biomarkers of disease, these changes are just one part of the disease pathology 
and progress (Borovecki, Lovrecic et al. 2005, Lovrecic, Kastrin et al. 2009). 
      Recent advances in the stem cell area and the discovery of reprogramming of fibroblasts 
into pluripotent cells which sharing many of the properties of embryonic stem cells open a new 
area to study the development and progression of human disease. These advances may also 
provide to identify potential drug targets and to investigate alternative cell sources for cell 
replacement therapy (Takahashi, Tanabe et al. 2007). Moreover, the possibility to differentiate 
these iPSCs into neurons open new doors for the investigation of the impact of mHTT. 
Currently, distinct stem cell systems are used for a better understanding of pathology and 
disease progress, including such as iPSCs, ESCs, as well as neural stem cells/neural progenitor 
cells (NSCs/NPCs) (Schwarz and Schwarz 2010, Maucksch, Vazey et al. 2013, Hargus, Ehrlich 
et al. 2014). 
      ESCs are capable to self-renew and they can be used to study the pathology and progress 
of HD in vitro (Ben-David, Kopper et al. 2012). Some of the HD lines are established from 
donated embryos which have 40-51 polyQ repeats in HTT (Verlinsky, Strelchenko et al. 2005, 
Glick, Barth et al. 2010, Bradley, Scott et al. 2011). Established ESCs lines are able to 
differentiate into terminally differentiated neurons carrying mHTT (Niclis, Trounson et al. 
2009, Bradley, Scott et al. 2011). However, these HD-ESCs and their differentiated 
counterparts have not revealed HD-related phenotypes (Kaye and Finkbeiner 2013). On the 
other hand, murine HD-ESCs can show HD-related phenotypes. The established murine HD-
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ESCs have either 150 or 77 polyqlutamine repeats in HTT and have similar neural proliferative 
characteristics with human subventicular zone cells in HD brains (Kaye and Finkbeiner 2013). 
The transcriptional profiling of murine HD-ESCs exhibit changes in gene expression of 
pathways involved in regulating axonal growth and neuronal differentiation, processes also 
observed in HD patients’ brains (Cha 2007). These results reveal that murine ESCs can 
recapitulate key aspects of HD. On the other hand, iPSC derived from HD patients may be used 
as invaluable source for studying HD and identification of novel therapeutic approaches without 
the ethical limitations posed by ESCs. The first HD iPSCs were derived from patients with 54 
expansion of CAG and 72 CAG in HTT by reprogramming from fibroblast using retroviral 
induction with a combination of four pluripotency factors: Oct4, Sox2, Klf4 and cMyc (Park, 
Arora et al. 2008). Recently, the generation and characterization of 14 different iPSCs lines 
from somatic cells of HD patients and control individuals have been reported by the HD iPSC 
Consortium (Consortium 2012). Notably, studies have suggested that HD iPSCs reveal HD-
related phenotypes such as the impairment in mitochondrial function, signaling by brain-
derived neurotrophic factor (BDNF), and caspase activity (Consortium 2012, Hargus, Ehrlich 
et al. 2014). Furthermore, neurons derived from HD-iPSCs are more vulnerable to oxidative 
stress, cellular excitotoxic factors and deprivation of growth factors. They have also increased 
caspase activity and basal lysosomal activity (Consortium 2012, Hargus, Ehrlich et al. 2014). 
Finally, transcriptome analysis of NPCs derived from iPSCs reveals that 1,601 genes were 
differentially regulated in HD-NPCs compared with control NPCs (Consortium 2012). Besides, 
pathways involved in cell cycle regulation, proliferation, axonal guidance and cell signaling are 
dysregulated in NPCs derived from HD-iPSC (Consortium 2012). 
      Taken together, modeling HD using pluripotent stem cells, especially iPSCs derived from 
HD patients, holds great promise for understanding the progress and pathology of HD. Research 
in HD-iPSCs and derived neurons may fill the gaps in knowledge from the rodent models. In 
addition, they are an invaluable source for drug screening to uncover potential novel therapies. 
 
 
 
 
 
 
29
 2) OBJECTIVES AND RATIONALITIES 
 
       Maintenance of cellular homeostasis is essential for controlling the aging process and it is 
determined by several mechanisms including proteostasis. Proteostasis is required for 
organismal development and function (Carmona and Michan 2016). Accumulation of damaged 
proteins or aggregates by a demise in proteostasis can disrupt cellular function and cause cell 
malfunction (Taylor and Dillin 2011). Moreover, the decline in proteostasis has been associated 
with multiple age-related diseases such as HD (Labbadia and Morimoto 2015). Recent studies 
have also suggested that proteostasis is required to maintain the function and identity of 
embryonic and many of adult stem cells (Moreno-Gonzalez and Soto 2011, Taylor and Dillin 
2011). A decline in proteostasis is considered a hallmark of aging (Lopez-Otin, Blasco et al. 
2013).  Strikingly, hESCs are immortal and replicate in the absence of senescence (Buckley, 
Aranda-Orgilles et al. 2012, Lopez-Otin, Blasco et al. 2013). It has been shown that hESCs 
have high proteasome activity compared with their differentiated counterparts (Vilchez, Boyer 
et al. 2012). In addition, it has been uncovered that PSMD11/Rpn-6, a key proteasome subunit, 
is required for stem cell identity as well as regulation of longevity and healthspan in C. elegans. 
Furthermore, FOXO4 modulates proteasome activity and is required for pluripotency through 
the regulation of PSDM11 expression in hESCs (Vilchez, Boyer et al. 2012, Vilchez, Morantte 
et al. 2012). These studies highlight the importance of the proteasome for both hESCs and 
aging. However, the mechanism(s) by which proteasome activity regulates hESC function 
remains unknown. Therefore, we proposed that understanding the regulation of the proteostasis 
network for self-renewal and identity of hESCs may provide valuable information for better 
understanding of hESC identity and aging process. For this purpose, we first aimed to define 
which E3 ubiquitin ligases are essential for pluripotency and differentiation capacity of hESCs. 
Our proteomics data have shown that 35 E3 enzymes are upregulated in hESC compared with 
their differentiated counterparts. Then, we focused on several of these enzymes after validation 
of our proteomics data by western blot. Among these up-regulated E3 ligases, there are HECT-
domain E3 ligases such as HERC2 and UBE3A and RING-domain E3 ligases such as UBR7 
and RNF181. We then sought to define possible substrates of these E3 ligases which could have 
a role in stemness and differentiation capacity of hESCs. Moreover, we also manipulated 
proteasome activity in hESCs to assess possible endogenous targets of the proteasome in these 
cells. Our systemic characterization of interactome of these E3 ligases suggests a link with 
hESCs identity. Moreover, the loss of function experiment for these E3 ligases reveals 
significant change in transcriptome and proteome level of hESCs. However, the loss of these 
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E3 ligases do not alter pluripotency or differentiation capacity of hESCs. On the contrary, we 
show that global proteasome inhibition impairs diverse biological processes required for hESCs 
identity, including telomere maintenance, protein synthesis, rRNA maturation and glycolytic 
metabolism. Thus, our data suggest that enhanced proteasome activity is linked with other 
determinant processes of hESCs identity. 
      In the second part of this study, our goal was to understand how enhanced proteasome 
activity determines the proteostasis of mHTT in pluripotent stem cells by specifically focusing 
on the intrinsic E3 ubiquitin ligase network. The decline in folding capacity and clearance of 
proteins is associated with the onset of age-related neurodegenerative disease such as HD 
(Lopez-Otin, Blasco et al. 2013). HD is an autosomal neurodegenerative disorder caused by 
expansion in CAG in HTT. This abnormal expansion of polyQ repeats in HTT protein causes 
its aggregation and neurodegeneration (Bates 2003). The onset of the disease is related to 
expansion number and patients affected by HD contains mHTT with greater than 35 polyQ 
repeats (Ross and Tabrizi 2011). Although the loss of normal HTT function could be a 
determinant in the pathology and progress of the disease, it has been shown that the gain of 
function of mHTT is toxic and causes neurodegeneration (Saudou and Humbert 2016). 
Interestingly, the length of pathological polyQ does not influence pluripotency, survival, and 
self-renewal of HD-iPSCs (Consortium 2012). Besides, HD-iPSCs do not exhibit accumulation 
of polyQ-expanded aggregates (Consortium 2012, Jeon, Lee et al. 2012, Noormohammadi, 
Khodakarami et al. 2016). Strikingly, during cell reprogramming from somatic cells to iPSCs, 
the proteostasis network is rewired and they acquire high levels of proteasome activity similar 
to hESCs (Vilchez, Boyer et al. 2012, Noormohammadi, Khodakarami et al. 2016, 
Noormohammadi, Calculli et al. 2018). These results suggest that iPSCs have enhanced 
mechanisms to maintain proteostasis of mHTT. Although several studies revealed a strong link 
between proteasomal impairment and HD, the underlying mechanisms by which proteasome 
regulates polyQ-expanded HTT are poorly understood (Koyuncu, Fatima et al. 2017). 
Therefore, in this study, we wanted to answer whether these cells have an intrinsic E3 ubiquitin 
ligase network to regulate proteostasis of mHTT. We observed that proteasome activity 
regulates HTT levels and prevents the accumulation of polyQ-expanded aggregates in HD-
iPSCs. Remarkably, iPSCs have enhanced levels of the E3 ubiquitin ligase UBR5. We found 
that UBR5 interacts with HTT and modulates the degradation of both mutant and wild-type 
HTT protein levels. Besides, the knockdown of UBR5 leads to accumulation of HTT protein 
as well as polyQ-expanded aggregates in HD-iPSCs. Interestingly, the loss of the orthologue of 
UBR5 hastens polyQ-expanded aggregation and neurotoxicity in a C. elegans model of HD. 
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Moreover, we also observed that ectopic expression of UBR5 induces polyubiquitination and 
degradation of mHTT, decreasing mHTT aggregates in HD cell models. Furthermore, increased 
UBR5 expression determines global proteostasis of iPSCs preventing the aggregation of 
misfolded proteins ensued from normal metabolism. Therefore, we suggested that UBR5 is a 
novel regulator of super-vigilant proteostasis of iPSCs. 
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Insights into the ubiquitin-
proteasome system of human 
embryonic stem cells
Isabel Saez1, Seda Koyuncu1, Ricardo Gutierrez-Garcia1, Christoph Dieterich2 & David Vilchez  1
Human embryonic stem cells (hESCs) exhibit high levels of proteasome activity, an intrinsic 
characteristic required for their self-renewal, pluripotency and differentiation. However, the 
mechanisms by which enhanced proteasome activity maintains hESC identity are only partially 
understood. Besides its essential role for the ability of hESCs to suppress misfolded protein 
aggregation, we hypothesize that enhanced proteasome activity could also be important to degrade 
endogenous regulatory factors. Since E3 ubiquitin ligases are responsible for substrate selection, we 
first define which E3 enzymes are increased in hESCs compared with their differentiated counterparts. 
Among them, we find HECT-domain E3 ligases such as HERC2 and UBE3A as well as several RING-
domain E3s, including UBR7 and RNF181. Systematic characterization of their interactome suggests 
a link with hESC identity. Moreover, loss of distinct up-regulated E3s triggers significant changes 
at the transcriptome and proteome level of hESCs. However, these alterations do not dysregulate 
pluripotency markers and differentiation ability. On the contrary, global proteasome inhibition impairs 
diverse processes required for hESC identity, including protein synthesis, rRNA maturation, telomere 
maintenance and glycolytic metabolism. Thus, our data indicate that high proteasome activity is 
coupled with other determinant biological processes of hESC identity.
Pluripotent stem cells can replicate indefinitely in an undifferentiated state while retaining their potential to 
differentiate into all cell lineages1,2. Embryonic stem cells (ESCs) derived from blastocysts are the gold standard 
of pluripotency. Moreover, somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) that 
share similar characteristics with ESCs3,4. Given their intrinsic abilities, pluripotent stem cells represent an inval-
uable resource to investigate development and disease, holding great promise for regenerative medicine. As the 
origin of multicellular organisms, a series of regulatory and quality control mechanisms must operate at high 
fidelity in these cells5. As such, protein homeostasis (proteostasis) is central for self-renewal, pluripotency and 
cell fate decisions6–9.
A key node of the proteostasis network is the ubiquitin proteasome system (UPS), the major selective pro-
teolytic mechanism in eukaryotic cells10,11. Notably, human ESCs (hESCs) and iPSCs have increased proteas-
ome activity compared with their differentiated counterparts12. This enhanced activity is induced by PSMD11/
RPN613, a scaffolding subunit that promotes proteasome assembly14. Besides PSMD11, other proteasome regula-
tors (e.g., Psmd14, POMP) are up-regulated in mouse and human pluripotent stem cells6,15,16. Conversely, a mild 
down-regulation of proteasome activity induces a demise of hESC identity, characterized by decreased mRNA 
and protein levels of pluripotency markers13,15,17. Concomitantly, pluripotent stem cells with reduced proteasome 
activity lose their ability to differentiate into neural cells while expressing high levels of markers of endoderm, 
mesoderm and fibroblast differentiation13.
These findings raise the intriguing question of why ESC function needs enhanced proteasome activity. 
The proteasome terminates damaged, misfolded and aggregated proteins ensued from stress conditions and 
misfolding-prone mutations11,18. The accumulation of damaged proteins could alter the immortality of pluripo-
tent stem cells5. Notably, growing evidence indicates that increased proteasome activity prevents the aggregation 
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of damaged proteins such as mutant huntingtin, which underlies Huntington’s disease9,12,13,19. Moreover, the pas-
sage of altered proteins to progenitor cells could compromise organismal development and aging. In this regard, 
enhanced proteasome activity participates in the degradation of damaged proteins in the early steps of mouse 
ESC differentiation, a key step to generate daughter cells with an intact proteome20,21.
The UPS also modulates half-life of a myriad of regulatory proteins22,23, in a dynamic process adjusted to the 
specific requirements of a particular cell type and status24,25. Since the differentiation process triggers numerous 
changes in the cellular proteome, the UPS determines successful organismal development5. In these lines, the pro-
teasome modulates the abundance of key pluripotency factors such as OCT4 or NANOG26–29. A chain of at least 
four 48-linked ubiquitins is the primary signal for recognition and degradation by the proteasome30,31. E3 ligases 
transfer ubiquitin to a target protein, providing specificity to the proteolytic process. Accordingly, over 600 E3 
ubiquitin ligases have been identified in humans so far. To prevent proteolysis, deubiqutinating enzymes (DUBs) 
perform the opposite action. Thus, both E3 and DUBs must operate in a balanced manner to maintain hESC 
function or activate differentiation26,27. Remarkably, the levels of distinct E3 and DUB enzymes undergo dramatic 
changes during differentiation of mouse ESCs and cell reprogramming6,9. Recent studies have revealed that dis-
tinct proteins with DUB activity such as USP2232,33, USP4434,35 or the proteasome component Psmd146 regulate 
the levels of core pluripotency transcription factors. Likewise, specific E3 enzymes modulate pluripotency and 
differentiation29. For instance, Huwe1 polyubiquitinates the pluripotency transcription factor N-myc, promoting 
its degradation by the proteasome and allowing for neural differentiation of mouse ESCs36.
To obtain further insights into the mechanisms by which increased proteasome activity sustain hESC identity, 
here we determine the interactome of highly-expressed E3 ligases in these cells (i.e., HERC2, UBE3A or RNF181). 
Moreover, we perform loss-of-function experiments of these E3s enzymes to examine their impact on hESC 
identity. Besides its role in the regulation of damaged proteins and endogenous substrates, increased proteasome 
activity could also be coupled to intrinsic characteristics of pluripotent stem cells. For instance, ESC and iPSCs 
exhibit up-regulated global translational rates37. To assess this hypothesis, we define the alterations induced by 
proteasome dysregulation using a shot label-free proteomic approach. Notably, we find changes in key biological 
processes of hESC identity such as RNA biogenesis, protein synthesis and telomere function, establishing the 
proteasome as a central regulator of hESCs.
Results
The levels of specific E3 enzymes decrease during differentiation. To obtain insights into the role 
of the UPS in hESC function, we examined changes in the expression of E3 ubiquitin ligases and DUBs during 
differentiation. For this purpose, we analysed available proteomics data comparing hESCs with their differenti-
ated neuronal counterparts9 (Supplementary Data 1). We identified 31 DUBs in both hESCs and neurons. Among 
them, 10 were upregulated and 15 were downregulated during differentiation into neurons. We found that 44 out 
of 99 identified E3 enzymes increase during neuronal differentiation. In contrast, 35 E3 enzymes were decreased 
during differentiation into neurons (Supplementary Data 1 and Supplementary Table 1). To identify potential 
substrates of the UPS in hESCs, we further examined their up-regulated E3 ubiquitin ligases. Our approach was 
supported by the fact that three of these E3 enzymes were previously reported as regulators of ESC identity (i.e., 
HUWE136, TRIM3338 and RNF40)34.
Among the 35 E3 enzymes significantly increased in hESCs, we found 6 ubiquitin ligases with HECT domain 
while the other E3 enzymes belonged to the RING-domain family39 (Supplementary Table 1). To validate these 
proteomics data, we performed western blot analysis of representative E3s of both families comparing hESCs with 
their neural progenitor cell (NPC) and neuronal counterparts. As a control, we also examined the levels of STUB1, 
an E3 enzyme which slightly increased during neuronal differentiation (Fig. 1a and Supplementary Data 1). At 
early neural stages, we already observed a downregulation in HECTD1, HERC2, HUWE1, UBE3A, KCMF1, 
RNF40, RNF181 and UBR7 levels (Fig. 1a). We corroborated the downregulation of distinct E3 ligases during 
neural differentiation in an independent hESC line (Supplementary Fig. 1). Moreover, these E3 enzymes were 
also decreased in terminally differentiated neurons validating our proteomics analysis (Fig. 1a and Supplementary 
Table 1). However, we could not confirm a decrease of TRIM33 levels during neurogenesis as we obtained incon-
sistent results among independent differentiation experiments (Fig. 1a and Supplementary Fig. 2).
The downregulation in the protein amount of the E3 ubiquitin ligases did not correlate with a reduction in 
their mRNA levels during neuronal differentiation (Fig. 1b), suggesting a post transcriptional or post-translational 
regulation of these enzymes. Since multiple E3 ligases are regulated by autoubiquitination rates40, decreased levels 
of E3s may also indicate their potential activation during differentiation. In hESCs, proteasome inhibition did not 
result in higher levels of the tested E3 enzymes (Supplementary Fig. 3a). Most importantly, proteasome inhibition 
did not up-regulate the levels of these E3 enzymes in neurons (Supplementary Fig. 3b). Thus, these data discard 
a faster turnover of our target E3 enzymes in differentiated cells induced by higher autoubiquination activity.
With the exception of RNF40, the protein levels of most of our target E3 enzymes were also decreased with dif-
ferentiation into endoderm, indicating that this is not a specific phenomenon associated with the neural lineage 
(Fig. 1c). Among them, HECTD1, HERC2, HUWE1, UBE3A, RNF181 and TRIM33 were dramatically downreg-
ulated while KCMF1 and UBR7 were reduced to a lesser extent (Fig. 1c). In contrast to neuronal differentiation, 
we also observed a downregulation at the mRNA level (Fig. 1d). Moreover, the gene expression of many of these 
E3 enzymes (e.g., HECTD1, HERC2, KCMF1) was also downregulated when hESCs differentiated into mesoder-
mal lineages (Fig. 1e). Overall, our results indicate that specific E3 enzymes such as HERC2, UBE3A and RNF181 
are highly abundant in hESCs and decrease during differentiation.
HECTD1 interacts with regulators of WNT signaling and glycolysis. To examine the role of 
up-regulated E3 enzymes in hESCs, we characterized their interactome. For this purpose, we performed 
co-immunoprecipitation experiments from hESCs followed by a single shot label-free proteomic approach. Our 
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Figure 1. The levels of distinct E3 ubiquitin ligases decrease during differentiation. (a) Western blot 
analysis of H9 hESCs compared with their neural and neuronal counterparts (i.e., neural precursor cells 
(NPCs) and terminally differentiated neurons, respectively) with antibodies against distinct E3 ubiquitin 
ligases. ß-actin is the loading control. E3 enzymes are shown following their classification into HECT 
and RING-domain families. The images are representative of at least two independent experiments. 
(b) Quantitative PCR (qPCR) of E3 ubiquitin ligases mRNA levels. Graphs represent the mean ± s.e.m. 
(relative expression to H9 hESCs) of three independent cells. (c) Western blot analysis of E3 ubiquitin 
ligases comparing H9 hESCs with their differentiated endoderm precursors counterparts. ß-actin is 
the loading control. The images are representative of two independent experiments. All cropped blots 
were run under the same experimental conditions. Uncropped versions of western blots are presented 
in Supplementary Fig. 13. (d) qPCR analysis of E3 ubiquitin ligases transcript levels upon definitive 
endodermal differentiation of H9 hESCs. Graphs represent the mean ± s.e.m. (relative expression to H9 
hESCs) of four independent cells. (e) mRNA levels of E3 enzymes in H1 hESCs and their differentiated 
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first target was HECTD1, a HECT E3 ubiquitin ligase involved in the negative regulation of β-catenin (CTNNB1). 
β-catenin is the main effector of WNT signaling41, one of the regulatory nodes of ESC pluripotency and neural 
differentiation42,43. We successfully immunoprecipitated significant levels of endogenous HECTD1 (Fig. 2a and 
Supplementary Fig. 4). Notably, interactome analysis indicated that HECTD1 binds β-catenin and GSK3B, a 
negative regulator of WNT signaling (Fig. 2b–c and Supplementary Data 2). We also found a strong interaction 
with subunits of the pyruvate dehydrogenase complex (PDC) (i.e., DLAT, PDHA1, PDHB, PDHX) (Fig. 2b–c). 
PDC catalyses the mitochondrial conversion of pyruvate into acetyl-CoA, which will be further metabolized 
through the tricarboxylic acid cycle and electron chain44. The metabolism of ESCs relies on glycolysis rather 
than mitochondrial respiration for energy production, a process achieved through an inactive PDC complex45. 
Thus, HECTD1 could participate in maintaining the glycolytic state of hESCs via modulation of PDC activity. 
In these lines, gene ontology biological process (GOBP) term analysis of the HECTD1 interactome indicated the 
strongest enrichment for proteins involved in the regulation of Acetyl-CoA biosynthetic process (Fig. 2d and 
Supplementary Data 2). Interestingly, SIN3A, a transcriptional regulatory protein required for both survival and 
pluripotency of ESCs46,47, also strongly interacted with HECTD1 (Fig. 2b–c), providing an additional putative link 
between HECTD1 and ESC function.
To determine whether HECTD1 binds these proteins specifically in hESCs, we performed 
co-immunoprecipitation experiments from NPCs and neurons. Among the 63 HECTD1 interactors identified 
in hESCs, 39.7% and 28.6% were also significant interactors in NPCs and neurons, respectively (Fig. 2e and 
Supplementary Data 3). These common interactors included GSK3B, PDC subunits (i.e., DLAT, PDHA1, PDHB, 
PDHX) and SIN3A in the three cell types tested. Thus, cell-type differences in HECTD1 abundance or activity 
could determine its regulatory impact on distinct pathways such as WNT signaling or Acetyl-CoA biosynthetic 
process. Our data also indicate a high percentage of specific interactions of HECTD1 depending on the cell type. 
Remarkably, 34 proteins interacted with HECTD1 in hESCs while we did not find a significant interaction in 
NPCs or neurons (Supplementary Data 3). Among these specific interactors, we found β-catenin as well as several 
regulators of cell cycle and proliferation (e.g., BIRC6, CCNK, CDH1, DDX41, PRPF40A, SRPK2, TAF1), provid-
ing a potential link of HECTD1 with the high division rates of these cells. We also identified a hESC-specific inter-
action of HECTD1 with AURKB, a regulator of telomerase activity in ESCs48. Moreover, HECTD1 specifically 
interacted in hESCs with proteins involved in gastrulation (i.e., DLD49) and embryonic cell differentiation (e.g., 
PAXBP150, SRGAP251 and THOC6)52. Thus, our data suggest that cell-specific interactions can also determine 
endogenous roles of up-regulated E3 enzymes in hESCs.
Knockout of HERC2 alters the transcriptome of hESCs. HERC2 is one of the most up-regulated 
E3 enzymes in hESCs when compared with their differentiated counterparts (Fig. 1a,c). HERC2 belongs to the 
HERC gene family, that contains a HECT domain and at least one RCC1-like domain (RLD). HERC2 interacts 
with chromatin via the RLD domain and participates in DNA repair, DNA replication as well as checkpoint 
control53. As such, HERC2 is located in a chromosomal region associated with neurodevelopmental disorders, 
including Prader-Willi and Angelman syndromes54. We immunoprecipitated endogenous HERC2 in hESCs 
(Fig. 3a and Supplementary Fig. 4) and identified 113 potential interactors (Supplementary Data 4). The three 
strongest interacting partners were SEC23IP, SRGAP2 and NEURL4 (Supplementary Fig. 5a), which are linked 
to development51,55,56. These proteins are already reported to interact with HERC2 in human cell lines, validating 
our data57. In differentiated cells, HERC2 has also been reported to interact with UBE3A, the primary E3 involved 
in Angelman syndrome58. Moreover, HERC2 has been recently associated with the kinase LRRK2, which plays 
a role in the familial Parkinson’s disease59. However, we did not observe these interactions in our proteomic data 
from hESCs, suggesting cell-type differences. On the other hand, the HERC2 interactome was strongly enriched 
for RNA-binding proteins (Supplementary Data 4). In addition, the most enriched GOBP pathways were related 
with RNA metabolism (Supplementary Fig. 5b and Supplementary Data 4). The high enrichment for pathways 
involved in RNA metabolism could indicate indirect interactions mediated by RNA and, therefore, ensuing from 
immunoprecipitation of RNA-protein complexes rather than direct protein-protein interactions60. To assess 
whether HERC2 directly interacted with these RBPs, we repeated the interactome analysis treating the samples 
with RNase A prior to immunoprecipitation with HERC2 antibody60. Whereas the interactions with SEC23IP, 
SRGAP2 and NEURL4 remained upon RNase treatment, the number of total significant interactors was reduced 
to 33 proteins (Fig. 3b and Supplementary Data 5). We found a significant interaction with centrosomal proteins 
(i.e., CENPF, CEP97) as well as RNA-binding proteins such as translation factors (i.e., EIF3A, EIF3C) and the 
helicase DDX20 (Supplementary Data 5). However, most of the interactions with RNA-binding proteins were lost 
upon RNase treatment. Moreover, GOBP analysis did not show an enrichment of RNA-related processes among 
these proteins (Fig. 3c and Supplementary Data 5). These data suggest that the previously identified RNA-binding 
proteins were immunoprecipitated due to secondary, RNA-mediated interactions.
With the high levels of HERC2 in hESCs and the role of one of its main interactors, SRGAP2, in neurogenesis 
and spine maturation61, we asked whether HERC2 regulates hESC function or differentiation. For this purpose, 
we generated a knockout hESC line by CRISPR/Cas9 genome editing (HERC2−/−) and performed transcrip-
tome analysis. We found 1494 transcripts significantly changed in HERC2−/− hESCs (Supplementary Data 6). 
Interestingly, GOBP analysis indicated strong enrichment for genes involved in the regulation of dendritic spine 
maintenance and regulation of glial cell proliferation (Fig. 3d and Supplementary Data 6). We also found an 
mesoderm and cardiomyocyte counterparts. qPCR data represents the mean ± s.e.m. of three independent 
experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. P-value: 
*(P < 0.05), **(P < 0.01), ***(P < 0.001).
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alteration in regulators of other developmental process, including nephron and placenta morphogenesis (Fig. 3d). 
Prompted by these findings, we examined whether these changes in the transcriptome impaired the levels of 
pluripotency markers. However, HERC2−/− hESCs did not exhibit alterations in the levels of pluripotency mark-
ers when compared to control hESCs (Fig. 3e–g), indicating that that the sole deletion of HERC2 does not majorly 
impact on hESCs function. In addition, we did not find an increase in the expression of markers of the distinct 
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Figure 2. HECTD1 interacts with regulators of WNT signaling and glycolysis. (a) Co-immunoprecipitation 
(co-IP) with HECTD1 and FLAG antibodies in H9 hESCs followed by western blot against HECTD1. We 
loaded 13.3% of total input and 20% of total immunoprecipitated sample. The images are representative of three 
independent experiments. All cropped blots were run under the same experimental conditions. The original 
blots are included in Supplementary Fig. 13. (b) Volcano plot of the interactome of HECTD1 in H9 hESCs 
(n = 4). Graph represents the −log (p-value) of a two-tailed t-test plotted against the log2 ratio of protein label-
free quantification (LFQ) values from co-IP experiments with HECTD1 antibody compared to control co-IP 
with FLAG antibody. Red colored dots beyond the curved lines indicate some of the most enriched interacting 
proteins after correction for multiple testing (False Discovery Rate (FDR) adjusted p-value (q-value) <0.2, 
s0 = 0.1). (c) Scheme indicating the Gene Ontology Molecular Function (GOMF) of HECTD1 interactors 
(Analysis tool: Cytoscape 3.6.0)137. (d) Bar graph representing the top GOBPs of HECTD1 interactome 
(P < 0.05) (Analysis tool: PANTHER138 and Gene Ontology Consortium). (e) Venn diagram represents 
total number and common significant interactors in hESCs, NPCs and neurons (FDR < 0.2 was considered 
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Figure 3. Knockout of HERC2 does not impair neural differentiation of hESCs. (a) co-IP with HERC2 and 
FLAG antibodies in H9 hESCs followed by western blot against HERC2. We loaded 13.3% of input and 20% 
of immunoprecipitated sample. The images are representative of three independent experiments. All cropped 
blots were run under the same experimental conditions. The original blots are included in Supplementary 
Fig. 13. (b) Volcano plot of the interactome of HERC2 treating H9 hESC samples with RNase A prior to 
immunoprecipitation (n = 4). Graph represents the –log (p-value) of a two-tailed t-test plotted against the 
log2 ratio of LFQ values from co-IP experiments with HERC2 antibody compared to control co-IP with 
FLAG antibody. Red colored dots indicate some of the most enriched interacting proteins after correction 
for multiple testing (FDR < 0.2, s0 = 0.1). (c) Bar graph representing the top GOBPs of HERC2 interactome 
(P < 0.05). (d) Bar graph representing the top GOBPs of the differentially expressed transcripts in HERC2−/− 
H9 hESCs (P < 0.05). Transcripts showing a log2-fold change at a FDR < 0.05 were retained as significantly 
differentially expressed. (e) Western blot analysis with antibodies to HERC2, OCT4 and SOX2 comparing 
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germ layers (Fig. 3f), suggesting that loss of HERC2 does not induce differentiation. We only observe a decrease 
in the mRNA levels of PAX6, an early marker of neuroectodermal differentiation62 (Fig. 3f). At the pluripo-
tent state, hESCs express marginal amounts of PAX663 making these results difficult to interpret. Nevertheless, a 
decrease in PAX6 levels at the hESC stage could indicate a dysfunction in their ability to differentiate into NPCs. 
To assess this hypothesis, we induced neural differentiation. Besides a mild decrease in the mRNA levels of TUJ1, 
we did not find a significant downregulation in the induction of NPC markers at both protein and transcript 
levels (Fig. 3h,i). Most importantly, both control and HERC2−/− cultures consisted mostly of PAX6-positive cells 
at the end of the neural induction treatment (Fig. 3j). Taken together, these results suggest that HERC2 has not a 
big impact in neural differentiation of hESCs.
Highly abundant E3s interact with stem cell regulators in hESCs. We continued our interac-
tome analysis of up-regulated E3 enzymes focusing on KCMF1, UBR7, UBE3A and RNF181 (Fig. 4a and 
Supplementary Fig. 4). We excluded HUWE1, TRIM33 and RNF40 as their role and targets have been previ-
ously defined in the context of hESC function34,36,38. KCMF1 is a poorly characterized RING finger-domain E3 
enzyme64. In Drosophila melanogaster, KCMF1 orthologue regulates MAPK levels through its interaction with 
UBR465, another E3 ubiquitin ligase. Moreover, the complex KCMF1-UBR4 promotes lysosomal degradation 
of the E2 ubiquitin protein RAD666. We identified 23 significant KCMF1 interactors in hESCs, including UBR4 
(Fig. 4b,c and Supplementary Data 7). One of the most enriched proteins was HMMR (Fig. 4b,c), an important 
regulator of stemness in murine ESCs through its role in signal transduction at microtubules67. TAF15, another 
significant KCMF1 interactor, has been previously reported as an epigenetic regulator of ESC pluripotency68. 
Among the most enriched GOBPs of KCMF1 interactors, we found processes involved in cotranslational protein 
targeting to the endoplasmic reticulum (Fig. 4d).
UBR7 belongs to the UBR-box family of E3 ligases. The UBR-box domain contains three zinc finger sites to 
bind proteins with modified N-terminal amino acid residues based on the N-end rule pathway69. In contrast 
to other members of the UBR-box family, little is known about UBR7. It was discovered in mammalian sperm, 
where it was shown to exhibit E3 ligase activity and suggested to be involved in spermiogenesis70. We identified 
18 significant interactors of UBR7 in hESCs (Fig. 4e,f and Supplementary Data 8). The most enriched interac-
tor was A2M, a regulator of cytokine availability in the local environment of hESCs and, thus, having a direct 
impact on pluripotency71 (Fig. 4e,f). Another strong UBR7 interactor was ZSCAN10, which is key for mouse ESC 
identity72. Similar to HECTD1, UBR7 interacted with distinct PDC subunits (i.e., DLAT, PDHA1 and PDHB) 
(Supplementary Data 8). Accordingly, GOBP analysis of UBR7 interactors indicated an enrichment in acetyl-CoA 
biosynthetic pathways (Fig. 4g).
UBE3A, also known as E6-AP, belongs to the family of HECT E3 ubiquitin ligases and was initially discovered 
as a modulator of p53 degradation73. Genetic abnormalities in the maternally inherited UBE3A are responsi-
ble for Angelman syndrome74,75. Conversely, duplication or increased expression of UBE3A is linked to autism 
spectrum disorders76. UBE3A plays a role in dendritic arborization and synapse maturation77–79, as well as cell 
cycle progression80. Additionally, UBE3A participates in the clearance of several aggregated proteins81,82. Among 
the UBE3A interactors in hESCs, the most enriched protein was SAE1, an important regulator for reprogram-
ming of human somatic cells83 (Fig. 5a–c and Supplementary Data 9). Another interactor of UBE3A was BCCIP, 
whose deficiency in mouse leads to impaired neural progenitor self-renewal and differentiation capabilities84. 
AHNAK, which was also significantly enriched in the UBE3A pull-down, is necessary for proper iPSC genera-
tion85. GOBP analysis of UBE3A interactors indicated enrichment for proteins involved in metabolic processes 
of cellular macromolecules, aromatic and nitrogen compounds as well as mRNAs (Fig. 5d and Supplementary 9). 
However, we cannot rule out that these interactions with RBPs involved in mRNA stability ensue from indirect 
RNA-mediated binding and further experiments will be required to asssess direct interaction (e.g., RNase A prior 
to immunoprecipitation).
The interactome of RNF181 was highly enriched for subunits of dynactin (specifically, DCTN2, ACTR1A, 
ACTR1B, DCTN4, DCTN1) (Fig. 5e,f and Supplementary Data 10), a macromolecular complex that regulates 
not only intracellular transport but also chromosome alignment and spindle organization during cell division86. 
Dynactin is necessary for proper asymmetric division of embryonic skin progenitors87 and thus may also play a 
role in the asymmetric divisions invoked by ESCs. Furthermore, RNF181 interacts with DZIP3, an E3 enzyme 
wild-type H9 (WT) with HERC2−/− H9 hESCs. ß-actin is the loading control. The images are representative 
of two independent experiments. All cropped blots were run under the same experimental conditions. The 
original blots are included in Supplementary Fig. 13. (f) Real-time PCR analysis of pluripotency (upper panel) 
and germ-layer markers (lower panel) in HERC2−/− H9 hESCs. Graphs (relative expression to wild-type H9 
hESCs (WT)) represent the mean ± s.e.m. of four independent experiments. Statistical comparisons were made 
by Student’s t-test for unpaired samples. P-value: ***(P < 0.001). (g) Immunocytochemistry of H9 hESC with 
antibodies against OCT4 and SOX2 (markers for pluripotency) and PAX6 (neuroectodermal marker). DAPI 
staining was used as a marker of nuclei. Scale bar represents 20 μm. (h) Western blot analysis with antibodies 
to HERC2, NESTIN and PAX6 after 10 days of neural induction. ß-actin is the loading control. The images are 
representative of three independent experiments. (i) Real-time PCR analysis of pluripotency (upper panel) 
and neuroectodermal markers (lower panel) in H9 cells after 10 days of neural induction. Graphs (relative 
expression to WT) represent the mean ± s.e.m. of four independent experiments. Statistical comparisons were 
made by Student’s t-test for unpaired samples. P-value: *P < 0.05. (j) Immunocytochemistry after 10 days of 
neural differentiation of HERC2−/− hESCs using antibodies against OCT4, PAX6, NES and SOX1. DAPI was 
used as a marker of nuclei. Scale bar represents 20 μm.
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Figure 4. Analysis of the interactome of KCMF1 and UBR7 in H9 hESCs. (a) Co-IP with KCMF1, UBR7 and 
FLAG antibodies in H9 hESCs followed by western blot against the respective E3 ubiquitin ligases. We loaded 
13.3% of input and 20% of immunoprecipitated sample. Arrows indicate the specific bands for KCMF1 and 
UBR7. The images are representative of three independent experiments. All cropped blots were run under the 
same experimental conditions. The original blots are included in Supplementary Fig. 13. (b) Volcano plot of 
the KCMF1 interactome (n = 4, FDR <0.2). Red colored dots indicate some of the most enriched interacting 
proteins after correction for multiple testing. (c) Scheme indicating the Gene Ontology Molecular Function 
(GOMF) of KCMF1 interactors (d) Bar graph representing the top GOBPs of KCMF1 interactome (P < 0.05). 
(e) Volcano plot of the UBR7 interactome (n = 4, FDR < 0.2). (f) Scheme indicating the GOMF of UBR7 
interactors (g) Bar graph representing the top GOBPs of UBR7 interactome (P < 0.05).
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Figure 5. Highly abundant E3s interact with stem cell regulators in hESCs. (a) Co-IP with UBE3A, RNF181 
and FLAG antibodies in H9 hESCs followed by western blot against the respective E3 ubiquitin ligases. 
We loaded 13.3% of input and 20% of immunoprecipitated sample. The images are representative of three 
independent experiments. All cropped blots were run under the same experimental conditions. The original 
blots are included in Supplementary Fig. 13. (b) Volcano plot of the UBE3A interactome (n = 3, FDR < 0.2). 
Red colored dots indicate some of the most enriched interacting proteins after correction for multiple testing. 
(c) Scheme indicating the Gene Ontology Molecular Function (GOMF) of UBE3A interactors (d) Bar graph 
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which regulates developmental genes in mouse ESCs by reorganizing 3D chromatin conformation88. Further 
experiments will be required to determine whether this interaction is direct or DNA-mediated. Besides the pro-
teasome subunit PSMD3, RNF181 also interacted with distinct subunits of the TRiC/CCT chaperonin complex 
which is critical for hESC proliferation and differentiation9 (Fig. 5f). The TRiC/CCT complex facilitates the fold-
ing of ∼10% of the eukaryotic proteome and mediates protein localization to Cajal bodies, a sub-organelle found 
in the nucleus of highly proliferative cells, such as hESCs89,90. Accordingly, the most enriched GOBP of RNF181 
interactors was the positive regulation of protein localization to Cajal bodies (Fig. 5g and Supplementary Data 10). 
Prompted by these findings, we examined whether RNF181 also interacts with these proteins in post-mitotic 
neuronal cells. Among the 46 RNF181 interactors found in hESCs, only 17% were also significant interactors 
in neurons (Supplementary Fig. 6 and Supplementary Data 11). Although RNF181 bound some of the dynactin 
subunits in neurons (i.e., DCTN2, ACTR1A, DCTN1), the interaction with DZIP3 as well as TRiC/CCT subunits 
was lost (Supplementary Fig. 6 and Supplementary Data 11). Taken together, the role of the interacting partners of 
up-regulated E3 ubiquitin ligases in hESCs indicated that these enzymes might be important for stem cell identity.
Loss of distinct up-regulated E3 enzymes induces changes in the proteome of hESCs. To 
assess the role of up-regulated E3 ligases in hESC function, we generated stable knockdown (KD) lines for UBR7, 
UBE3A and RNF181 and analysed their proteome by quantitative proteomics (Supplementary Data 12). We iden-
tified the significantly changed proteins upon E3 knockdown and performed GOBP analysis (Supplementary 
Data 12). Loss of UBR7 changed the levels of 506 proteins, which were enriched for regulators of the generation 
of energy and metabolites as well as the purine metabolic process (Fig. 6a and Supplementary Data 12). These 
changes could have an impact on hESCs, which rely on highly active nucleotide synthesis rates for sustaining 
their rapid proliferation rates and de novo DNA and RNA production91,92. Among the 661 proteins changed upon 
UBE3A knockdown, GOBP analysis indicated the strongest enrichment for factors involved in the negative reg-
ulation of ubiquitin-ligase activity (Fig. 6b and Supplementary Data 12). This is consistent with previous studies, 
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Figure 6. Loss of distinct up-regulated E3 enzymes induces changes in the hESC proteome. (a) Loss of UBR7 
changed the levels of 506 proteins in H9 hESCs (FDR <0.2 was considered significant, n = 3). GOBP analysis 
(P < 0.05) revealed a strong enrichment for regulators of the purine metabolic process as well as generation of energy 
and metabolites. (b) Loss of UBE3A changed the levels of 661 proteins in H9 hESCs (FDR < 0.2 was considered 
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Figure 7. Loss of UBR7, UBE3A and RNF181 does not affect the expression of pluripotency markers and 
neural differentiation. (a) Western blot analysis with antibodies to UBR7 and OCT4 comparing non-targeting 
shRNA (NT) with UBR7 knockdown (KD) H9 hESCs. We used two independent shRNAs to UBR7 (KD1 
and KD2, respectively). ß-actin is the loading control. The images are representative of two independent 
experiments. All cropped blots were run under the same experimental conditions. The original blots are 
included in Supplementary Fig. 13. (b) Real-time PCR analysis of pluripotency (left panel) and germ-layer 
markers (right panel) in UBR7 KD H9 hESCs. Graphs (relative expression to NT shRNA) represent the 
mean ± s.e.m. of four independent experiments. (c) Western blot analysis after 10 days of neural induction 
of UBR7 KDH9 hESCs. ß-actin is the loading control. The images are representative of two independent 
experiments. (d) Immunocytochemistry after 10 days of neural differentiation. OCT4, PAX6, and DAPI 
staining were used as markers of pluripotency, neuroectodermal differentiation, and nuclei, respectively. Scale 
bar represents 20 μm. (e) Real-time PCR analysis of pluripotency (upper panel) and neuroectodermal markers 
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that showed that UBE3A interacts and ubiquitinates several proteasome subunits93,94 and regulates the activity of 
the proteasome in a ligase-dependent way95,96. Thus, UBE3A could be involved in the regulation of hESC identity 
through modulation of the proteasome, which is central for maintaining pluripotency13. Loss of RN181 changed 
the hESC proteome to a lesser extent (202 proteins) compared with UBR7 and UBE3A KD (Supplementary 
Data 12). Proteins dysregulated in RNF181 KD hESCs were involved mainly in mRNA processing-related path-
ways (Fig. 6c). Transcription hyperactivity has been proposed as a hallmark of pluripotent stem cells, as the 
transcription rates markedly decline during differentiation97. In these lines, mRNA-related proteins deregulated 
in RNF181 KD lines -such as SNRPD1, SRSF5 or HNRNPK- have been proven necessary for stemness in pluripo-
tent cells98–100. If E3 interactors are activated for proteasomal degradation by the respective E3 enzyme, we would 
expect them to increase upon loss of the ubiquitin ligase. However, only a marginal number of the interacting 
partners were up-regulated upon E3 knockdown despite the numerous changes in the proteome induced by loss 
of E3 ligases (Fig. 6d).
One step further was to examine whether loss of UBR7, UBE3A or RNF181 alters hESC identity and differ-
entiation. Loss of UBR7 did not result in significant differences in pluripotency markers compared with control 
hESCs (Fig. 7a,b). Furthermore, the expression of markers of the distinct germ layers was not impaired (Fig. 7b). 
We induced neural differentiation of UBR7 KD hESCs and monitored the expression of PAX6. After 10 days of 
neural induction, PAX6 levels were increased at the same extent in control and UBR7 KD lines (Fig. 7c–e). We 
also analysed the levels of other neural and neuronal markers and found no differences at this stage (Fig. 7e). To 
assess whether UBR7 was required for proper differentiation into other germ lineages, we differentiated UBR7 
KD hESCs into endoderm (Supplementary Fig. 7). The induction of distinct endoderm markers was similar 
between control and UBR7 KD lines, suggesting no major role of UBR7 in cell fate decisions towards the endo-
dermal lineage (Supplementary Fig. 7).
We observed similar results in UBE3A and RNF181 KD hESCs, as pluripotency and differentiation markers 
remained unchanged after reducing the expression of these E3 enzymes (Fig. 7f–h). We also performed neural 
(Fig. 7i–j and Supplementary Fig. 8) and endodermal differentiation (Supplementary Fig. 9) from UBE3A and 
RNF181 KD hESCs and found no differences compared with control cells. Altogether, these results indicate that 
loss of UBR7, UBE3A or RNF181 alone does not alter the commitment of hESCs to a neuroectodermal or endo-
dermal fate.
Proteasome inhibition induces numerous changes in the proteome of hESCs. To assess whether 
E3 enzymes potentially regulate proteasomal degradation of specific interactors, we induced acute proteasome 
dysfunction with the potent MG-132 proteasome inhibitor followed by a shot label-free proteomic approach 
(Fig. 8a,b). We identified 2735 proteins and hierarchical clustering indicated a clear separation of MG-132-treated 
hESCs compared with control hESCs based on global protein expression profiles (Supplementary Fig. 10). 
Quantitative analysis revealed that 899 proteins were significantly changed in MG-132-treated hESCs as com-
pared to control hESCs (Fig. 8b and Supplementary Data 13). Among them, 552 proteins were down-regulated 
whereas 347 were up-regulated upon proteasome inhibition (Fig. 8b and Supplementary Data 13). Since the 
latter group could be putative proteasome targets, we integrated these data with the statistically significant E3 
interactors. We identified several interactors of each E3 which were also up-regulated upon proteasome inhibitor 
(Fig. 8c). Among them, we confirmed by western blot the interactions of HECTD1 with EXOC5 and RNF181 with 
PSMD3 (Fig. 8d). Proteasome inhibition induced a slight increase in both EXOC5 and PSMD3 as we observed 
by proteomics and western blot (Fig. 8e, Supplementary Fig. 11 and Supplementary Data 13). Thus, a detailed 
analysis and validation of other E3 interacting partners could reveal novel proteasome targets in hESCs. However, 
it is also important to note the low number of up-regulated proteins commonly identified in E3 KD lines and 
proteasome inhibitor-treated hESCs (Fig. 8f). Among the 256 proteins up-regulated in UBR7 KD hESC, only 11 
proteins were also increased upon proteasome inhibition (Fig. 8f). Loss of UBE3A resulted in 407 up-regulated 
proteins. Among them, 22 were also increased upon MG-132 treatment, including TRIOBP and MFGE8, both 
important for ESC function101,102 (Fig. 8f). Knockdown of RN181 only induced an increase in 4 proteins that 
were also up-regulated under proteasome inhibition (Fig. 8f). Thus, although a E3-based approach could lead 
to the discovery of potential proteasomal targets in hESCs, our results indicate that E3s are regulating multiple 
processes in a proteasome-independent manner that can complicate our analysis. Moreover, we cannot discard 
compensatory mechanisms or potential functional redundancies among different E3 enzymes103–106 as suggested 
by the lack of strong phenotypes in our loss-of-function experiments. In these lines, we have observed multiple 
common interactors between distinct E3 enzymes (Supplementary Fig. 12).
(lower panel) in UBR7 KD H9 hESCs after 10 days of neural differentiation. Graphs (relative expression to NT) 
represent the mean ± s.e.m. of three independent experiments. (f,g) Western blots of UBE3A and OCT4 (f) 
and RNF181 and OCT4 (g) protein levels. ß-actin is the loading control. The images are representative of two 
independent experiments. (h) Real-time PCR analysis of pluripotency (upper panel) and germ-layer markers 
(lower panel) in UBE3A and RNF181 KD H9 hESCs. Graphs (relative expression to NT shRNA) represent the 
mean ± s.e.m. of three independent experiments. (i) Western blot analysis after 10 days of neural induction 
of UBE3A and RNF181 KD H9 hESCs. ß-actin is the loading control. The images are representative of two 
independent experiments. (j) Immunocytochemistry after 10 days of neural differentiation. OCT4, PAX6, and 
DAPI staining were used as markers of pluripotency, neuroectodermal differentiation, and nuclei, respectively. 
Scale bar represents 20 μm. All the statistical comparisons were made by Student’s t-test for unpaired samples. 
P-value: *(P < 0.05), **P < 0.01, ***(P < 0.001), ****(P < 0.0001).
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Figure 8. Proteasome inhibition induces profound changes in the proteome of ESCs. (a) Chymotrypsin-like 
proteasome activity in H9 hESCs treated with 1 µM MG-132 for 24 h (relative slope to H9 hESCs treated with 
DMSO). Graph represents the mean ± s.d. of two independent experiments. Statistical comparisons were made by 
Student’s t-test for unpaired samples. P-value: **(P < 0.01). (b) Volcano plot of LFQ intensities in MG-132-treated H9 
hESCs as compared to control DMSO-treated hESCs. The significance of a two-tailed t-test is plotted against the log2 
fold change of LFQs (FDR = 0.2, s0 = 1). Proteasome inhibitor: 1 µM MG-132 for 24 h. (c) Common proteins between 
interacting partners of the E3 ubiquitin ligases and proteins up-regulated in hESCs upon proteasome inhibition. (d) 
Co-IP with HECTD1, RNF181 and FLAG antibodies in H9 hESCs followed by western blot against EXOC5 and 
PSMD3. (e) Western blot analysis with antibodies to EXOC5 and PSMD3 of MG-132-treated H9 hESCs. ß-actin 
is the loading control. The images are representative of three independent experiments. All cropped blots were run 
under the same experimental conditions. The original blots are included in Supplementary Fig. 13. (f) Common up-
regulated proteins between E3 knockdown hESCs and MG-132-treated hESCs. (g) Bar graph representing the top 
GOBPs of the up-regulated proteins upon proteasome inhibitor treatment (P < 0.05). (h) Bar graph representing the 
top GOBPs of the down-regulated proteins upon proteasome inhibitor treatment (P < 0.05).
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Another potential hypothesis is that enhanced proteasome activity of hESCs is not directly linked to the 
degradation of endogenous substrates. In this model, increased proteasome activity could be coupled with 
intrinsic characteristics of pluripotent stem cells. In support of this hypothesis, we observed a higher number 
of down-regulated proteins than increased proteins under proteasome inhibition (552 down-regulated versus 
347 up-regulated). To gain insight into the effects of proteasome dysfunction in hESCs, we performed GOBP 
term analysis of these altered proteins. Analysis of up-regulated proteins indicated strong enrichment for genes 
involved in proteasomal-mediated ubiquitin degradation, including numerous proteasome subunits (Fig. 8g and 
Supplementary Data 13). Among them, we found an up-regulation of the proteasome activator PSMD11/RPN613. 
Thus, these data suggest that hESCs trigger the expression of proteasome subunits as a compensatory mechanism 
to ameliorate the proteostasis decline induced by proteasome inhibition. In line with these results, we also found 
a marked up-regulation of proteins involved in chaperone-mediated protein folding and refolding (e.g., HSPA1A, 
DNAJC7, DNAJB1, HSPA8, HSPD1 and the stress-induced HSP90AA1), protein folding in the endoplasmic 
reticulum (ER) and ubiquitin-dependent ER-associated degradation (ERAD) (e.g., ERLIN2, VCP). Moreover, 
we found GOBP enrichment for regulators of stem cell differentiation, cell cycle and WNT signalling pathway 
(Fig. 8g and Supplementary Data 13). However, this enrichment was essentially due to increased levels of protea-
some subunits, which are well-known regulators of the aforementioned biological processes.
On the other hand, GOBP term analysis of down-regulated proteins upon MG-132 treatment revealed a strong 
enrichment for factors involved in different pathways linked with hESC maintenance (Fig. 8h and Supplementary 
Data 13). For instance, proteasome dysfunction induced downregulation of activators of ribosome biogene-
sis and translation (Fig. 8h), a process that may compensate the decline in proteolytic ability. However, these 
changes could also trigger differentiation as ESCs rely on enhanced expression of ribosomal subunits and global 
translational rates to sustain their self-renewal and pluripotency37,107. Moreover, ESCs produce high levels of 
pre-rRNA108 and we found a down-regulation of proteins involved in maturation of rRNA (TSR1, HEATR1, 
EMG1) (Fig. 8h). In addition, proteasome dysfunction decreased the levels of distinct modulators of mRNA 
transport such as the nuclear pore complex protein NUP153, which is required for ESC pluripotency109.
Notably, proteasome inhibition also induced the down-regulation of factors involved in telomere mainte-
nance and organization (e.g., RIF1, NOP10) (Fig. 8h), a key process for hESC maintenance110,111. Besides these 
changes, we found a decrease in the levels of multiple proteins involved in catabolic carbohydrate process (e.g., 
the glycogen phosphorylases PYGL/PYGB) as well as generation of precursor metabolites and energy (Fig. 8h). 
Remarkably, we observed a downregulation of hexokinase II (HK2), which is required for the high glycolytic rates 
of hESCs92. We also found a decrease in LIN28A (Supplementary Data 13), a core component of hESC identity 
that regulates the translation and stability of numerous mRNAs112–115, modulating key biological processes such 
as metabolism116. Thus, proteasome dysfunction impairs the protein levels of multiple factors involved in biolog-
ical processes required for hESC function, suggesting a potential link between enhanced proteasome and other 
determinants of hESC identity such as metabolism, RNA biogenesis and telomere maintenance.
Discussion
Pluripotent stem cells exhibit intrinsic high levels of proteasome activity12. Recent work demonstrates that this 
enhanced proteasome activity is essential for the striking ability of hESCs to maintain their proteostasis9,12,13,19. 
Besides this role in protein quality control, here we aimed to uncover additional molecular mechanisms by which 
proteasome activity regulates hESC function. First, we assessed whether increased proteasome is also required to 
regulate the concentration of endogenous targets in these cells by identifying highly-expressed E3 enzymes. Then, 
we characterized the interactome of the up-regulated E3 ligases and integrated these data with our proteomics 
experiments in E3-knockdown and proteasome inhibitor-treated hESCs. Unexpectedly, we identified a relatively 
low number of potential E3 substrates which were also increased upon proteasome inhibition. The difficulties in 
the identification of E3 substrates have been previously shown to be notoriously challenging117,118. First, protein 
ubiquitination is a highly dynamic process modulated by the coordinated action of E3 ligases and DUBs, which 
can remove the ubiquitin chains of E3 substrates. The balanced regulation of both competing processes could 
determine the fate of specific targets depending on the cellular status and environment. In this context, changes 
in the activity of specific DUBs could compensate the silencing of E3 enzymes. In a further level of complexity, 
DUBs can directly modulate the activity and turnover of E3 ligases119. Thus, a further understanding of the equi-
librium between DUB and E3 activities in proteasomal degradation of pluripotency factors is of central impor-
tance. Secondly, the interaction between the E3 ligases and the substrates is rapid and weak. Hence, this transient 
interaction will make it especially challenging to isolate the complex E3-substrate120. Finally, we believe that sig-
nificant degrees of redundancy and compensatory mechanisms among the E3 enzymes could be particularly rele-
vant for our study. A substrate may be ubiquitinated by multiple E3s in the same or different lysines and even one 
single protein might be ubiquitinated by distinct enzymes under different conditions or even within single cellu-
lar compartments121. E3 substrates can be modified with a single ubiquitin or chains of ubiquitin at one or multi-
ple sites. This variety in the ubiquitination generates a highly diverse topology of poly-ubiquitin chains, which not 
always targets the substrate towards degradation through the proteasome, but will have several different functions 
(i.e., intracellular signalling events)122. Thus, the interacting partners found in our proteomic analysis could not be 
substrates of the proteasome, but rather have their activity/function modified upon ubiquitination or simply be 
interacting proteins which might participate in an E3-containing protein complex. Nevertheless, our interactome 
analysis in hESCs may contribute to the understanding of the role of these E3 ubiquitin ligases.
In order to establish whether the E3 ubiquitin ligases have an impact on hESC identity, we silenced their 
expression and analysed stem cell pluripotency and differentiation capacities. However, we did not find a major 
effect on stem cell markers and their differentiation capacity upon loss of single E3 ubiquitin ligases. As men-
tioned above, that could be explained by potential functional redundancies between E3 ligases, as it has been 
previously shown for distinct E3s105. One example is the yeast transcriptional repressor alpha2, which can be 
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independently marked for proteasomal degradation by the E3 enzymes Doa10 and Slx5/Slx8106. Moreover, the 
E3 ligases SAN1 and UBR1 can independently regulate the chaperone-dependant ubiquitination of misfolded 
proteins in yeast103. In mammalian cells, the tumour suppressor p53 can be degraded through the action of many 
E3 ligases, such as COP1, WWP1, E4F1 and PIRH2, which provides an additional layer of complexity in the 
regulation of the UPS104. These redundant mechanisms could ensure proper degradation of a particular sub-
strate, even when one of the E3s might not be functional or overloaded by the number of targets to ubiquitinate. 
Furthermore, the different E3s might show subtle differences depending on their distinct subcellular localizations 
to enable intracellular-specific ubiquitination of the same substrate. Given the complex roles of E3s in maintain-
ing cellular homeostasis and development, pluripotent stem cells likely rely on a tight coordination of redundant 
and compensatory mechanisms to maintain their function. Thus, simultaneous deletion of distinct E3 ligases 
might be necessary to induce a strong demise in their pluripotency. In addition, we cannot discard that the lack of 
phenotype of E3-depleted hESCs ensues from the activation of other proteostatic pathways that counterbalance 
UPS disturbances. For instance, it has been demonstrated that inhibition of proteasome induces autophagy as a 
compensatory response, in a p62-mediated manner123,124.
In parallel to this approach, we also performed quantitative proteomic analysis of hESCs treated with protea-
some inhibitor. By integrating these data with our interactome and loss of function experiments for distinct E3 
ligases, we identified potential targets of the proteasome in hESCs. Most importantly, global proteasome inhibi-
tion experiments showed that besides its key role in maintaining proteostasis in hESCs, the proteasome is also 
coupled to other determinant biological processes of hESC identity, such as their intrinsic metabolism, RNA bio-
genesis and telomere maintenance. Overall, here we provide a comprehensive characterization of the UPS system 
in hESCs that could have important implications for a further understanding of these cells.
Experimental Procedures
hESCs culture and differentiation. The human H9 (WA09) and H1 (WA01) lines were obtained from 
WiCell Research Institute. H9 and H1 were maintained on Geltrex (ThermoFisher Scientific) using mTeSR1 
(Stem Cell Technologies). Undifferentiated hESCs colonies were passaged using a solution of dispase (2 mg ml−1) 
and scraping the colonies with a glass pipette. All the cell lines used in this study were tested for mycoplasma 
contamination at least once every three weeks and no mycoplasma contamination was detected. All research 
involving hESCs lines was performed with approval of the German Federal competent authority (Robert Koch 
Institute) and in accordance with the relevant guidelines and regulations.
Neural differentiation of H9 cell line was performed following the monolayer culture method as described 
previously125 with STEMdiff Neural Induction Medium (Stem Cell Technologies) on polyornithine (15 μg ml−1)/
laminin (10 μg ml−1)-coated plates. Undifferentiated hESCs were rinsed once with PBS and then we added 
1 ml Gentle Dissociation Reagent (Stem Cell Technologies) for 5 min. After incubation at 5 min, we gently col-
lected hESCs and 2 ml of Dulbecco’s Modified Eagle Medium (DMEM)-F12 + 10 μM ROCK inhibitor (Abcam). 
Afterward, we centrifuged cells at 300 g for 10 min. Cells were resuspended on STEMdiff Neural Induction 
Medium + 10 μM ROCK inhibitor and plated on polyornithine (15 μg ml−1)/laminin (10 μg ml−1)-coated plates. 
For neuronal differentiation, NPC at passage 4 were dissociated with Accutase (Stem Cell Technologies) and 
plated into neuronal differentiation medium (DMEM/ F12, N2, B27 (ThermoFisher Scientific), 1 mg ml−1 laminin 
(ThermoFisher Scientific), 20 ng ml−1 brain-derived neurotrophic factor (BDNF) (Peprotech), 20 ng ml−1 glial 
cell-derived neurotrophic factor (GDNF) (Peprotech), 1 mM dibutyryl-cyclic AMP (Sigma) and 200 nM ascorbic 
acid (Sigma)) onto polyornithine/laminin-coated plates. Cells were differentiated for 1 month, with weekly feed-
ing of neuronal differentiation medium. Endoderm differentiation of H9 hESCs was performed using STEMdiff 
Definitive Endoderm Kit (Stem Cell Technologies).
Cardiomyocyte differentiation of H1 hESCs was performed as described in ref.126. Confluent H1 hESCs were 
dissociated into single cells with Accutase at 37 °C for 10 min followed by inactivation using two volumes of F12/
DMEM. Cells were counted and 230,000 cells cm2 where plated in ITS medium (Corning), containing 1.25 mM 
CHIR 99021 (AxonMedchem) and 1.25 ng ml−1 BMP4 (R&D), and seeded on Matrigel-coated 24-well plates. 
After 24 h, medium was changed to TS (transferrin/selenium) medium. After 48 h, medium was changed to TS 
medium supplemented with 10 mM canonical Wnt-Inhibitor IWP-2 (Santa Cruz) for 48 h. Then, medium was 
changed to fresh TS until beating cells were observed at days 8–10. Finally, medium was changed to Knockout 
DMEM (ThermoFisher Scientific) supplemented with 2% FCS, L-Glutamine and Penicillin/Streptomycin until 
cells were used for downstream analysis.
Lentiviral infection of H9 hESCs. Lentivirus (LV)-non-targeting shRNA control, LV-UBR7 shRNA #1 
(TRCN0000037025), LV-UBR7 shRNA #2 (TRCN0000037026), LV-UBE3A shRNA #1 (TRCN0000419838), 
LV-UBE3A shRNA #2 (TRCN0000003368), LV-RNF181 shRNA #1 (TRCN0000364405) and LV-RNF181 
shRNA #2 (TRCN0000022389) in pLKO.1-puro vector were obtained from Mission shRNA (Sigma). For gen-
eration of stable hESCs transfected lines, H9 hESCs growing on Geltrex were incubated with 10 μM ROCK 
inhibitor for one hour and then individualized using Accutase. Fifty thousand cells were infected in suspension 
with 25 μL of concentrated virus in the presence of 10 μM ROCK inhibitor. Cell suspension was centrifuged to 
remove the virus and plated back on a feeder layer of mitotically inactivated MEF in CDF12 media contain-
ing ROCK inhibitor (DMEM/F12 plus 20% Knock-out Serum Replacement, β-mercaptoethanol (0.1%), 0.1 mM 
non-essential-aminoacids, Glutamax (1%), and 10 ng/mL bFGF). After few days in culture, cells were selected for 
lentiviral integration with 2 µg ml−1 puromycin (ThermoFisher Scientific) and remaining colonies were manually 
passaged onto fresh MEFs to establish new hESC lines.
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Generation of HERC2−/− hESCs by CRISPR/Cas9 system and colony analysis. HERC2 genomic 
sequence was obtained from ENSEMBL Genome browser. Two guide sequences (Guide A, targeting the intron 
4–5, F: CCTCAGTTTCTTCATCCATAAAAC, and R: CAGCACTGCTTGACAGTGCTGGG; Guide B, targeting 
the fifth exon, F: CCGTCCAGTCAGCCACCACCACC, and R: CAGCCCTGCGACTCAAGCAGAGG), were 
generated using the Zinc Finger Consortium online resource (http://zifit.partners.org/ZiFiT/). Guide-carrying 
plasmid were designed as previously described in refs127,128 using Cas9-puromycine selection plasmid 
(pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A) was a gift from Feng Zhang (Addgene plasmid # 42335)). 
H9 hESCs were plated on MEF-containing plates and transfected with 1 μg of each of the guide-carrying plas-
mids using FuGene HD (Promega). 24 h after the transfection, 0.5 μg ml−1 puromycine selection was performed 
for 24 h followed by maintenance of hESCs with CDF12 media. Single cell split was performed prior to col-
ony pick for genotyping. Genomic DNA isolation was done using QuickExtract (Epicentre). PCR using primer 
pairs surrounding HERC2 fifth exon was performed (Forward: TAGAGAGAGGCAGTGTGCCA, and Reverse: 
TGGCTGGCTTCCACAGTTAC) to identify HERC2−/− hESCs.
Immunoprecipitation of HERC2, HECTD1, RNF181, KCMF1 and UBR7 for interaction analysis. 
hESCs were lysed in RIPA buffer (50 mM Tris-HCl (pH 6.7), 150 mM NaCl, 1% Triton x-100, 1% sodium deox-
ycholate, 1 mM EDTA, 1 mM PMSF) and supplemented with protease inhibitor (Roche). Lysates were homoge-
nized through syringe needle (27 G) and centrifuged at 13,000 g for 15 min at 4 °C. For RNase A-treated samples, 
the supernatant was incubated with 125 µl ml−1 RNAse A (ThermoFischer) for one hour on ice. Otherwise, 
incubation with the antibody was performed. 330 µg of protein-containing samples were incubated for 30 min-
utes with HERC2 antibody (Abcam, # ab85832, 4 µg) or UBR7 antibody (Thermo Scientific, # PA5-31559, 4 µg) 
or KCMF1 antibody (Abcam, # ab80287, 4 µg) or RNF181 antibody (Thermo Scientific, PA5-31008, 4 µg) or 
HECTD1 antibody (Abcam, #ab101992, 4 µg) on ice. As a control, the same amount of protein was incubated with 
anti-FLAG antibody (SIGMA, F7425, 4 µg). Subsequently samples were incubated with 100 µl of µMACS Micro 
Beads for 1 h at 4 °C with overhead shaking. After incubation, samples were loaded to precleared µMACS column 
(# 130-042-701). Beads were washed three times with 50 Mm Tris (pH 7.5), 150 mM NaCl, 5% glycerol, 0.05% 
Triton and then five times with 50 Mm Tris (pH 7.5) and 150 mMNaCl. For elution of the proteins for further 
Western Blot analysis, the beads were incubated with 50 µl of pre-heated (95 °C) 1X Laemmli Buffer for 5 minutes 
and collected into eppendorf tubes. The samples were boiled for 5 minutes at 95 °C and loaded in a SDS-PAGE gel. 
In Supplementary Fig. 4, we also show flow-through controls, that correspond to the supernatant that remains 
after centrifuging the tubes containing the antibody as well as the beads. For proteomics analysis, after the washes 
we performed partial digestion on the beads using 25 µl of 2 M Urea in 25 mM Tris, 7.5 Mm ammonium bicarbo-
nate, 1 mM DTT and 5 ng/ml trypsin, pH = 8.0 for 30 minutes at room temperature. The samples were then eluted 
twice with 50 µl of 2 M Urea, 25 mM Tris, 7.5 mM ammonium bicarbonate, 5 mM Iodacetamide and left for fully 
digestion overnight at room temperature in the dark. For stopping the digestion, 5 µl of 100% formic acid was 
added to samples. Peptides were cleaned up using stage tip extraction129.
Immunoprecipitation of UBE3A for interaction analysis. hESCs were lysed in RIPA buffer (50 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton x-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM 
PMSF) supplemented with protease inhibitor (Roche). Lysates were homogenized through syringe needle (27 G) 
and centrifuged at 13,000 g for 15 min at 4 °C. After preclearing the supernatant with Protein A agarose beads 
(Pierce), the samples were incubated overnight with UBE3A antibody (Cell Signaling, # 7526 1:50) on the over-
head shaker at 4 °C. As a control, the same amount of protein was incubated with anti-FLAG antibody (SIGMA, 
F7425, 1:50) in parallel. Subsequently, samples were incubated with 30 µl of Protein A beads for 1 h at room tem-
perature. After this incubation, samples were centrifuged 5 minutes at 5,000 g at room temperature and the pellet 
was washed three times with the RIPA buffer. For elution of the proteins for further western blot analysis, the 
pellet was incubated with pre-heated (95 °C) 2X Laemmli Buffer, boiled for 5 minutes and centrifuged 5 minutes at 
maximum speed. The supernatant was taken and loaded in a SDS-PAGE gel. For further proteomics analysis, after 
the washing steps, partial digestion of the proteins was performed on the agarose beads using 25 µl of 2 M Urea in 
25 mM Tris, 7.5 mM ammonium bicarbonate, 1 mM DTT and 5 ng/ml trypsin, pH = 8.0 for 30 minutes at room 
temperature. Then, the samples were eluted 2 times with 50 µl of 2 M Urea, 25 mM Tris, 7.5 mM AmBic 5 mM 
Iodacetamide and were fully digested overnight at room temperature in the dark. For stopping the digestion, 5 µl 
of 100% formic acid was added to the samples. Peptides were cleaned up using stage tip extraction129.
Sample preparation for quantitative proteomics and analysis. For analysis of MG132 inhibited cells 
and hESCs, NPC and neurons we performed tandem mass tag (TMT) proteomics. Cells were collected in 8 M urea 
buffer, 50 mM ammonium bicarbonate, homogenized with a syringe and cleared using centrifugation (16,000 g, 
20 min). Supernatants were reduced by addition of DTT to a final concentration of 5 mM and incubated at room 
temperature for 30 minutes. Iodoacetamide was added to the samples to a final concentration of 5 mM to alkylate 
the cysteines and incubated in the dark for 45 minutes. Lys-C (Wako, Richmond, VA) was added for digestion at 
a ratio 1:100 enzyme/substrate and incubated for three hours at room temperatures. Then, lysates were diluted 
to 2 M Urea with 50 mM ammonium bicarbonate, after which 10 ng μl−1 Trypsin was added and incubated over-
night at room temperature. Trypsin digestion was stopped by addition of formic acid and peptides were cleaned 
up using stage tip extraction129. The liquid chromatography tandem mass spectrometry (LC-MS/MS) equipment 
consisted out of an EASY nLC 1000 coupled to the quadrupole based QExactive instrument (Thermo Scientific) 
via a nano-spray electroionization source. Peptides were separated on an in-house packed 50 cm column (1.9 µm 
C18 beads, Dr. Maisch) using a binary buffer system: A) 0.1% formic acid and B) 0.1% formic acid in ACN. The 
content of buffer B was raised from 7% to 23% within 120 min and followed by an increase to 45% within 10 min. 
Then, within 5 min buffer B fraction was raised to 80% and held for further 5 min after which it was decreased 
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to 5% within 2 min and held there for further 3 min before the next sample was loaded on the column. Eluting 
peptides were ionized by an applied voltage of 2.2 kV. The capillary temperature was 275 °C and the S-lens RF level 
was set to 60. MS1 spectra were acquired using a resolution of 70,000 (at 200 m/z), an Automatic Gain Control 
(AGC) target of 3e6 and a maximum injection time of 20 ms in a scan range of 300–1750 Th. In a data dependent 
mode, the 10 most intense peaks were selected for isolation and fragmentation in the HCD cell using a normal-
ized collision energy of 25 at an isolation window of 2.1 Th. Dynamic exclusion was enabled and set to 20 s. The 
MS/MS scan properties were: 17.500 resolution at 200 m/z, an AGC target of 5e5 and a maximum injection time 
of 60 ms. All label-free proteomics data sets were analysed with the MaxQuant software130 (release 1.5.3.8). We 
employed the LFQ mode131 and used MaxQuant default settings for protein identification and LFQ quantifica-
tion. All downstream analyses were carried out on LFQ values with Perseus (v. 1.5.2.4)132.
Quantitative proteomics analysis of E3 enzymes. For the characterization of protein expression dif-
ferences in E3 enzymes comparing H9 hESCs with their neuronal counterparts, we analysed the quantitative 
proteomics data published in ref.9. Statistical comparisons were made by Student’s t-test. Discovery Rate (FDR) 
adjusted p-value (q-value) was calculated using the Benjamini–Hochberg procedure. All the proteins at a FDR 
level below 0.2 were retained as significantly differentially expressed (Supplementary Data 1). Then, we inter-
sected the human E3 network annotated in133 with this proteomics dataset (Supplementary Table 1).
RNA sequencing. Total RNA was extracted using RNAbee (Tel-Test Inc.). Libraries were prepared using 
the TruSeq Stranded mRNA Library Prep Kit. Library preparation started with 1 µg total RNA. After selection 
(using poly-T oligo-attached magnetic beads), mRNA was purified and fragmented using divalent cations under 
elevated temperature. The RNA fragments underwent reverse transcription using random primers followed by 
second strand cDNA synthesis with DNA Polymerase I and RNase H. After end repair and A-tailing, indexing 
adapters were ligated. The products were then purified and amplified (20 µl template, 14 PCR cycles) to cre-
ate the final cDNA libraries. After library validation and quantification (Agilent 2100 Bioanalyzer), equimolar 
amounts of library were pooled. The pool was quantified by using the Peqlab KAPA Library Quantification Kit 
and the Applied Biosystems 7900HT Sequence Detection System. The pool was sequenced on an Illumina HiSeq. 
4000 sequencer with a paired- end (2 × 75 bp) protocol. We used the human genome sequence and annotation 
(EnsEMBL 79) together with the splice-aware STAR read aligner134 (release 2.5.1b) to map and assemble our 
reference transcriptome. Subsequent transcriptome analyses on differential gene and transcript abundance were 
carried out with the cufflinks package135.
Western Blot. Cells were scraped from tissue culture plates and lysed in non-denaturing lysis buffer (10 mM 
Tris-HCL, pH 7.4, 10 mM EDTA, 50 mM NaCl, 50 mM NaF, 1% Triton X-100, 0.1%SDS, supplemented with 2 mM 
sodium orthovanadate, 1 mM PMSF and protease inhibitor (Roche)) and homogenized through a syringe needle 
(27 G). Cell lysates were centrifuged at 15,000 g for 15 min at 4 °C and protein concentration was measured from 
the supernatant using BCA protein assay (Thermo Scientific). Approximately 30 μg of total protein was separated 
by SDS–PAGE, transferred to PVDF membranes (Millipore) and subjected to immunoblot. Western blot analysis 
was performed with anti-HERC2 antibody (Abcam, # ab85832 1:2000), anti- UBR7 antibody (Thermo Scientific, 
# PA5-31559 1:2000), anti- KCMF1 antibody (Abcam, # ab80287, 1:3000), anti-RNF181 antibody (Thermo 
Scientific, PA5-31008, 1:2000), anti- HECTD1 antibody (Abcam, #ab101992, 1:1000), anti-UBE3A antibody (Cell 
Signaling, # 7526 1:1000), anti-RNF40 (Cell Signaling, #12187, 1:1000), anti-HUWE1 (Cell Signaling, #5695, 
1:1000) anti-TRIM33 (Cell Signaling, #13387, 1:1000), anti-STUB1 (Cell Signaling, #2080, 1:1000), anti-OCT4 
(Abcam, #ab19857, 1:5000), anti-SOX2 (Abcam, #97959, 1:1000), anti-PAX6 (Stem Cell Technologies, #60094, 
1:1000), anti-NESTIN (Stem Cell Technologies, # 60091, 1:1000), anti-PSMD3 (Proteintech, # 12054-1-AP, 
1:1000), anti-EXOC5 (Proteintech, # 17593-1-AP, 1:1000) and anti-ß-actin (Abcam, #8226, 1:10000). Uncropped 
versions of western blots are presented in Supplementary Fig. 13.
Immunocytochemistry. Cells were fixed with paraformaldehyde (4% in PBS) for 20 min, followed by 
permeabilization (0.2% Triton X-100 in PBS for 10 min) and blocking (3% BSA in 0.2% Triton X-100 in PBS 
for 10 min). Human cells were incubated in primary antibody for 1,5 h at room temperature with anti-OCT4 
(Stem Cell Technology, #60093, 1:200), anti-PAX6 (Stem Cell Technology, #60094, 1:300) or anti-SOX1 (Stem 
Cell Technology, #60095, 1:100). Then, cells were washed with PBS and incubated with secondary antibody 
(Alexa Fluor 488 goat anti-mouse (Thermo Fisher Scientific, A-11029), Alexa Fluor 568 F(ab’)2 Fragment of Goat 
Anti-Rabbit IgG (H + L) (Life Technologies, #A21069) and DAPI (Life Technologies, #1306) for 45 minutes at 
room temperature. PBS and distilled water wash were followed before the cover slips were mounted on Mowiol 
(Sigma, #324590).
RNA isolation and quantitative RT–PCR. Total RNA was isolated using RNAbee (Tel-Test Inc.). cDNA 
was generated from 1 μg of RNA using qScript Flex cDNA synthesis kit (Quantabio). SybrGreen real-time qPCR 
experiments were performed with a 1:20 dilution of cDNA using a CFC384 Real-Time System (Bio-Rad) follow-
ing the manufacturer’s instructions. Data were analysed with the comparative 2ΔΔCt method using the geomet-
ric mean of ACTB and GAPDH as housekeeping genes. See Supplementary Information for details about the 
primers used for this assay.
26S proteasome fluorogenic peptidase assays. The in vitro assay of 26 S proteasome activities was 
performed as previously described136. Cells were collected in proteasome activity assay buffer (50 mM Tris-HCl, 
pH7.5, 250 mM sucrose, 5 mM MgCl2, 0.5 mM EDTA, 2 mM ATP and 1 mM DTT) and lysed by passing ten times 
through syringe needle (27 G). Then, lysate was centrifuged at 10,000 g for 10 min at 4 °C. 25 μg of total protein of 
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cell lysates were transferred to a 96-well microtiter plate (BD Falcon) and incubated with the fluorogenic substrate 
Z-Gly-Gly-Leu-AMC (Enzo Lifescience). Fluorescence (380 nm excitation, 460 nm emission) was monitored on 
a microplate fluorometer (EnSpire, Perkin Elmer) every 5 min for 2 h at 37 °C.
Data availability. All the mass spectrometry proteomics data as well as the transcriptomic data are available 
in the Supplementary Information. All the other data are also available from the corresponding author upon 
request.
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Supplementary Figure 1 
 
 
 
 
 
 
Supplementary Figure 1. Analysis of E3 protein levels in H1 hESCs. Western blot with 
antibodies against HECTD1, HERC2, KCMF1, RNF181 and UBR7 comparing H1 hESCs with 
their neural (NPC) counterparts. ß-actin is the loading control. 
  
 
Supplementary Figure 2 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Analysis of TRIM33 protein levels in H9 hESCs. Western blot 
with antibody against TRIM33 comparing H9 hESCs with their differentiated neural (NPC) 
and neuronal counterparts. ß-actin is the loading control. Although two independent 
experiments showed a decrease in TRIM33 levels during neuronal differentiation as we 
observed in our proteomics analysis, this downregulation was not consistent in other neural 
differentiation experiments (please see Fig. 1a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3 
 
 
 
 
 
Supplementary Figure 3. Proteasome inhibition does not change protein levels of the 
tested E3 ligases. Western Blot analysis with antibodies against the indicated E3 enzymes of 
(a) H9 hESCs and (b) terminally differentiated neurons upon proteasome inhibition. Cells were 
treated with 1 µM MG132 for 16 h. ß-actin is the loading control. The images are representative 
of at least two independent experiments. All cropped blots were run under the same 
experimental conditions.   
  
Supplementary Figure 4 
 
 
 
 
 
Supplementary Figure 4. Flow-through controls indicate significant immunoprecipitation 
of endogenous E3 enzymes. Co-immunoprecipitation (co-IP) with HERC2, HECTD1, 
UBE3A, RNF181 and FLAG antibodies from H9 hESCs followed by western blot against the 
respective E3 ubiquitin ligases. We loaded the same amount of total input and flow-through 
(8% of the sample) for direct comparison. We loaded 20% of total immunoprecipitated sample. 
The images are representative of two independent experiments.  
  
 Supplementary Figure 5 
 
 
 
Supplementary Figure 5. Significant enriched proteins upon co-immunoprecipitation 
with HERC2 antibody under standard conditions (no RNase treatment). (a) Volcano plot 
of the interactome of HERC2 in H9 hESCs under standard immunoprecipitation conditions (n= 
4). Graph represents the –log (p-value) of a two-tailed t-test plotted against the log2 ratio of 
protein label-free quantification (LFQ) values from co-IP experiments with HERC2 antibody 
compared to control co-IP with FLAG antibody. Red colored dots indicate the most enriched 
interacting proteins after correction for multiple testing (FDR <0.2, s0=0.1). (b) Bar graph 
representing the top GOBPs of HECTD1 interactome (P<0.05). 
Supplementary Figure 6 
 
 
 
 
 
 
Supplementary Figure 6. Venn diagram represents total number and common significant 
interactors in hESCs and their differentiated neuronal counterparts (FDR <0.2 was considered 
significant, hESCs (n= 4) and neurons (n= 3). 
  
Supplementary Figure 7 
 
 
 
 
 
 
Supplementary Figure 7. Loss of UBR7 does not affect differentiation of hESCs into 
definitive endoderm. Real-time PCR analysis of endodermal markers in UBR7 KD H9 hESCs 
after definitive endodermal differentiation. Graphs (relative expression to NT) represent the 
mean ± s.e.m. of two independent experiments. Statistical comparisons were made by Student’s 
t-test for unpaired samples. 
 
 
  
Supplementary Figure 8 
 
 
 
 
 
 
Supplementary Figure 8. Analysis of neural markers upon differentiation of UBE3A and 
RNF181 KD hESCs. Real-time PCR analysis of pluripotency (upper panel) and 
neuroectodermal markers (lower panel) in UBE3A and RNF181 KD H9 hESCs after 10 days 
of neural differentiation. Graphs (relative expression to NT) represent the mean ± s.e.m. of two 
independent experiments. Statistical comparisons were made by Student’s t-test for unpaired 
samples. P-value: *P<0.05, ***P<0.001. 
 
  
Supplementary Figure 9 
 
 
 
 
Supplementary Figure 9. Loss of UBE3A and RNF181 does not affect differentiation of 
hESCs into definitive endoderm. Real-time PCR analysis of endodermal markers in UBE3A 
(upper panel) and RNF181 (lower panel) KD H9 hESCs after definitive endodermal 
differentiation. Graphs (relative expression to NT) represent the mean ± s.e.m. of two 
independent experiments. Statistical comparisons were made by Student’s t-test for unpaired 
samples.  
  
Supplementary Figure 10 
 
 
 
 
Supplementary Figure 10. Label-free quantification (LFQ) of 2735 proteins reveals partial 
separation of MG-132-treated H9 hESCs and control DMSO-treated H9 hESCs (n= 6). 
Proteins (rows) and samples (columns) are clustered according to euclidean distance (red= 
low, green= high abundance). Proteasome inhibitor: 1 µM MG-132 for 24 h. 
Supplementary Figure 11 
 
 
 
 
 
 
Supplementary Figure 11. Proteasome inhibition results in increased levels of PSMD3 and 
EXOC5. Quantification of the western blots presented in Figure 8e. The graph represents the 
relative percentage values to DMSO-treated H9 of PSMD3 and EXOC5 corrected for β-actin 
loading control (mean ± s.e.m. of three independent experiments). Statistical comparisons were 
made by Student’s t-test for unpaired samples. P-value: *P<0.05. 
 
 
 
 
  
Supplementary Figure 12 
 
 
 
 
 
 
Supplementary Figure 12. Schematic network showing proteins that interact with at least 
two of the tested E3 enzymes. 
  
Supplementary Figure 13 
 
 
 
 
 
Supplementary Figure 13. Uncropped images of western blots experiments. Uncropped 
images are presented with molecular weight ladders. 
 
 
 
 
 
  
 
Supplementary Table 1. List of E3 ubiquitin ligases increased in hESCs compared with 
their neuronal counterparts. Statistical comparisons were made by Student’s t-test (n= 6). 
False Discovery Rate (FDR) adjusted p-value (q-value) <0.2 was considered significant. Up-
regulated E3s in hESCs are ranked according to the q-value.   
Protein 
names Domain
hESCs vs 
Neurons
(fold 
enrichment)
-Log p-value q-value
Differences 
supported by 
Western blot
FBXO22 RING 1.85 5.43 0 Not tested
KLHL4 RING 2.22 5.69 0 Not tested
TRIM24 RING 1.42 8.01 0 Not tested
TRIM28 RING 1.26 11.20 0 Not tested
TRIP12 HECT 2.08 7.,20 0 Not tested
UBR5 HECT 2.98 6.99 0 Not tested
IVNS1ABP RING 3.20 4.01 0.0000124 Not tested
KLHL7 RING 1.72 4.26 0.0000136 Not tested
RBX1 RING 1.01 5.54 0.0000138 Not tested
TRIM33 RING 1.31 4.81 0.0000139 NO
PPIL2 RING 1.96 4.28 0.0000145 Not tested
UHRF1 RING 2.42 3.71 0.0000180 Not tested
SKP2 RING 1.77 3.86 0.0000242 Not tested
KEAP1 RING 2.69 3.31 0.0000380 Not tested
ARIH2 RING 0.79 4.94 0.0000506 Not tested
UBR7 RING 2.28 3.08 0.0000536 YES
RBBP6 RING 2.81 2.66 0.0000964 Not tested
ZNF598 RING 1.55 2.80 0.000143 Not tested
UBE4B RING 0.89 3.33 0.000191 Not tested
TRIM65 RING 1.46 2.51 0.000283 Not tested
UBE3A HECT 0.63 3.64 0.000345 YES
RNF2 RING 0.67 3.07 0.000645 Not tested
NOSIP RING 0.69 2.96 0.000680 Not tested
TRIM56 RING 1.21 1.96 0.00139 Not tested
RNF40 RING 0.43 3.48 0.00166 YES
RNF20 RING 0.38 3.37 0.00285 Not tested
HERC2 HECT 0.79 1.91 0.00288 YES
RNF181 RING 1.53 1.53 0.00307 YES
HECTD1 HECT 0.55 2.61 0.00367 YES
KCMF1 RING 0.73 1.83 0.00379 YES
RNF138 RING 1.15 0.77 0.0468 Not tested
KCTD15 RING 0.59 0.79 0.0645 Not tested
BRAP RING 0.78 0.71 0.0702 Not tested
TRAF2 RING 0.25 1.08 0.0934 Not tested
HUWE1 HECT 0.12 2.45 0.162 YES
Primers for Real Time PCR used in this study 
 
Gene Primer sequence 
HERC2 F GCCTTACACGCAGCCATTACT 
HERC2 R TTCCTTCTGTGCTTCTTTTTTGG 
UBE3A F GACTCAAAGTTAGACGTGACCATATCA 
UBE3A R CTTCAAGTCTGCAGGATTTTCCA 
UBR7 F TGCCGGCTCTAGTTCTGAATC 
UBR7 R TTCTGCGTTGAGGCTTTCATT 
KCMF1 F GCCCCTAGAGATTTAGATGAATCG 
KCMF1 R CCCGGCCAGGGTGAAA 
RNF181 F CCTTGCCATCACCTTTTCCA 
RNF181 R GGACAGGAATTTGTCTTGCTTAGC 
HECTD1 F CAACAATTGTAAGTCTGCTCTCAACA 
HECTD1 R TCACCCTGCAATGCACTTTC 
TRIM33 F CACAGCCTACAAGCACCATGA 
TRIM33 R TGTGAGAATTGGATAAACCTGATGA 
RNF40 F CTCCCACCTGCGACACATC 
RNF40 R CCTCTGTGCGTAGCTTCTTCTG 
HUWE1 F CACAAGAAGGAGAGGAAATGGAA 
HUWE1 R AGTGCTGCTCGTTGTGGAATAC 
GAPDH F GCACCGTCAAGGCTGAGAAC 
GAPDH R GGATCTCGCTCCTGGAAGATG 
ACTIN F CTGGCACCCAGCACAATG 
ACTIN R CCGATCCACACGGAGTACTTG 
 
OCT4 F GGAGGAAGCTGACAACAATGAAA 
OCT4 R GGCCTGCACGAGGGTTT 
NANOG F AAATCTAAGAGGTGGCAGAAAAACA 
NANOG R GCCTTCTGCGTCACACCATT 
SOX 2 F TGCGAGCGCTGCACAT 
SOX 2 R TCATGAGCGTCTTGGTTTTCC 
DPPA4 F CTGGTGCCAACAATTGAAGCT 
DPPA4 R AGGCACACAGGCGCTTATATG 
MSX1 F CTCCGCAAACACAAGACGAAC 
MSX1 R CACATGGGCCGTGTAGAGTC 
GATA4 F TCCGTGTCCCAGACGTTCTC 
GATA4 R GAGAGGACAGGGTGGATGGA 
GATA6 F AGCGCGTGCCTTCATCA 
GATA6 R GTGGTAGTTGTGGTGTGACAGTTG 
ALBUMIN F TGAGGTTGCTCATCGGTTTAAA 
ALBUMIN R GCAATCAACACCAAGGCTTTG 
PAX6 F CATACCAAGCGTGTCATCAATAAAC 
PAX6 R TGCGCCCATCTGTTGCT 
NESTIN F TGAAGGGCAATCACAACAGG 
NESTIN R TGACCCCAACATGACCTCTG 
MAP2 F AAAGAAGCTCAACATAAAGACCAGACT 
 
MAP2 R GTGGAGAAGGAGGCAGATTAGC 
 
SOX1 F GCTGACACCAGACTTGGGTT 
SOX1 R GTGCTTGGACCTGCCTTACT 
TUJ1 F GGCCAAGTTCTGGGAAGTCA 
TUJ1 R CGAGTCGCCCACGTAGTTG 
SOX17 F TGGCGCAGCAGAATCCA 
SOX17 R CGACTTGCCCAGCATCTTG 
CD117 F CCAAGGCCGACAAAAGGA 
CD117 R GGCGGGAGTCACATCTCTTTC 
CDXR4 F GGCCGACCTCCTCTTTGTC 
CDXR4 R TTGCCACGGCATCAACTG 
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The ubiquitin ligase UBR5 suppresses proteostasis
collapse in pluripotent stem cells from
Huntington’s disease patients
Seda Koyuncu 1, Isabel Saez1, Hyun Ju Lee1, Ricardo Gutierrez-Garcia1, Wojciech Pokrzywa1,2, Azra Fatima1,
Thorsten Hoppe 1 & David Vilchez 1
Induced pluripotent stem cells (iPSCs) undergo unlimited self-renewal while maintaining their
potential to differentiate into post-mitotic cells with an intact proteome. As such, iPSCs
suppress the aggregation of polyQ-expanded huntingtin (HTT), the mutant protein under-
lying Huntington’s disease (HD). Here we show that proteasome activity determines HTT
levels, preventing polyQ-expanded aggregation in iPSCs from HD patients (HD-iPSCs). iPSCs
exhibit high levels of UBR5, a ubiquitin ligase required for proteasomal degradation of both
normal and mutant HTT. Conversely, loss of UBR5 increases HTT levels and triggers polyQ-
expanded aggregation in HD-iPSCs. Moreover, UBR5 knockdown hastens polyQ-expanded
aggregation and neurotoxicity in invertebrate models. Notably, UBR5 overexpression induces
polyubiquitination and degradation of mutant HTT, reducing polyQ-expanded aggregates in
HD-cell models. Besides HTT levels, intrinsic enhanced UBR5 expression determines global
proteostasis of iPSCs preventing the aggregation of misfolded proteins ensued from normal
metabolism. Thus, our ﬁndings indicate UBR5 as a modulator of super-vigilant proteostasis of
iPSCs.
DOI: 10.1038/s41467-018-05320-3 OPEN
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As the origin of multicellular organisms, a series of cellularquality control mechanisms must operate at high ﬁdelityin pluripotent stem cells1. In culture, embryonic stem cells
(ESCs) derived from blastocysts do not undergo senescence and
can replicate indeﬁnitely while maintaining their capacity to
differentiate into all cell lineages2. Alternatively, somatic cells can
be reprogrammed to generate induced pluripotent stem cells
(iPSCs), which are similar to ESCs in many respects, such as their
gene expression, potential for differentiation and ability to
replicate continuously3. This unlimited self-renewal capacity
requires stringent quality control mechanisms, including
increased DNA damage responses and antioxidant defense
systems1,4–7. Growing evidence indicates that pluripotent stem
cells also have intrinsic mechanisms to maintain the integrity of
the proteome, a critical process for organismal development and
cell function7–9. Hence, deﬁning the mechanisms of super-
vigilant proteostasis in these cells is of central importance.
The proteostasis network is formed by multiple integrated
processes that control the concentration, folding, location and
interactions of proteins from their synthesis through their
degradation10. Defects in proteostasis lead to the accumulation of
damaged, misfolded and aggregated proteins that may alter the
immortality of pluripotent stem cells. During the asymmetric
divisions invoked by these cells, the passage of damaged proteins
to progenitor cells could compromise organismal development
and aging. Thus, pluripotent stem cells have a tightly regulated
proteostasis network linked with their intrinsic characteristics and
biological function1,7. While ESC identity requires enhanced
global translational rates11, these cells also exhibit high levels of
distinct chaperones to assure proper protein folding5,9. For
instance, ESCs have increased assembly of the TRiC/CCT (T-
complex protein-1 (TCP-1) ring complex)/(chaperonin contain-
ing TCP-1) complex12, a chaperonin that facilitates the folding of
approximately 15% of the proteome and reduces the aggregation
of disease-related mutant proteins13. To terminate damaged
proteins, ESCs possess a powerful proteolytic machinery induced
by high levels of PSMD11/RPN614–16, a scaffolding subunit that
promotes the assembly of active proteasomes16,17.
Remarkably, pluripotent stem cells are able to maintain enhanced
proteostasis while proliferating indeﬁnitely in their undifferentiated
state1,7,8. However, the differentiation process triggers a rewiring of
the proteostasis network that reduces their ability to sustain pro-
teome integrity7–9. In addition, post-mitotic and progenitor cells as
well as somatic stem cells undergo a progressive decline in their
protein folding and clearance activities with age8,18,19. This demise
of proteostasis is linked with the onset of age-related disorders such
as Alzheimer’s, Parkinson’s and Huntington’s disease (HD)10,18. On
the other hand, the proteostasis network of somatic cells is rewired
during cell reprogramming to generate iPSCs with high assembly of
active TRiC/CCT and proteasome complexes, resembling
ESCs9,12,16,20.
HD is a fatal neurodegenerative disorder characterized by cog-
nitive deﬁcits, psychosis and motor dysfunction. The disease is
inherited in a dominant manner and caused by mutations in the
huntingtin (HTT) gene, which translates into an expanded poly-
glutamine stretch (polyQ)21. The wild-type HTT gene encodes a
large protein of approximately 350 kDa that contains 6–35 polyQ
repeats. In individuals affected by HD, HTT contains greater than
35 polyQ repeats21. Although loss of normal HTT function could
also be a determinant of HD22, the dominant inheritance pattern of
the disease and numerous experiments in model organisms indicate
that gain of function of mutant HTT is toxic and induces
neurodegeneration21,23,24. PolyQ-expanded HTT is prone to
aggregation, and the accumulation of mutant HTT ﬁbrils as well as
intermediate oligomers formed during the aggregation/disaggrega-
tion process contributes to neurodegeneration21,23,24. The longer
the polyQ-expanded repeat, the earlier HD symptoms (e.g., neu-
rodegeneration) typically appear21. However, the length of the
pathological polyQ does not affect survival, self-renewal and plur-
ipotency of iPSCs derived from HD patients (HD-iPSCs), which
can proliferate indeﬁnitely as control iPSCs25,26. Moreover, HD-
iPSCs do not accumulate polyQ-expanded inclusions12,25,27. These
ﬁndings indicate that iPSCs have increased mechanisms to main-
tain proteostasis of mutant HTT. Once differentiated into neural
progenitors and neurons, these cells exhibit HD-associated phe-
notypes such as altered gene expression, increased vulnerability to
excitotoxic stressors and cumulative risk of death over time25,28.
However, HD neurons lack polyQ aggregates and robust
neurodegeneration phenotype12,25,27, supporting a proteostasis-
rejuvenating process during cell reprogramming that allows
for HD-iPSC differentiation into neurons with an intact proteome.
Although cumulative evidence indicates a strong link between
HD-related changes and proteasomal dysfunction29, the
mechanisms by which the proteasome recognizes polyQ-
expanded HTT are poorly understood. With the high levels of
proteasome activity exhibited by iPSCs16, we ask whether these
cells have an intrinsic E3 ubiquitin ligase network to regulate
proteostasis of polyQ-expanded HTT. We ﬁnd that iPSCs have
increased levels of UBR5, a HECT domain E3 enzyme that pro-
motes proteasomal degradation of both mutant and wild-type
HTT. Notably, an impairment of mutant HTT levels induced by
UBR5 downregulation triggers the accumulation of polyQ-
expanded aggregates in HD-iPSCs. Prompted by these ﬁndings,
we examine whether modulation of UBR5 impinges on polyQ-
expanded aggregation in distinct models. Since HD iPSC-derived
neurons lack aggregates even upon proteasome inhibition,
we assess Caenorhabditis elegans and human cells lines
that accumulate polyQ-expanded aggregates. We ﬁnd that loss of
UBR5 worsens polyQ-expanded aggregation and neurotoxicity in
C. elegans models. Notably, ectopic expression of UBR5 is sufﬁ-
cient to promote polyubiquitination of HTT, resulting in
decreased levels and aggregation of mutant HTT in human cell
models. Thus, we identify UBR5 as a potential modulator of HTT
proteostasis by studying immortal pluripotent stem cells.
Results
The proteasome suppresses mutant HTT aggregation in iPSCs.
iPSCs derived from HD patients do not accumulate polyQ-
expanded HTT aggregates12,27. Since pluripotent stem cells
exhibit high proteasome activity16, we assessed whether this
activity is required to prevent mutant HTT aggregation in iPSCs
generated from two individuals with juvenile-onset HD (i.e., Q71
and Q180)25 (Supplementary Table 1). Indeed, downregulation of
proteasome activity triggered accumulation of mutant HTT
aggregates, which were mostly located in the cytoplasm (Fig. 1a
and Supplementary Fig. 1a–b). Although the size of aggregates
was generally smaller in iPSCs that express longer polyQ repeats
(Q180), these cultures exhibited a higher percentage of aggregate-
containing cells (Fig. 1a). Moreover, proteasome inhibition also
induced a high percentage of mutant HTT aggregation in iPSCs
derived from an individual with adult-onset HD (Q57) (Supple-
mentary Fig. 1c–d). On the contrary, we did not detect accu-
mulation of polyQ aggregates in three distinct control iPSCs upon
proteasome inhibition (Fig. 1a and Supplementary Fig. 1e).
Likewise, proteasome inhibition did not induce HTT aggregation
in two isogenic counterparts of the Q180-iPSC line (Supple-
mentary Fig. 2), in which the 180 CAG expansion was corrected
to a nonpathological repeat length30.
To further examine the link between proteasome activity and
polyQ-expanded aggregation in iPSCs, we tested different
concentrations of proteasome inhibitor. Lower concentrations
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reduced approximately 50% of the proteasome activity, which was
sufﬁcient to induce mutant HTT aggregation as assessed by both
ﬁlter trap and immunoﬂuorescence experiments (Fig. 1b–d and
Supplementary Fig. 3). Since these analyses were performed in
iPSCs treated with proteasome inhibitor for 12 h, we examined
whether this treatment reduces cell viability, a process that could
trigger proteostasis collapse and, in turn, dysregulation of protein
aggregation. Whereas different concentrations of proteasome
inhibitor resulted in polyQ-expanded aggregation (Fig. 1c, d),
only higher concentrations induced a mild increase (∼8%) in cell
death (Fig. 1e). In addition, we found accumulation of mutant
HTT aggregates at an earlier time point (4 h) of the proteasome
inhibition treatment when higher concentrations did not trigger
cell death (Fig. 1d, e). Thus, these results indicate that a decline in
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Fig. 1 Proteasome inhibition triggers mutant HTT aggregation in HD-iPSCs. a Immunocytochemistry of control and HD-iPSC lines treated with 5 µM MG-
132 for 12 h. We used an antibody against polyQ-expanded protein to detect mutant HTT aggregates. Cell nuclei were stained with Hoechst 33342. Scale
bar represents 10 μm. The images are representative of six independent experiments. b Chymotrypsin-like proteasome activity in HD Q180-iPSC line
treated with MG-132 for 12 h (relative slope to Q180-iPSCs treated with DMSO). Graph represents the mean ± s.e.m. of three independent experiments.
c Filter trap analysis of the indicated control and HD-iPSCs. Proteasome inhibition with MG-132 for 12 h results in increased levels of polyQ aggregates in
HD-iPSCs lines (detected by anti-polyQ-expansion diseases marker antibody). However, proteasome inhibition does not induce accumulation of polyQ
aggregates in control iPSC lines. The images are representative of ﬁve independent experiments. d Graph represents the percentage of polyQ aggregate-
positive cells/total nuclei in the indicated iPSC lines (mean ± s.e.m., 3 independent experiments, 300–350 total cells per treatment for each line). e Graph
represents the percentage of propidium iodide-positive cells/total nuclei in the indicated iPSC lines (mean ± s.e.m., 3 independent experiments, 500–600
total cells per treatment for each line). For each time point, MG-132-treated lines were statistically compared with their respective DMSO-treated line. All
the statistical comparisons were made by Student’s t-test for unpaired samples. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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proteasome activity promotes mutant HTT aggregation in HD-
iPSCs, a process that cannot only be explained by impairment
of cell viability. Remarkably, control and HD-iPSCs
exhibited similar sensitivity to proteasome inhibition (Fig. 1e),
suggesting that mutant HTT aggregation does not induce cell
death in iPSCs.
Proteasome dysfunction impairs HTT levels in iPSCs. With the
link between proteasome inhibition and mutant HTT aggrega-
tion, we asked whether HTT levels are regulated by the protea-
some in HD-iPSCs. For this purpose, we characterized in our
model two antibodies that recognize HTT and polyQ-expanded
proteins, respectively12,31. First, we validated that these antibodies
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detect endogenous levels of HTT in iPSCs (Supplementary
Fig. 4a–c). The HD-iPSCs used in this study express one mutant
allele of HTT but also one normal copy (Supplementary Table 1)
12,25,32–34. Since the length of the polyQ stretch diminishes the
electrophoretic mobility of proteins31, we could discriminate
normal HTT and mutant HTT in both HD Q71 and Q180-iPSC
lines by western blot using anti-HTT antibody (Fig. 2a and
Supplementary Fig. 4a). In HD Q57-iPSCs, the differences in the
electrophoretic mobilities of both alleles were marginal and they
were not efﬁciently separated on western blot assays (Fig. 2a). We
also observed that anti-HTT antibody was less immunoreactive to
mutant HTT (Fig. 2a and Supplementary Fig. 4d). These differ-
ences were more pronounced in HD-iPSCs that express longer
polyQ repeats (Q180), as mutant HTT was only detected after
high exposure times in these cells (Fig. 2a). Thus, we used the
antibody to polyQ-expanded proteins to examine the expression
of mutant HTT in these cells (Fig. 2a). We conﬁrmed that this
antibody only recognizes mutant HTT on western blots and the
intensity of the signal correlates with the length of the polyQ
expansion (Fig. 2a and Supplementary Fig. 4d), as previously
reported31. Although Q57 expansion was not detected with anti-
polyQ-expanded proteins by western blot, this antibody strongly
detected mutant HTT in Q71 and Q180 lines (Fig. 2a).
Once we characterized these antibodies in iPSCs, we assessed
whether proteasome dysfunction impairs HTT levels. In control
iPSCs, proteasome inhibition resulted in upregulated HTT
protein levels (Fig. 2b and Supplementary Fig. 5a, b). In HD-
iPSCs, proteasome dysregulation not only increased the amounts
of normal HTT but also aggregation-prone HTT (Fig. 2c, d and
Supplementary Fig. 5c, d). Although these results suggest a direct
link between proteasome activity with HTT levels and aggrega-
tion, another possibility is that HTT dysregulation ensues from a
global proteostasis collapse induced by proteasome inhibition. To
assess this hypothesis, we inhibited the autophagy–lysosome
system, which also modulates proteostasis of HTT through its
proteolytic activity29. Although autophagy inhibition induced
mutant HTT aggregation in HD Q71-iPSCs, these aggregates
were less compact and the percentage of aggregate-containing
cells were lower when compared to proteasome inhibition
treatment (Fig. 2e, f and Supplementary Fig. 7a, b). In HD
Q180-iPSCs, autophagy inhibition only induced aggregation in a
low percentage of cells (Fig. 2e, f). Whereas proteasome inhibition
increased HTT levels, autophagy downregulation resulted in
decreased amounts of HTT protein (Fig. 2g and Supplementary
Fig. 8a–c). This decrease in HTT levels was not associated with
potential changes in cell viability or a compensatory upregulation
of the proteasome, as we did not ﬁnd signiﬁcant changes in
these parameters upon autophagy inhibition (Supplementary
Fig. 8d–e). The differences between autophagy and proteasome
inhibition supported a direct role of the proteasome in HTT
degradation of iPSCs. In these lines, proteasome dysfunction
results in increased levels of both normal HTT and aggregation-
prone HTT. Since the impairment of clearance of misfolded
proteins is key to their accumulation19, the increase in mutant
HTT levels upon proteasome inhibition could contribute to
diminish the ability of HD-iPSCs to suppress HTT aggregation.
UBR5 prevents mutant HTT aggregation in HD-iPSCs. To
assess whether pluripotent stem cells have an intrinsic proteos-
tasis to regulate HTT levels, we examined their E3 ubiquitin ligase
network. For this purpose, we analyzed available quantitative
proteomics data35 and found 26 E3 ligases signiﬁcantly increased
in hESCs compared with their differentiated neuronal counter-
parts (Supplementary Table 2). Notably, UBR5 was one of the
most upregulated E3 enzymes (Supplementary Table 2). UBR5-
shows a striking preference for Lys48 linkages of ubiquitin36,
which is the primary signal for proteasomal degradation19. Under
proteotoxic stress, UBR5 cooperates with Lys11-speciﬁc ligases to
produce K11/K48 heterotypic chains, promoting proteasomal
clearance of misfolded nascent polypeptides36. Recently, a
genome-wide association analysis has identiﬁed that genetic
variations in the chromosome region containing UBR5 gene
hasten the clinical onset of HD37. Remarkably, loss of UBR5
reduces the modiﬁcation of overexpressed HTT protein with K11/
K48-linked ubiquitin chains in a human cell line36. Thus,
increased endogenous expression of UBR5 could provide a link
between proteostasis and regulation of HTT levels in pluripotent
stem cells.
Besides its downregulation during differentiation of hESCs
(Supplementary Fig. 9a and Supplementary Table 2), we
conﬁrmed that UBR5 protein levels are also increased in both
control and HD-iPSC compared with their neuronal counterparts
(Fig. 3a–c and Supplementary Fig. 10). In all the lines tested, we
observed that UBR5 downregulation is already signiﬁcant when
iPSCs differentiate into neural progenitor cells (NPCs) (Fig. 3a–c
and Supplementary Fig. 10). The decrease in UBR5 protein levels
correlated with a downregulation of messenger RNA (mRNA)
amounts during differentiation (Fig. 3d–f and Supplementary
Fig. 9b).
Since UBR5 promotes microRNA-mediated transcript desta-
bilization in mouse ESCs38 and may be involved in transcrip-
tional repression during development39, we examined whether
UBR5 downregulation during differentiation correlates with
Fig. 2 Loss of proteasome activity increases HTT levels in iPSCs. a Western blot of iPSCs with antibodies to total HTT, polyQ-expanded proteins and β-
actin. Arrow indicates mutant HTT detected with total HTT antibody in HD Q180-iPSCs. The images are representative of three independent experiments.
b Western blot of control iPSCs #2 treated with MG-132 (12 h). The graph represents the relative percentage values to DMSO-treated iPSCs of normal
huntingtin (nHTT) detected with total HTT antibody and corrected for β-actin loading control (mean ± s.e.m., three independent experiments). c Western
blot of HD Q71-iPSC line #1 treated with MG-132 (12 h). Graphs represent the relative percentage values to DMSO-treated iPSCs (corrected for β-actin)
of nHTT and mutant HTT (mHTT) detected with antibodies to total HTT and polyQ-expanded proteins (mean ± s.e.m., three independent experiments).
dWestern blot of HD Q180-iPSCs treated with MG-132 (12 h). The graphs represent the relative percentage values to DMSO-treated iPSCs (corrected for
β-actin) of nHTT and mHTT detected with antibodies to total HTT and polyQ-expanded proteins, respectively (mean ± s.e.m., four independent
experiments). Supplementary Fig. 6 presents a higher exposure time of the same membrane for a better comparison of mHTT levels detected with HTT
antibody. e Immunocytochemistry of control and HD-iPSCs treated with 0.5 µM MG-132 or 0.25 µM baﬁlomycin for 12 h. PolyQ-expanded and Hoechst
33342 staining were used as markers of mutant HTT aggregates and nuclei, respectively. Scale bar represents 10 μm. The images are representative of
three independent experiments. f Graph represents the percentage of polyQ aggregate-positive cells/total nuclei in the indicated iPSC lines treated with
MG-132 or baﬁlomycin for 12 h (mean ± s.e.m., four independent experiments, 300–350 total cells per treatment for each line). gWestern blot of HD Q71-
iPSCs #1 treated with baﬁlomycin (12 h) using antibodies to total HTT, polyQ-expanded proteins, LC3 and P62. Graphs represent the relative percentage
values to DMSO-treated iPSCs (corrected for β-actin) of nHTT and mHTT (mean ± s.e.m., three independent experiments). Statistical comparisons were
made by Student’s t-test for unpaired samples. *P < 0.05, **P < 0.01, ***P < 0.001
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increased HTT mRNA levels. However, the amounts of HTT
mRNA were either downregulated or not signiﬁcantly changed
with iPSC differentiation (Supplementary Fig. 11). As a more
formal test, we assessed whether knockdown of UBR5 alters the
transcript levels of HTT in distinct iPSC/hESC lines and found no
differences (Fig. 4a and Supplementary Fig. 12). On the contrary,
knockdown of UBR5 induced an increase in the protein levels of
HTT in human pluripotent stem cells (Fig. 4b–e and Supple-
mentary Fig. 13). We assessed three independent control iPSCs as
well as two hESC lines and obtained similar results (Fig. 4b, c and
Supplementary Fig. 13a–c). In HD Q71 and Q180-iPSC lines, the
loss of UBR5 not only impaired the levels of normal HTT but also
mutant HTT at a similar extent (Fig. 4d, e and Supplementary
Fig. 13d). Although we could not discriminate normal and polyQ-
expanded HTT in HD Q57-iPSCs, we conﬁrmed an upregulation
of total HTT protein levels in these cells upon UBR5 knockdown
(Supplementary Fig. 13e). Since loss of UBR5 did not impair HTT
mRNA levels (Fig. 4a and Supplementary Fig. 12), our data
supported a role of this E3 enzyme in post-translational
regulation of HTT. To examine whether UBR5 modulates HTT
levels in a proteasome-dependent manner, we blocked proteaso-
mal degradation in iPSCs. Notably, UBR5 knockdown and MG-
132-treated cells exhibited similar levels of HTT (Fig. 4b–e). Most
importantly, UBR5 downregulation did not further increase the
levels of HTT in both control and HD-iPSCs with reduced
proteasome activity (Fig. 4b–e), indicating a role of UBR5 in
proteasomal degradation of HTT. Given that pluripotent stem
cells exhibit high levels of proteasome activity compared with
their differentiated counterparts16, we assessed whether UBR5 is
required for this activity. However, loss of UBR5 did not affect
global proteasome activities in iPSCs (Fig. 4f and Supplementary
Fig. 14), suggesting a speciﬁc link between UBR5 and HTT
modulation. Besides UBR5, other E3 ligases are also increased in
pluripotent stem cells (Supplementary Table 2 and Supplemen-
tary Fig. 15a). We knocked down four of these upregulated
enzymes (i.e., UBE3A, RNF181, UBR7, TRIM71) and found
no differences in HTT levels of HD-iPSCs (Supplementary
Fig. 15b–g). Moreover, UBR5 interacted with both normal and
polyQ-expanded HTT in HD-iPSCs, whereas we were not able to
detect this interaction with a distinct upregulated E3 enzyme
(Fig. 4g and Supplementary Fig. 16).
Taken together, these results suggest that intrinsic high
expression of UBR5 determines HTT levels in iPSCs, a process
that could contribute to the remarkable ability of these cells to
maintain proteostasis of mutant HTT. In support of this
hypothesis, loss of UBR5 triggered the accumulation of mutant
HTT aggregates in all the HD-iPSCs tested as we conﬁrmed by
immunocytochemistry and ﬁlter trap experiments (Fig. 5a–e and
Supplementary Fig. 17a). In contrast, we did not observe
accumulation of polyQ aggregates in control iPSCs as well as
corrected isogenic counterparts of HD Q180-iPSCs despite the
upregulation of normal HTT levels (Fig. 5a, b, f, g and
Supplementary Figs. 17b, 18).
Notably, proteasome inhibition did not further increase the
accumulation of aggregates induced by loss of UBR5 in HD-iPSCs
(Fig. 5h–l and Supplementary Fig. 19), indicating that UBR5
regulates proteostasis of mutant HTT via its proteasomal
degradation. To further determine the impact of UBR5 on HTT
levels and aggregation, we examined other components of the
ubiquitin–proteasome system (UPS) network previously asso-
ciated with HTT regulation. In particular, we focused on UBE3A,
an E3 enzyme that promotes proteasomal degradation of polyQ-
expanded HTT in cell lines40. In addition, we examined UBE2K,
an E2 enzyme that was found to interact with HTT in a yeast two-
a
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hybrid screen and reduce polyQ aggregation in cell lines41,42.
Although both UBE3A and UBE2K are upregulated in pluripo-
tent stem cells35, their knockdown did not increase mutant HTT
levels and aggregation in HD-iPSCs (Fig. 6a, b and Supplemen-
tary Fig. 20). Thus, these results further support a speciﬁc role of
UBR5 as a key determinant of HTT levels in iPSCs. Whereas the
UPS regulates HTT degradation facilitating its proteostasis, the
chaperone network is essential to modulate different steps of the
aggregation process29. Remarkably, pluripotent stem cells exhibit
an intrinsic chaperone network that could contribute to
preventing mutant HTT aggregation12. For instance, these cells
have increased levels of HTT-interacting protein K (HYPK)35, a
chaperone that reduces polyQ-expanded HTT aggregates in
mouse neuroblastoma cell lines43. However, loss of HYPK did not
trigger aggregation of mutant HTT in HD-iPSCs (Fig. 6b).
Pluripotent stem cells also exhibit increased assembly of the
TRiC/CCT complex12, a chaperonin that suppresses mutant HTT
aggregation44,45. In hESCs/iPSCs, increased assembly of the
TRiC/CCT complex is induced by high levels of CCT8 subunit12.
As UBR5 knockdown, loss of CCT8 triggers aggregation of
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mutant HTT in HD-iPSCs (Fig. 6b)12. In contrast, CCT8
downregulation did not affect HTT protein levels in HD-iPSCs
(Fig. 6a), supporting a direct role of the TRiC/CCT complex in
mutant HTT aggregation rather than degradation. Altogether, our
results indicate a key role of UBR5 in monitoring HTT levels, a
process that could facilitate mutant HTT regulation by other
proteostasis nodes such as enhanced TRiC/CCT complex.
Loss of UBR5 triggers aggresome formation in hESCs/iPSCs.
Besides its role in HTT regulation, we asked whether UBR5
modulates other disease-associated proteins. To assess this
hypothesis, we ﬁrst examined ataxin-3 (ATXN3), a distinct
polyQ-containing protein. An abnormal expansion of CAG tri-
plets (>52) in the ATXN3 gene causes Machado–Joseph disease
(MJD), a neurodegenerative disorder characterized by neuronal
loss in the cerebellum and progressive ataxia46,47. Here we used
iPSCs derived from two individuals with MJD (MJD-iPSCs)
(Supplementary Table 1), both expressing one normal copy of
ATXN3 and one mutant allele with 74 CAG repeats (Fig. 6c). As
previously reported48, these MJD-iPSCs did not accumulate
polyQ-expanded aggregates (Fig. 6d). To examine whether the
UPS regulates proteostasis of ATXN3 in iPSCs, we downregulated
proteasome activity by using MG-132 proteasome inhibitor. In
contrast with HD-iPSC lines, the treatment with proteasome
inhibitor for 12 h induced acute cell death and detachment of
MJD-iPSCs. To reduce these effects, we performed our analysis at
an earlier time point of the treatment (6 h) (Supplementary
Fig. 21). Notably, proteasome inhibition did not change the levels
of normal and mutant ATXN3, whereas the amounts of HTT
were upregulated in these cells (Fig. 6c). Thus, our results suggest
that the UPS does not modulate the levels of ATXN3 in iPSCs.
However, proteasome inhibition triggered polyQ-expanded
ATXN3 aggregation (Fig. 6d), a process that could be linked
with the global proteostasis collapse induced by this treatment.
Although loss of UBR5 increased HTT levels in MJD-iPSCs, we
did not ﬁnd changes in either normal or mutant ATXN3 (Fig. 6e,
f). Moreover, we found that UBR5 binds HTT but it does not
interact with wild-type or mutant ATXN3 in MJD-iPSCs (Sup-
plementary Fig. 22a). In contrast to global proteasome inhibition,
UBR5 downregulation did not induce aggregation of polyQ-
expanded ATXN3 (Fig. 6g). This phenotype differed from HD-
iPSCs lines, where upregulation of mHTT levels upon UBR5
knockdown was sufﬁcient to trigger polyQ-expanded HTT
aggregation (Fig. 5). Thus, these data indicate that not all polyQ-
containing proteins are modulated by UBR5.
To further assess the role of UBR5 in the proteostasis of
aggregation-prone proteins, we used iPSCs carrying mutations in
the RNA-binding protein FUS49. These mutations are linked with
amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative
disorder characterized by loss of motor neurons and concomitant
progressive muscle atrophy49,50. Although wild-type FUS shuttles
between the nucleus and cytoplasm, it is mostly localized in the
nucleus in normal conditions51. However, many of the ALS-
related FUS mutations disrupt the nuclear import of the protein,
resulting in aberrant localization and aggregation of FUS in the
cytoplasm52,53. As previously reported49, wild-type FUS was
essentially located in the nucleus of iPSCs (Fig. 7a). Likewise, FUS
was predominantly detected in the nucleus of iPSCs (FUSR521C/
wt) derived from a patient affected by ALS in mid-late age49,50
(Fig. 7a). In iPSCs expressing a FUS variant linked with severe
and juvenile ALS (FUSP525L/P525L), the protein was mostly
located in the cytoplasm49 (Fig. 7a). Under oxidative stress, the
cells form stress granules (SGs) where mutant variants of FUS are
recruited54. Despite the induction of cytoplasmic SGs, wild-type
FUS remains in the nucleus in iPSCs under oxidative stress49. On
the contrary, mutant variants of FUS colocalize with SGs49.
Similar to oxidative stress, proteasome inhibition induced the
accumulation of SGs in iPSCs (Fig. 7a). In control iPSCs, FUS
remained in the nucleus upon proteasome dysfunction (Fig. 7a).
Although FUS signal was mostly nuclear in FUSR521C-iPSCs
upon proteasome inhibition, we also found cytoplasmic FUS
speckles co-localizing with SGs as reported for oxidative stress49
(Fig. 7a). On the other hand, FUSP525L variant showed a strong
co-localization with SGs under proteasome inhibition (Fig. 7a).
Remarkably, loss of UBR5 did not stimulate SG formation or FUS
delocalization in control or ALS-iPSC lines (Fig. 7a). In addition,
UBR5 knockdown did not impair wild-type or mutant FUS levels,
whereas HTT was upregulated in these cells (Fig. 7b). Accord-
ingly, UBR5 interacted with HTT in both control and ALS-iPSC
lines, but we could not detect interaction with wild-type
or mutant FUS in these cells (Supplementary Fig. 22b, c). Thus,
these results indicate a speciﬁc role of UBR5 on HTT regulation.
Although UBR5 was dispensable for ATXN3 and FUS proteos-
tasis, we cannot discard a role of UBR5 in the control of other
aggregation-prone proteins associated with disease.
Besides its role in HTT modulation, we asked whether UBR5
also determines the global proteostatic ability of pluripotent cells.
Under normal conditions, misfolded proteins are refolded by
chaperones or terminated via proteolytic systems10. Metabolic
and environmental conditions (e.g., heat stress) challenge the
structure of proteins, increasing the load of misfolded and
damaged proteins. When proteolytic systems are overwhelmed,
misfolded proteins accumulate into aggresomes. In these lines, we
observed that heat stress induces the accumulation of aggresomes
in pluripotent stem cells despite their increased proteolytic ability
Fig. 5 UBR5 suppresses mutant HTT aggregation in HD-iPSCs. a Immunocytochemistry of control iPSC line #1 (Q21), control iPSC line #2 (Q33) and HD
Q71-iPSC line #1 upon UBR5 knockdown. PolyQ-expanded and Hoechst 33342 staining were used as markers of aggregates and nuclei, respectively. Scale
bar represents 10 μm. The images are representative of four independent experiments. b Immunocytochemistry of Q180-iPSCs and two isogenic
counterparts (i.e., HD-C#1 and HD-C#2), in which the 180 CAG expansion was corrected to a nonpathological repeat length. Scale bar represents 10 μm.
The images are representative of three independent experiments. c–g Filter trap analysis of the indicated control and HD-iPSC lines upon UBR5 knockdown
with anti-polyQ-expansion diseases marker antibody. The images are representative of at least three independent experiments for each cell line.
h Immunocytochemistry of HD Q71-iPSC line #2 upon knockdown of UBR5. PolyQ-expanded and Hoechst 33342 staining were used as markers of
aggregates and nuclei, respectively. Scale bar represents 10 μm. Proteasome inhibitor treatment: 5 µM MG-132 for 12 h. The images are representative of
four independent experiments. i Graph represents the percentage of polyQ aggregate-positive cells/total nuclei in HD Q71-iPSC line #2 (mean ± s.e.m.,
3 independent experiments, 500–600 total cells per condition). Proteasome inhibitor treatment: 5 µM MG-132 for 12 h. j Graph represents the percentage
of polyQ aggregate-positive cells/total nuclei in HD Q180-iPSCs (mean ± s.e.m., 3 independent experiments, 300–400 total cells per condition).
Proteasome inhibitor treatment: 5 µMMG-132 for 12 h. k Filter trap analysis of the indicated control and HD-iPSC lines with anti-polyQ-expansion diseases
marker antibody. Proteasome inhibitor treatment: 5 µM MG-132 for 12 h. The images are representative of three independent experiments. l Filter trap
analysis of HD Q180-iPSCs with anti-polyQ-expansion diseases marker antibody. Proteasome inhibitor treatment: 5 µM MG-132 for 12 h. The images are
representative of three independent experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. ****P < 0.0001
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(Fig. 7c). Notably, loss of UBR5 was sufﬁcient to induce the
accumulation of aggresomes in these cells (Fig. 7c). Thus, our
data suggest that UBR5 not only regulates the levels of speciﬁc
proteins such as HTT, but is also involved in the degradation of
misfolded proteins ensued during normal metabolism.
Mutant HTT aggregates do not affect neural differentiation.
Loss of UBR5 did not impair the levels of pluripotency and germ
layer markers in control iPSCs (Supplementary Fig. 23a–c). With
the pronounced accumulation of mutant HTT aggregates induced
by UBR5 knockdown in HD-iPSCs (Fig. 5), we asked whether
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these inclusions alter iPSC identity. However, the accumulation of
aggregates did not result in decreased expression of pluripotency
markers in HD-iPSCs (Fig. 8a and Supplementary Fig. 24).
Likewise, we did not observe increased levels of markers of the
distinct germ layers (Fig. 8a), indicating that polyQ-expanded
HTT aggregates do not induce differentiation. Accordingly, we
did not ﬁnd a decrease in the number of cells expressing the
pluripotency marker OCT4 (Fig. 8b and Supplementary Fig. 25).
Most importantly, UBR5 knockdown HD-iPSCs could differ-
entiate into neural cells (Fig. 8c and Supplementary Fig. 26).
Under neural induction treatment, naive HD-iPSCs differentiated
into NPCs with no detectable amounts of polyQ-expanded-HTT
aggregates (Fig. 8d and Supplementary Fig. 27). However, neural
cells derived from HD-iPSCs with impaired expression of UBR5
exhibited increased levels of mutant HTT and accumulation of
aggregates (Fig. 8d–h and Supplementary Figs. 27–29). Overall,
our results indicate that intrinsic high levels of UBR5 are essential
to suppress mutant HTT aggregation in iPSCs, contributing to
their ability to generate neural progenitor cells with no detectable
polyQ-expanded aggregates. One step further was to determine
whether these cells are able to generate terminally differentiated
neurons. Since GABAergic medium spiny neurons (MSNs)
undergo the greatest neurodegeneration in HD55, we differ-
entiated iPSCs into striatal neurons56. Among those cells
expressing the neuronal marker microtubule-associated protein-2
(MAP2), ∼30–60% also expressed GABA depending on the cell
line (Supplementary Fig. 30a, b). As previously reported25, these
differences were not associated with the expression of mutant
HTT (Supplementary Fig. 30a, b). Knockdown of UBR5 at the
iPSC stage did not reduce their ability to differentiate into striatal
neurons (Supplementary Fig. 30a–g). In contrast to NPCs,
terminally differentiated neurons derived from HD-iPSCs with
downregulated UBR5 levels did not accumulate polyQ-expanded
aggregates (Supplementary Fig. 31). Thus, the lack of defects in
neurogenesis and aggregates in these cells indicate that other
mechanisms activate during neuronal differentiation to facilitate
proteostasis of mutant HTT.
UBR5 loss hastens neurotoxicity in polyQ nematode models.
Although HD-iPSCs can terminally differentiate into MSNs, these
cells do not exhibit mutant HTT aggregates even after the addi-
tion of proteasome and autophagy inhibitors or the induction of
oxidative stress12,20,25,27. Thus, these ﬁndings support a rejuve-
nation process during cell reprogramming that prevents aberrant
aggregation in differentiated neurons. In addition, the lack of
polyQ-expanded aggregates in these cells could reﬂect the long
period of time before aggregates accumulate in HD25. In these
lines, HD-MSNs derived from iPSCs do not accumulate detect-
able polyQ-expanded inclusions at 12 weeks after transplantation
into HD rat models. However, they accumulate aggregates after
33 weeks of transplantation27. Proteasome inhibition did not
induce upregulation of HTT protein levels or aggregation in HD-
MSNs differentiated from iPSCs (Supplementary Fig. 32a–d).
Likewise, knockdown of UBR5 in differentiated HD-MSNs was
not sufﬁcient to induce mutant HTT aggregation and upregulated
HTT levels (Supplementary Fig. 33, 34). In addition, UBR5
knockdown did not reduce cell viability of HD-MSNs (Supple-
mentary Fig. 35).
Given the challenges presented by MSNs derived from HD-
iPSCs to study the role of UBR5 in polyQ-expanded aggregation
and toxicity, we used a distinct model. Remarkably, a RNA
interference (RNAi) screen against E3 ubiquitin ligases found
that knockdown of the worm UBR5 ortholog (ubr-5) accelerates
paralysis in a C. elegans model expressing 35 polyQ repeats
fused to yellow ﬂuorescent protein (YFP) in body wall muscle
cells57. To assess the requirement of ubr-5 for resistance to
polyQ neurotoxicity, we examined a C. elegans model that
expresses polyQ-expanded YFP in the nervous system58. In
these worms, polyQ aggregation and neurotoxicity correlates
with the age and length of the polyQ repeat, with a pathogenic
threshold of 40 glutamine repeats58. Notably, loss of ubr-5
resulted in increased levels of polyQ67-expanded protein with
concomitant aggregation (Fig. 9a, b). Knockdown of ubr-5 had a
strong effect in the aggregation propensity of head neurons,
resulting in more aggregates in the circumpharyngeal nerve ring
and chemosensory processes (Fig. 9c). We also observed more
propensity aggregation in the neurons of the animal mid-body
(Fig. 9c and Supplementary Fig. 36). To assess whether the
polyQ67-YFP foci were immobile protein aggregates, we
performed a quantitative ﬂuorescence recovery after photo-
bleaching analysis of head neurons. In both empty vector and
ubr-5 RNAi-treated worms, most of the polyQ67-YFP foci
signal could not be recovered, indicating an immobile state
(Supplementary Fig. 37a). However, ubr-5 RNAi induced a
faster incorporation of new polyQ67-YFP peptides into the
aggregates (Supplementary Fig. 37b).
Although ubr-5 RNAi was sufﬁcient to induce a pronounced
increase of polyQ-expanded aggregates (Fig. 9b), it is important
to note that neurons are less sensitive to RNAi when compared
with other tissues59. For this reason, we introduced a rrf-3
mutation in the polyQ-YFP neuronal models, which confers
hypersensitivity to RNAi in all the tissues, including neurons60.
Accordingly, we found that ubr-5 RNAi treatment induced a
strong increase in polyQ67-YFP aggregation of rrf-3 mutants
(Fig. 9d). On the contrary, ubr-5 knockdown did not induce
Fig. 6 UBR5 maintains proteostasis of HTT but not ATXN3 in iPSCs. a Western blot analysis of HD Q71-iPSC line #1 with antibody to HTT. The graph
represents the nHTT and mHTT relative percentage values (corrected for β-actin loading control) to NT shRNA iPSCs (mean ± s.e.m. of three independent
experiments). b Immunocytochemistry of HD Q71-iPSC line #1 upon knockdown of the indicated proteostasis components. PolyQ-expanded and Hoechst
33342 staining were used as markers of aggregates and nuclei, respectively. Scale bar represents 10 μm. The images are representative of three
independent experiments. cWestern blot analysis with antibodies to HTT and ATXN3 of iPSCs derived from two individuals with MJD (MJD-iPSC lines #1
and #2) and control iPSCs. Anti-ATXN3 antibody detects both normal (nATXN3) and mutant ATXN3 (mATXN3). Proteasome inhibitor treatment: 5 µM
MG-132 for 6 h. The graphs represent the HTT, nATXN3, mATXN3 relative percentage values to the respective DMSO-treated iPSCs corrected for β-actin
loading control (mean ± s.e.m. of three independent experiments). d Immunocytochemistry of control iPSCs #2, MJD-iPSC lines #1 and #2 upon
proteasome inhibition (5 µM MG-132 for 6 h). PolyQ-expanded and Hoechst 33342 staining were used as markers of aggregates and nuclei, respectively.
Scale bar represents 10 μm. The images are representative of three independent experiments. e, f Western blot analysis with antibodies to HTT and
ATXN3 of MJD-iPSC lines #1 and #2 upon UBR5 knockdown. The graphs represent the relative percentage values of HTT, nATXN3 and mATXN3 to the
respective NT shRNA iPSCs corrected for β-actin loading control (mean ± s.e.m. of three independent experiments for each line). g Immunocytochemistry
of MJD-iPSC lines #1 and #2 upon UBR5 knockdown. Proteasome inhibitor: 5 µM MG-132 for 6 h. PolyQ-expanded and Hoechst 33342 staining were used
as markers of aggregates and nuclei, respectively. Scale bar represents 10 μm. The images are representative of three independent experiments. All the
statistical comparisons were made by Student’s t-test for unpaired samples. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 7 Loss of UBR5 triggers aggresome formation in pluripotent stem cells. a Immunocytochemistry of control iPSCs #4 (FUSwt/wt), ALS-iPSCs #1
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aggregation of polyQ19-peptides, even in the RNAi-
hypersensitive mutant strain (Fig. 9d).
Since the neurotoxic effects of polyQ-expanded aggregation
correlate with impairment of coordinated movement58, we
performed motility assays to quantify the role of ubr-5 in the
resistance to polyQ-toxicity. Notably, loss of ubr-5 hastened the
detrimental effects on motility induced by polyQ67 repeats
(Fig. 9e), correlating with increased polyQ aggregation. On the
contrary, knockdown of ubr-5 did not affect the motility of
polyQ19-expressing worms (Fig. 9e). Altogether, these results
provide a direct link between UBR5 function and polyQ-
expanded aggregation with age.
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Ectopic expression of UBR5 suppresses mutant HTT aggre-
gation. Since loss of UBR5 hastened polyQ-expanded aggrega-
tion, we asked whether ectopic expression of this HECT E3
enzyme is sufﬁcient to ameliorate the accumulation of polyQ
aggregates. To assess this hypothesis, we generated human cell
models that express either control (Q23) or polyQ-expanded
(Q100) HTT protein. In these cells, overexpression of mutant
HTT resulted in the accumulation of polyQ-expanded aggregates,
whereas control HTT did not form aggregates (Fig. 10a). Notably,
ectopic expression of UBR5 ameliorated polyQ-expanded aggre-
gation in Q100-HTT cells (Fig. 10a), a process blocked by pro-
teasome inhibition (Fig. 10b). In contrast, UBR5 overexpression
did not reduce the insolubility of aggregation-prone β-amyloid
protein (Supplementary Fig. 38).
In support of a direct role of UBR5 in modulation of HTT, we
found that UBR5 overexpression decreases the protein levels of
mutant HTT (Fig. 10c). To further determine the role of UBR5,
we overexpressed a UBR5 mutant with two point mutations that
causes a change in an amino acid (C2769A) located in the HECT
domain, resulting in ubiquitin ligase-dead UBR561. Remarkably,
similar overexpression levels of this catalytic inactive UBR5
mutant did not diminish polyQ-expanded HTT protein levels and
aggregation (Fig. 10a–c). Given that our results in iPSCs indicate
that UBR5 regulates HTT levels via the proteasome, we tested
whether UBR5 overexpression promotes proteasomal degradation
of Q100-HTT. Indeed, proteasome inhibition blocked the
reduction of Q100-HTT levels induced by enhanced wild-type
UBR5 expression (Fig. 10d). To further assess the link between
UBR5 and HTT regulation, we performed immunoprecipitation
experiments and examined polyubiquitination of HTT. Prior to
immunoprecipitation, we treated the cells with proteasome
inhibitor to block the degradation of HTT induced by UBR5.
Under these conditions, we immunoprecipitated similar amounts
of HTT in cells overexpressing wild-type UBR5 when compared
with cells expressing empty vector or catalytic inactive UBR5
(Fig. 10e). Notably, we found that ectopic expression of UBR5
induces a dramatic increase in polyubiquitination of mutant HTT
(Fig. 10e). In contrast, overexpression of the catalytic inactive
UBR5 mutant did not promote polyubiquitination of Q100-HTT
protein (Fig. 10e). In support of our ﬁndings, a recent study
reported that UBR5 downregulation decreases the modiﬁcation of
overexpressed HTT protein with K11/K48-linked polyubiquitin
chains in HeLa human cells36. Moreover, this study revealed K11/
K48-linked polyubiquitin modiﬁcations at Lys337 of HTT by
proteomics experiments36. We performed proteomics analysis of
immunoprecipitated HTT in Q100-HTT-overexpressing cells to
determine potential lysine sites modiﬁed by UBR5
(Supplementary Fig. 39a, b). Although we did not detect
ubiquitination at Lys337 of HTT in our assays, we identiﬁed
two other ubiquitinated lysine sites: Lys631 and Lys2097.
However, only Lys631 shows a small but signiﬁcant higher
ubiquitination in cells overexpressing wild-type UBR5 when
compared to catalytic inactive UBR5 (Supplementary Fig. 39b),
suggesting that this site could be ubiquitinated by UBR5. Taken
together, our data indicate that the ubiquitin ligase activity of
UBR5 modulates proteasomal degradation of mutant HTT, a
process that ameliorates polyQ-expanded aggregation.
Discussion
While the transcriptional, epigenetic and signaling networks of
pluripotency have been a primary focus of research efforts,
emerging evidence indicates that pluripotent stem cells also
exhibit intrinsic proteostasis mechanisms8,12,14,17. Thus, a com-
prehensive understanding of this proteostasis network could be
necessary for pluripotent stem cells to hold a great promise for
regenerative medicine. As an invaluable resource to generate
terminally differentiated cells, pluripotent stem cells can facilitate
the study of human diseases and drug screening. This is parti-
cularly fascinating in the context of proteostasis-related disorders.
At least 30 different human diseases are directly associated with
aberrant protein folding protein and aggregation62. Whereas a
collapse in proteostasis of somatic cells could underlie these
diseases, pluripotent stem cells exhibit a striking ability to correct
and suppress proteostatic deﬁciencies. Thus, investigating plur-
ipotent stem cells from patients could contribute to identifying
super-vigilant proteostasis mechanisms that could be mimicked
in somatic tissues to ameliorate disease.
Despite expressing signiﬁcant amounts of mutant HTT25,
several studies have demonstrated that HD-iPSCs do not accu-
mulate polyQ-expanded HTT aggregates even after multiple
passages12,25,27. In addition, HD-iPSCs can terminally differ-
entiate into neurons lacking the aggregation phenotype char-
acteristic of HD12,25,27, indicating a rejuvenation process during
reprogramming that prevents polyQ-expanded aggregation in
neurons prior to proteostasis collapse with age. Here we show
that increased proteasome activity of iPSCs regulates the levels of
both normal and mutant HTT, contributing to suppressing
polyQ-expanded HTT aggregation in HD-iPSCs. Conversely, a
dysfunction in proteasome activity results in impaired HTT
levels, leading to aggregation of mutant HTT in HD-iPSCs.
Importantly, we have uncovered that intrinsic high expression of
UBR5 is a key component of the UPS to regulate HTT levels in
iPSCs. This E3 enzyme interacts with HTT and promotes
Fig. 8 UBR5 determines HD-iPSC differentiation into NPCs with no aggregates. a qPCR of pluripotency (OCT4, NANOG, SOX2, DPPA4), endodermal
(GATA6, AFP), mesodermal (MSX1) and ectodermal markers (PAX6, NES) in HD Q71-iPSC line #1. The graph represents the relative expression to NT
shRNA HD-iPSCs (mean ± s.e.m. (n= four independent experiments)). b Immunocytochemistry of HD Q71-iPSC line #1. OCT4 and Hoechst
33342 staining were used as markers of pluripotency and nuclei, respectively. Scale bar represents 20 μm. The images are representative of four
independent experiments. c After neural induction of HD Q71-iPSC line #1 with downregulated levels of UBR5, we observed similar numbers of PAX6-
positive cells compared to NT shRNA control. Scale bar represents 20 μm. d Upon neural induction of HD-iPSCs with downregulated levels of UBR5, NPCs
accumulate mutant HTT aggregates. PolyQ-expanded and Hoechst 33342 staining were used as markers of aggregates and nuclei, respectively. Scale bar
represents 10 μm. The images are representative of three independent experiments. e Filter trap analysis of polyQ-expanded aggregates in NPCs derived
from HD Q71-iPSCs #1 with downregulated levels of UBR5. The images are representative of four independent experiments. f Filter trap of control NPCs #2
and HD Q180-NPCs derived from iPSCs with downregulated levels of UBR5. The images are representative of three independent experiments. g HD Q71-
iPSCs #1 with downregulated UBR5 levels were differentiated into NPCs and analyzed by western blot. Graphs represent the relative percentage values to
NT shRNA NPCs (corrected for β-actin) of nHTT and mHTT detected with antibodies to total HTT and polyQ-expanded proteins (mean ± s.e.m. of three
independent experiments). h Western blot analysis of NPCs derived from HD Q180-iPSCs with downregulated levels of UBR5. Graphs represent the
relative percentage values to NT shRNA NPCs (corrected for β-actin) of nHTT and mHTT detected with antibodies to total HTT and polyQ-expanded
proteins (mean ± s.e.m. of three independent experiments), respectively. In g, h arrow indicates polyQ-expanded HTT detected with total HTT antibody.
Statistical comparisons were made by Student’s t-test for unpaired samples. *P < 0.05, **P < 0.01
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proteasomal degradation of both normal and polyQ-expanded
HTT. Since the clearance of misfolded and aggregation-prone
proteins is key to their aggregation, the impairment of HTT levels
could be particularly relevant in iPSCs expressing mutant HTT.
Accordingly, UBR5 downregulation and concomitant dysregula-
tion of HTT levels results in polyQ-expanded HTT aggregation
in HD-iPSCs. Thus, our results suggest that UBR5 monitors
HTT levels, facilitating the regulation of mutant HTT by
other proteostasis nodes. For instance, pluripotent stem cells
also exhibit increased activity of the TRiC/CCT chaperone
complex to tightly suppress the aggregation of mutant HTT12.
We found that the HECT domain containing the E3 ligase
activity of UBR5 is required for HTT degradation, providing
a further link between increased proteasome activity and strin-
gent control of mutant HTT. It is important to note that plur-
ipotent stem cells also express high levels of other E3 ligases.
Although our results discard a direct role of several of these E3s
(i.e., UBR7, UBE3A, RNF181) in modulation of HTT levels in
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iPSCs, it will be fascinating to examine the impact of the other
upregulated E3s.
Whereas our data highlight the importance of UBR5 in pro-
teostasis of iPSCs, the intrinsic high levels of this enzyme could
also suggest a role in pluripotency via the ubiquitination of
endogenous substrates. Interestingly, a study has reported that
Ubr5 knockdown results in signiﬁcant loss of pluripotency
markers in mouse ESCs14. However, a different study did not ﬁnd
impairment of pluripotency markers in murine ESCs upon Ubr5
RNAi treatment63. Likewise, we did not ﬁnd changes in the
expression of pluripotency or germ layer markers in control
hESCs/iPSCs upon loss of UBR5. Interestingly, knockdown of
Ubr5 reduces the induction of Sonic hedgehog (Shh) in murine
pluripotent stem cells upon retinoic-acid treatment63. In these
lines, a conditional Ubr5 mutant mouse presents decreased
hedgehog signaling during embryogenesis63. Although this model
exhibits shorter limbs, the differences were not signiﬁcant and the
mutants do not have other obvious morphological defects63. Since
our striatal neuronal differentiation protocol is based on the
induction of hedgehog signaling, we tested whether UBR5 is
necessary for the generation of MSNs from human iPSCs.
However, loss of UBR5 did not affect their differentiation into
MSNs, indicating that these cells conserved their ability to induce
the hedgehog signaling. The distinct impact of UBR5 in plur-
ipotency and differentiation could be associated with genetic
differences between mouse and human species. Moreover, it is
important to note the distinct pluripotent states exhibited by
murine ESCs and hESCs/iPSCs3. Mouse ESCs are cultured in the
presence of serum and leukemia inhibitory factor (LIF), and
exhibit a naive state resembling the pluripotent state observed in
the inner cell mass of the pre-implantation embryo3. On the other
hand, hESCs as well as human iPSCs do not require LIF signaling
and exhibit a more primed state that resembles post-implantation
embryonic conﬁgurations3.
Although loss of UBR5 did not impair pluripotency markers in
human control iPSCs, it induced the formation of misfolded
protein aggregates (i.e., aggresomes). However, we found that the
accumulation of polyQ-expanded aggregates in HD-iPSCs does
not impair pluripotency markers or induce their differentiation.
Most importantly, these cells retain the ability to differentiate into
neural cells that also accumulate polyQ-expanded aggregates.
With these results, we speculate that increased proteostasis of
pluripotent stem cells may be required to avoid the generation of
precursor cells that accumulate protein aggregates at early orga-
nismal stages, a process that could be detrimental to organismal
survival and healthspan. However, it is important to remark that
most of our studies were performed in iPSCs, and further evi-
dence in hESCs as well as in vivo experiments using mouse
models are necessary to assess this intriguing possibility. On the
other hand, HD-iPSCs with decreased levels of UBR5 can be
further differentiated into MSNs with no aggregates. These results
could imply the activation of additional proteostatic control
mechanisms to scavenge aggregates during terminal neuronal
differentiation. It will be fascinating to deﬁne these mechanisms
due to its implications for development and organismal aging.
Notably, genetic variations in a region of the chromosome 8
that contains the UBR5 gene, among others (i.e., RRM2B,
MIR5680, NCALD), have been associated with an early onset of
HD by genome-wide association analysis37. Whereas our results
demonstrate that UBR5 levels decrease during differentiation, an
intriguing possibility is that a further dysfunction of UBR5
activity with age could contribute to the onset of diseases such as
HD. However, modeling HD as well as other neurodegenerative
disorders using patient-speciﬁc neurons is challenging, as neu-
rons differentiated from iPSCs lack aggregates and strong cell
death phenotype12,20,25,27. Moreover, iPSC-derived neurons do
not exhibit HTT mutant aggregates even after the addition of
cellular stressors such as proteasome inhibitors. Although the
relevance of UBR5 in HD pathology remains unclear due to these
limitations, we ﬁnd that ectopic expression of UBR5 is sufﬁcient
to reduce the protein levels of polyQ-expanded HTT and its
aggregation in mutant HTT-overexpressing cell models. More-
over, UBR5 knockdown hastens the deleterious changes induced
by polyQ-expanded expression in C. elegans models, providing
direct evidence of a link between UBR5 activity and polyQ-
expanded aggregation with age. It is important to note that these
C. elegans models express polyQ-expanded fused to YFP but not
HTT protein. Thus, these results suggest that UBR5 could also
have a role in the proteostasis of other polyQ-containing proteins
related with disease. However, we found that UBR5 knockdown
does not impair polyQ-expanded ATXN3 levels and aggregation
in MJD-iPSCs. Thus, we conclude that not all polyQ-containing
proteins are regulated via UBR5 activity. In these lines, we
observed that UBR5 does not impinge upon cellular localization
and aggregation of FUS variants linked with ALS. Although these
results suggest speciﬁcity of UBR5 for HTT regulation, we cannot
discard a role in the proteostasis of other aggregation-prone
proteins associated with disease. Notably, UBR5 downregulation
is sufﬁcient to induce the accumulation of aggresomes in control
hESCs/iPSCs. Since aggresomes form from the accumulation of
misfolded proteins when proteolytic systems are overwhelmed,
UBR5 may also be involved in the degradation of misfolded
proteins ensued from normal metabolism. Taken together, our
studies in immortal pluripotent stem cells identiﬁed UBR5 as a
determinant of their super-vigilant proteostasis.
Methods
hESC/iPSC lines and culture. The H9 (WA09) and H1 (WA01) hESC lines were
obtained from the WiCell Research Institute. The H9 and H1 hESCs used in our
study matches exactly the known short tandem repeat (STR) proﬁle of these cells
across the 8 STR loci analyzed (Supplementary Table 3a). No STR polymorphisms
other than those corresponding to H9 and H112 were found in the respective cell
Fig. 9 UBR5 loss hastens aggregation and neurotoxicity in HD C. elegans models. a Western blot analysis of C. elegans with antibodies to GFP and β-actin
loading control. The graph represents the Q67-YFP relative percentage values to Q67, vector RNAi-C. elegans corrected for β-actin loading control (mean ±
s.e.m. of three independent experiments). b Filter trap analysis indicates that ubr-5 knockdown increases polyQ aggregates (detected by anti-GFP antibody)
in C. elegans. The images are representative of four independent experiments. c Representative images of Q67-YFP aggregation under ubr-5 knockdown in
whole adult worms. On the right, a higher magniﬁcation of head neurons is presented. For higher magniﬁcation of C. elegans mid-body, please see
Supplementary Fig. 36. The images are representative of ﬁve independent experiments. Scale bar represents 100 μm. White arrows and red arrows indicate
nerve ring and chemosensory processes, respectively. DIC, differential interference contrast. d Filter trap analysis with anti-GFP antibody of polyQ-
expressing neuronal models in wild-type and rrf-3(pk1426) background. The images are representative of ﬁve independent experiments. e Loss of ubr-5
hastens the motility defects of polyQ67 worms. Bar graphs represent average ( ± s.e.m.) thrashing movements over a 30 s period on day 3 of adulthood
(Q19 fed vector RNAi (n= 62) versus Q19 fed ubr-5 RNAi (n= 64), P= 0.11; Q19 fed vector RNAi versus Q67 fed vector RNAi (n= 65), P < 0.0001; Q67
fed vector RNAi versus Q67 fed ubr-5 RNAi (n= 65), P < 0.0001). All the statistical comparisons were made by Student’s t-test for unpaired samples.
**P < 0.01, ****P < 0.0001
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lines, indicating correct hESC identity and no contamination with any other
human cell line. The control iPSCs #3 and HD Q71-iPSC lines #1 were a gift from
G.Q. Daley. These cells were generated using retroviral induction of c-Myc, Klf4,
Oct4 and Sox2 and fully characterized for pluripotency in refs.26,64. HD Q71-iPSC
line #2 (ND42230) was obtained from NINDS Human Cell and Data Repository
(NHCDR) through Coriell Institute. These cells were generated from the same
parental ﬁbroblast as HD Q71-iPSC line #1 via episomal expression of l-Myc, Klf4,
Oct4, Sox2 and LIN28 reprogramming factors. Likewise, ND42242 (control iPSC
line #1, Q21), ND36997 (control iPSC line #2, Q33), ND41656 (HD Q57-iPSC)
and ND36999 (HD Q180-iPSC) were also obtained from NHCDR through Coriell
Institute. Corrected isogenic counterparts of Q180-iPSCs (i.e., HD-C#1 and HD-
C#2) were a gift from M.A. Pouladi30. By STR analysis, we conﬁrmed correct
genetic identity of the control and HD-iPSCs used in our study with the corre-
sponding parental ﬁbroblast lines when ﬁbroblasts were available (that is, control
iPSCs #1, control iPSCs #2, HD Q71-iPSCs, HD Q57-iPSCs and HD Q180-iPSCs;
Supplementary Table 4). Parental ﬁbroblasts GM02183 (control #2), GM04281
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(HD Q71) and GM09197 (HD Q180) were obtained from Coriell Institute, whereas
ND30014 (control #1) and ND33392 (HD Q57) ﬁbroblasts were obtained from
NHCDR through RUCDR Inﬁnite Biologics at Rutgers University.
UKBi001-B (MJD Q74-iPSC line #1) and UKBi003-A (MJD Q74-iPSC line #2)
were obtained from the European Bank for induced pluripotent Stem Cells
(EBiSC). These MJD-iPSC lines were generated using retroviral expression of
reprogramming factors (i.e., c-Myc, Klf4, Oct4 and Sox2) and fully characterized
for pluripotency in ref.48. The MJD-iPSCs used in our study matches exactly the
STR proﬁle of the parental ﬁbroblasts provided by the depositor of the lines
(Supplementary Table 3b).
Control iPSCs #4 (FUSwt/wt), ALS-iPSCs #1 (FUSR521C/wt) and ALS-iPSCs #2
(FUSP525L/P525L) were kindly provided by A. Rosa and I. Bozzoni. All of them were
produced and characterized for pluripotency in ref.49. Brieﬂy, control iPSCs #4
were derived from a control donor and checked for absence of mutation in FUS49
whereas ALS-iPSCs #1 were generated from a patient affected by ALS in mid-late
age50. Both iPSCs lines were established via lentiviral expression of c-Myc, Klf4,
Oct4 and Sox2. ALS-iPSCs #2 were raised from control iPSCs #4 by TALEN
(transcription activator-like effector nucleases)-directed mutagenesis and are
homozygote for a FUS mutation (P525L) linked with severe and juvenile ALS49.
We conﬁrmed that the STR proﬁle of the ALS-iPSCs #2 used in our experiments
matches with the proﬁle of control iPSCs #4 (Supplementary Table 4).
The hESCs and iPSCs were maintained on Geltrex (ThermoFisher Scientiﬁc)
using mTeSR1 (Stem Cell Technologies). Undifferentiated hESC/iPSC colonies
were passaged using a solution of dispase (2 mgml−1), and scraping the colonies
with a glass pipette. Alternatively, cells were individualized with Accutase (1 unit
ml−1, Invitrogen) and seeded into Geltrex-coated plates for experiments with
proteasome and autophagy inhibitors to facilitate homogenous treatment of
cultures. All the hESC and iPSC lines used in our experiments had a normal diploid
karyotype as assessed by single nucleotide polymorphism (SNP) genotyping
(Supplementary Fig. 40). Moreover, all the cell lines used in this study were tested
for mycoplasma contamination at least once every 3 weeks. No mycoplasma
contamination was detected. Research involving hESC lines was performed with
approval of the German Federal competent authority (Robert Koch Institute).
SNP genotyping. The molecular karyotype was analyzed by SNP genotyping with
Illumina’s HumanOmniExpressExome-8-v1.2 BeadArray (Illumina, Inc., San
Diego, USA) at the Institute for Human Genetics (Department of Genomics, Life &
Brain Center, University of Bonn, Germany). Processing was performed on
genomic DNA following the manufacturer’s procedures. Copy number regions
were detected using the cnvPartition version 3.1.6.
STR analysis. STR analysis of H9 and H1 hESCs was conducted using the Pro-
mega PowerPlex 21 system (Promega Corporation) by Euroﬁns Genomics (Ger-
many). We analyzed loci D5S818, D13S317, D7S820, D16S539, vWA, TH01, TP0X
and CSF1P0 to compare with the known STR proﬁle of these hESC lines12. The
STR analysis of MJD-iPSC lines was also performed by Euroﬁns Genomics using
the Promega PowerPlex 21 system.
Genotype comparison of control and HD-iPSCs lines with their parental
ﬁbroblasts was performed using the following microsatellite markers: D17S1303,
D16S539, vWA, THO1, CSF1PO and TPOX. Fluorescently labeled PCR products
were electrophoresed and detected on an automated 3730 DNA Analyzer and data
were analyzed using Genemapper software version 3.0 to compare allele sizes
between iPSCs and their parental ﬁbroblasts (Applied Biosystems).
Neural differentiation. To obtain NPC cultures, we induced neural differentiation
of iPSCs with STEMdiff Neural Induction Medium (Stem Cell Technologies)
following the monolayer culture method65. Undifferentiated iPSCs were rinsed
once with phosphate-buffered saline (PBS) and then we added 1 ml of Gentle
Dissociation Reagent (Stem Cell Technologies) for 10 min. After the incubation
period, we gently dislodged pluripotent cells and added 2 ml of Dulbecco’s Mod-
iﬁed Eagle Medium (DMEM)/F12 (ThermoFisher Scientiﬁc)+10 μM ROCK inhi-
bitor (Abcam). Then, we centrifuged cells at 300 × g for 10 min. Cells were
resuspended on STEMdiff Neural Induction Medium+10 μM ROCK inhibitor and
plated on poly-ornithine (15 μg ml−1)/laminin (10 μg ml−1)-coated plates at a
density of 200,000 cells cm−2.
Striatal neuron differentiation. iPSCs were differentiated into striatal neurons by
induction of hedgehog signaling pathway56. iPSCs were detached by incubating
with dispase (1 mgml−1) for 20 min. The detached colonies were cultured in
suspension as free-ﬂoating embryoid bodies (EBs) in the differentiation medium
consisting of DMEM/F12, 20% knockout serum replacement, 100 μM β-
Mercaptoethanol (Sigma), 1× minimum essential medium (MEM) non-essential
amino acids and 2 mM L-glutamine. On day 4, the medium was replaced with a
neural induction medium consisting of DMEM/F12, N2 supplement (Thermo-
Fisher Scientiﬁc), 1× MEM non-essential amino acids, 2 mM glutamine and 2 μg
ml−1 heparin. On day 7, the EBs were attached to the laminin (ThermoFisher
Scientiﬁc)-coated substrate in a 35 mm culture Petri dish and cultured in the neural
induction medium. In the next week, the EBs ﬂattened and columnar neuroe-
pithelia organized into rosette appeared in the center of individual colonies. On day
12, 0.65 μM purmorphamine (Stem Cell Technologies) was added for 14 days (until
day 25). From day 26, neuroepithelial spheres were dissociated with Accutase
(1 unit ml−1, Invitrogen) at 37 °C for 5 min and placed onto poly-ornithine/lami-
nin-coated cover slips in Neurobasal medium containing a set of trophic factors,
including brain-derived neurotrophic factor (20 ng ml−1), glial-derived neuro-
trophic factor (10 ng ml−1), insulin-like growth factor-1 (10 ng ml−1), and cAMP
(1 μM) (all from R&D Systems). DARPP32-expressing neurons appeared by day 32
as assessed by immunohistochemistry using Rabbit anti-DARPP32 (Abcam,
ab40801, 1:50). We performed the experiments between days 32 and 35 of the
differentiation protocol.
Lentiviral infection of iPSCs. Lentivirus (LV)-non-targeting small hairpin RNA
(shRNA) control, LV-HTT shRNA (TRCN0000322961), LV-UBR5 shRNA #1
(TRCN0000003411), LV-UBR5 shRNA #2 (TRCN0000226458), LV-UBE3A
shRNA (TRCN0000419838), LV-UBR7 shRNA (TRCN0000037025), LV-RNF181
shRNA #1 (TRCN0000364405), LV-RNF181 shRNA #2 (TRCN0000022389), LV-
TRIM71 shRNA #1 (TRCN0000245956) and LV-TRIM71 shRNA #2
(TRCN0000245959) in pLKO.1-puro vector were obtained from Mission shRNA
(Sigma). Transient infection experiments were performed as follows. iPSCs colo-
nies growing on Geltrex were individualized using Accutase. Hundred thousand
cells were plated on Geltrex plates and incubated with mTesR1 medium containing
10 μM ROCK inhibitor for 1 day. Then, cells were infected with 5 µl of con-
centrated lentivirus. Plates were centrifuged at 800 × g for 1 h at 30 °C. Cells were
fed with fresh media the day after to remove the virus. After 1 day, cells were
selected for lentiviral integration using 2 µg ml−1 puromycin (ThermoFisher Sci-
entiﬁc). Cells were split for further experiments and collected after 5–7 days of
infection.
Transfection of HEK293T cells. HEK293T cells (ATCC) were plated on 0.1%
gelatin-coated plates and grown in DMEM supplemented with 10% fetal bovine
serum and 1% MEM non-essential amino acids (ThermoFisher Scientiﬁc) at 37 °C,
5% CO2 conditions. Cells were transfected once they reached 80–90% conﬂuency.
Then, 1 μg GFP-UBR5 wild-type or GFP-UBR5 ∆HECT overexpression plasmid
Fig. 10 Upregulation of UBR5 suppresses polyQ-expanded HTT aggregation. a Filter trap analysis with anti-polyQ-expansion diseases marker antibody of
HEK293 human cells overexpressing (OE) Q23-HTT or Q100-HTT. Ectopic expression of UBR5 reduces the accumulation of aggregates in Q100-HTT(OE)
cells. On the contrary, overexpression of a catalytic inactive UBR5 mutant (UBR5 ∆HECT) does not ameliorate polyQ-expanded aggregation. The images
are representative of three independent experiments. b Filter trap analysis of Q100-HTT(OE) HEK293 cells. Proteasome inhibition with 0.5 µMMG-132 for
16 h blocks the reduction of polyQ-expanded aggregation induced by ectopic expression of wild-type UBR5. The images are representative of three
independent experiments. c Western blot analysis of Q100-HTT(OE) HEK293 cells with antibodies to HTT and UBR5. Overexpression of wild-type UBR5
reduces the levels of Q100-HTT, whereas similar levels of UBR5 ΔHECT do not decrease mutant HTT levels. The graph represents the relative percentage
values of Q100-HTT to empty vector cells corrected for β-actin loading control (mean ± s.e.m. of three independent experiments). dWestern blot analysis
of whole cell lysates from Q100-HTT(OE) HEK293 cultures with antibodies to HTT and β-actin loading control. Proteasome inhibition with 0.5 µMMG-132
for 16 h blocks proteasomal degradation of Q100-HTT levels induced by wild-type UBR5 overexpression. The graph represents the relative
percentage values of Q100-HTT to DMSO-empty vector cells corrected for β-actin loading control (mean ± s.e.m. of three independent experiments).
e Immunoprecipitation with anti-HTT and anti-FLAG antibodies in Q100-HTT(OE) HEK293. Immunoprecipitation was followed by western blot with
antibodies to HTT and polyubiquitinated proteins (polyUb) to detect immunoprecipitated total HTT protein and polyUb-HTT, respectively. Prior to
immunoprecipitation, cells were treated with proteasome inhibitor (0.5 µM MG-132, 16 h) to block the degradation of HTT induced by UBR5 so we could
immunoprecipitate similar amounts of HTT for direct comparison of polyubiquitination among the distinct conditions. The images are representative of
three independent experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. *P < 0.05, ****P < 0.0001
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and 0.5 μg pARIS-mCherry-httQ23-GFP or pARIS-mCherry-httQ100-GFP were
used for transfection, using Fugene HD (Promega) following the manufacturer’s
instructions. After 36 h of incubation in normal medium, the cells were harvested
for further experiments. GFP-UBR5 wild-type and GFP-UBR5 ∆HECT over-
expression plasmids (Addgene plasmids #52050 and # 52051, respectively) were a
gift from D. Saunders and were ﬁrst published in ref.61. The pARIS-mCherry-
httQ23-GFP and pARIS-mCherry-httQ100-GFP66 plasmids were a gift from
F. Saudou.
Analysis of β-amyloid aggregation. N-terminal c-Myc-tagged β23 protein con-
struct was a gift from F.U. Hartl67. For mammalian expression, c-Myc-tagged
β23 sequence was cloned into pCDH-CMV-MCS-EF1 from pcDNA3.1 using XbaI
and BamHI enzymes. Cell fractionation was performed following the protocol
described in ref.67. Brieﬂy, cells were collected and resuspended in lysis buffer
(50 mM Tris (pH 7.8), 150 mM NaCl, 1% (v/v) NP40, 0.25% sodium deoxycholate,
1 mM EDTA and 1 tablet protease inhibitor cocktail (Roche) per 10 ml). The cell
lysate was then centrifuged at 20,000 × g for 30 min at 4 °C. The supernatant was
applied for analyzing soluble fraction and pellets were dissolved in SDT buffer (4%
(w/v) sodium dodecyl sulfate (SDS), 100 mM Tris-HCl (pH 7.6) and 0.1 M
dithiothreitol (DTT)). Anti-Myc antibody (Proteintech, #66004-1-Ig, 1:2000) was
used for western blot to detect c-Myc-tagged β23 protein.
Protein immunoprecipitation for interaction analysis. iPSCs were lysed in RIPA
buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF)) supplemented with protease inhibitor cocktail (Roche). Lysates were
homogenized by passing 10 times through a 27-gauge (27 G) needle attached to a
1 ml syringe and centrifuged at 13,000 × g for 15 min at 4 °C. After pre-clearing the
supernatant with Protein A agarose beads (Pierce), the samples were incubated
overnight with UBR5 antibody (Cell Signaling, #8755, 1:50) on the overhead shaker
at 4 °C. As a control, the same amount of protein was incubated with anti-FLAG
(SIGMA, F7425, 1:50) or anti-UBE3A antibody (Cell Signaling, #7526, 1:50) in
parallel. Subsequently, samples were incubated with 30 µl of Protein A beads for 1 h
at room temperature. After this incubation, samples were centrifuged for 5 min at
5,000 × g and the pellet was washed three times with RIPA buffer. For elution of the
proteins, the pellet was incubated with 2× Laemmli Buffer, boiled for 5 min and
centrifuged for 5 min at maximum speed. The supernatant was taken and loaded
onto a sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gel
for western blot analysis.
Protein immunoprecipitation for assessing polyubiquitination. HEK293 cells
were lysed in protein lysis buffer (50 mM Tris-HCl (pH 6.7), 150 mM NaCl, 1%
NP40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO,
1 mM NaF) supplemented with protease inhibitor cocktail. Lysates were homo-
genized through a syringe needle (27 G) and centrifuged at 13,000 × g for 15 min at
4 °C. The samples were incubated for 30 min with HTT antibody (Cell Signaling,
ab#5656, 1:1000) on ice. As a negative control, the same amount of protein was
incubated with anti-FLAG antibody (SIGMA, F7425) in parallel. Subsequently,
samples were incubated with 50 µl of µMACS Micro Beads for 1 h at 4 °C with
overhead shaking. After this incubation, samples were loaded to pre-cleared
µMACS column (#130-042-701). Beads were washed three times with 50 mM Tris
(pH 7.5) buffer containing 150 mM NaCl, 5% glycerol and 0.05% Triton and then
washed ﬁve times with 50 mM Tris (pH 7.5) and 150 mM NaCl. For protein
elution, the beads were incubated with 1× Laemmli Buffer for 5 min and collected
into tubes. The samples were boiled for 5 min at 95 °C and loaded in a SDS–PAGE
gel for western blot analysis.
Proteomics analysis of HTT ubiquitination sites. HEK293 cells were lysed in
protein lysis buffer (50 mM Tris-HCl (pH 6.7), 150 mM NaCl, 1% NP40, 0.25%
sodium deoxycholate, 1 mM EDTA, 1 mM NaF) supplemented with protease
inhibitor cocktail. Lysates were homogenized through syringe needle (27 G) and
centrifuged at 13,000 × g for 15 min at 4 °C. The samples were incubated for 30 min
with HTT antibody (Cell Signaling, ab#5656, 1:1000) on ice. Subsequently, samples
were incubated with 50 μl of μMACS Micro Beads for 1 h at 4 °C with overhead
shaking. After this incubation, samples were loaded to pre-cleared μMACS column
(#130-042-701). Beads were washed three times with 50 mM Tris (pH 7.5) buffer
containing 150 mM NaCl, 5% glycerol and 0.05% Triton and then washed ﬁve
times with 50 mM Tris (pH 7.5) and 150 mM NaCl. Then, columns were subjected
to in-column tryptic digestion containing 7.5 mM ammonium bicarbonate, 2 M
urea, 1 mM DTT and 5 ng ml−1 trypsin. Digested peptides were eluted using two
times 50 μl of elution buffer 1 containing 2 M urea, 7.5 mM Ambic, and 5 mM
iodoacetamide. Digests were incubated overnight at room temperature with mild
shaking in the dark. Samples were stage-tipped the next day for label-free quan-
titative proteomics. All samples were analyzed on a Q-Exactive Plus (Thermo
Scientiﬁc) mass spectrometer that was coupled to an EASY nLC 1200 UPLC
(Thermo Scientiﬁc)68. Peptides were loaded with solvent A (0.1% formic acid in
water) onto an in-house packed analytical column (50 cm × 75 µm I.D., ﬁlled with
2.7 µm Poroshell EC120 C18, Agilent). Peptides were chromatographically sepa-
rated at a constant ﬂow rate of 250 nl min−1 using 150 min methods: 5–30%
solvent B (0.1% formic acid in 80% acetonitrile) within 119 min, 30–50% solvent B
within 19 min, followed by washing and column equilibration. The mass spec-
trometer was operated in data-dependent acquisition mode. The MS1 survey scan
was acquired from 300 to 1750 m/z at a resolution of 70,000. The top 10 most
abundant peptides were subjected to higher collisional dissociation fragmentation
at a normalized collision energy of 27%. The AGC (automatic gain control) target
was set to 5e5 charges. Product ions were detected in the Orbitrap at a resolution of
17,500.
All mass spectrometric raw data were processed with Maxquant (version
1.5.3.8) using default parameters. Brieﬂy, MS2 spectra were searched against the
human Uniprot database, including a list of common contaminants. False
discovery rates (FDRs) on protein and peptide–spectrum match (PSM) level were
estimated by the target-decoy approach to 0.01% (Protein FDR) and 0.01% (PSM
FDR) respectively. The minimal peptide length was set to 7 amino acids and
carbamidomethylation at cysteine residues was considered as a ﬁxed modiﬁcation.
Oxidation (M), GlyGly (K) and Acetyl (Protein N-term) were included as variable
modiﬁcations. The match-between runs option was enabled. Label-free
quantiﬁcation (LFQ) was enabled using default settings. The resulting output was
processed using Perseus as follows: protein groups ﬂagged as “reverse”, “potential
contaminant” or “only identiﬁed by site” were removed from the proteinGroups.
txt. LFQ values were log2 transformed. Missing values were replaced using an
imputation-based approach (random sampling from a normal distribution using a
down shift of 1.8 and a width of 0.3). Signiﬁcant differences between the groups
were assessed using Student’s t-test. A permutation-based FDR approach was
applied to correct for multiple testing.
Western blot. Cells were scraped from tissue culture plates by cell scraping and
lysed in protein cell lysis buffer (50 Mm Hepes pH 7.4, 150 Mm NaCl, 1 mM
EDTA, 1% Triton X-100) supplemented with 2 mM sodium orthovanadate, 1 mM
PMSF and protease inhibitor mix). Lysates were homogenized through syringe
needle (27 G) followed by centrifugation at 8000 × g for 5 min at 4 °C and then
supernatants were collected (with the exception of the western blots showed in
Fig. 6d, where we loaded whole cell lysates without centrifugation because pro-
teasome inhibition induced high concentration of Q100-HTT (OE) in the pellet
fraction). Protein concentrations were determined with a standard BCA protein
assay (ThermoFisher Scientiﬁc). Approximately 30 μg of total protein was sepa-
rated by SDS–PAGE, transferred to polyvinylidene diﬂuoride membranes (Milli-
pore) and subjected to immunoblotting. Western blot analysis was performed with
anti-UBR5 (Stem Cell Technologies, #60094, 1:1000), anti-UBE3A (Cell Signaling,
ab#7526, 1:1000), anti-RNF181 (ThermoFisher Scientiﬁc, PA5-31008, 1:2000),
anti-UBR7 (ThermoFisher Scientiﬁc, PA5-31559, 1:1000), anti-ATXN3 (Merck,
MAB5360, 1:500), anti-FUS (Abcam, #154141, 1:1000), anti-GFP (Immuno-
kontakt, 210-PS-1GF, 1:5000), anti-polyubiquitinylated conjugates (Enzo,
PW8805-0500, 1:1000), anti-p62 (Progen, GP62-C, 1:1000), anti-LC3 (Sigma,
L7543, 1:1000), anti-DARPP32 (Abcam, #40801, 1:1000) and anti-β-actin (Abcam,
#8226, 1:5000). To detect HTT protein, we used anti-HTT (Cell Signaling, ab#5656,
1:1000), a monoclonal antibody produced by immunizing animals with a synthetic
peptide corresponding to residues surrounding Pro1220 of human HTT protein.
To detect mutant HTT, we used anti-polyQ-expansion diseases marker (Millipore,
MAB1574, 1:1000), a monoclonal antibody raised against TATA-binding protein
that recognizes peptides overlapping the polyQ stretch of this protein. This anti-
body also recognizes polyQ-containing proteins such as HTT and ATXN3 with the
remarkable property of detecting much better the polyQ-expanded pathological
proteins than the wild-type proteins12,31. Uncropped versions of all important
western blots are presented in Supplementary Fig. 41.
Immunocytochemistry. Cells were ﬁxed with paraformaldehyde (4% in PBS) for
20 min, followed by permeabilization (0.2% Triton X-100 in PBS for 10 min) and
blocking (3% bovine serum albumin in 0.2% Triton X-100 in PBS for 10 min).
Human iPSCs/NPCs were incubated in primary antibody for 2 h at room tem-
perature (Mouse anti-polyQ (Millipore, MAB1574, 1:50), Mouse anti-OCT4 (Stem
Cell Technologies, #60093, 1:200), Rabbit anti-PAX6 (Stem Cell Technologies,
#60094, 1:300), Mouse anti-FUS (Abcam, #154141, 1:500), Rabbit anti-G3BP1
(MBL, #RN048PW, 1:500), Rabbit anti-DARPP32 (Abcam, #40801, 1:50), Rabbit
anti-GABA (Sigma, #A2052, 1:100) and Chicken anti-MAP2 (Abcam, #5392,
1:500). Then, cells were washed with 0.2% Triton-X/PBS and incubated with sec-
ondary antibody (Alexa Fluor 488 Goat anti-Mouse (ThermoFisher Scientiﬁc, #A-
11029, 1:500), Alexa Fluor 568F(ab’)2 Fragment of Goat Anti-Rabbit IgG (H+L)
(ThermoFisher Scientiﬁc, #A-21069, 1:500)), Alexa Fluor 647 Donkey anti-Chicken
(Jackson ImmunoResearch, #A-703-605-155, 1:500) and Hoechst 33342 (Life
Technologies, #1656104) for 1 h at room temperature. PBS and distilled water wash
were followed before the cover slips were mounted on Mowiol (Sigma, #324590).
Aggresome detection. Pluripotent stem cells were cultured at 37 °C or under heat
stress conditions at 42 °C for 4 h. Aggresome formation was detected by PRO-
TEOSTAT Aggresome Detection Kit (ENZO, #ENZ-51035), following the manu-
facturer’s instructions. Brieﬂy, the cells were ﬁxed in 4% formaldehyde solution and
permeabilized with 0.5% Triton X-100, 3 mM EDTA, pH 8.0, in 1× assay buffer
from the detection kit. Then, aggresomes were stained with PROTEOSTAT
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Aggresome Detection reagent, including Hoechst 33342 for nuclear staining.
Imaging of aggresomes was performed using a standard rhodamine ﬁlter set.
Propidium iodide staining. Cells were incubated with 2 µg ml−1 propidium iodide
(Sigma, #81845) and Hoechst 33342 (Life Technologies, #1656104) for 1.5 h. Then,
cover slips were mounted using FluorSave Reagent (Calbiochem, #345789).
TUNEL staining. TUNEL (terminal deoxynucleotidyl transferase dUTP nick end
labeling) measurement was performed with the In situ BrdU-Red DNA Frag-
mentation (TUNEL) Assay Kit (Abcam, #66110) according to the manufacturer’s
protocol. Brieﬂy, cells were washed twice and stained with TdT enzyme and
BrdUTP for 1 h at 37 °C. A second incubation with an Anti-BrdU-Red antibody
was performed at room temperature for 30 min. Nuclei were stained with Hoechst
33342 (Life Technologies, #1656104).
RNA isolation and quantitative reverse transcription-PCR. Total RNA was
extracted using RNAbee (Tel-Test Inc.). Complementary DNA (cDNA) was gen-
erated using qScript Flex cDNA synthesis kit (Quantabio). SybrGreen real-time
quantitative PCR (qPCR) experiments were performed with a 1:20 dilution of
cDNA using a CFC384 Real-Time System (Bio-Rad) following the manufacturer’s
instructions. Data were analyzed with the comparative 2ΔΔCt method using the
geometric mean of ACTB and GAPDH as housekeeping genes. See Supplementary
Table 5 for details about the primers used for this assay.
26S proteasome ﬂuorogenic peptidase assays. Cells were collected in protea-
some activity assay buffer (50 mM Tris-HCl, pH 7.5, 250 mM sucrose, 5 mM
MgCl2, 0.5 mM EDTA, 2 mM ATP and 1mM DTT) and lysed by passing 10 times
through a 27 G needle attached to a 1 ml syringe needle. Lysates were centrifuged at
10,000 × g for 10 min at 4 °C. Then, 25 μg of total protein of cell lysates were
transferred to a 96-well microtiter plate (BD Falcon) and incubated with the
ﬂuorogenic proteasome substrate. To measure the chymotrypsin-like activity of the
proteasome we used either Z-Gly-Gly-Leu-AMC (Enzo) or Suc-Leu-Leu-Val-Tyr-
AMC (Enzo). We used Z-Leu-Leu-Glu-AMC (Enzo) to measure the caspase-like
activity of the proteasome, and Ac-Arg-Leu-Arg-AMC (Enzo) for the proteasome
trypsin-like activity. Fluorescence (380 nm excitation, 460 nm emission) was
monitored on a microplate ﬂuorometer (EnSpire, Perkin Elmer) every 5 min for 1 h
at 37 °C.
Quantitative proteomics analysis of E3 enzymes. For the characterization of
protein expression differences in E3 enzymes comparing H9 hESCs with their
neuronal counterparts, we analyzed quantitative proteomics data35 available via
ProteomeXchange with identiﬁer PXD007738. Then, we intersected the annotated
human E3 network from KEGG (Kyoto Encyclopedia of Genes and Genomes)
database69 with this proteomics dataset. Statistical comparisons were made by
Student’s t-test. FDR-adjusted P value (q value) was calculated using the
Benjamini–Hochberg procedure.
C. elegans strains and maintenance. C. elegans strains were maintained at 20 °C
using standard methods17. AM23 (rmIs298[pF25B3.3::Q19::CFP]) and AM716
(rmIs284[pF25B3.3::Q67::YFP]) strains were a gift from R. I. Morimoto. For the
generation of the strains DVG144 (rmIs298[F25B3.3p::Q19::CFP]; rrf-3(pk1426))
and DVG145 (rmIs284[pF25B3.3::Q67::YFP]; rrf-3(pk1426)), NL2099 strain (rrf-3
(pk1426)) was crossed to AM23 and AM716, respectively. Screening of rrf-3
(pk1426) worms was done by PCR using the forward primer F: GTTTTGACGC
CAAACGGTGA and two reverse primers: TGCAGCATGTCCAGACACAA,
which outﬂanks the deleted region in rrf-3(pk1426), and CCATTCTGTGCACGT
TTCCA, which binds inside the deletion.
RNAi experiments in C. elegans. RNAi-treated strains were fed Escherichia coli
(HT115) containing an empty control vector (L4440) or expressing double-
stranded ubr-5 RNAi. ubr-5 RNAi construct was obtained from the Ahringer RNAi
library and sequence veriﬁed.
Imaging of polyQ aggregates in C. elegans. AM716 and AM23 strains were
grown at 20 °C until L4 stage and then grown at 25 °C on E. coli (HT115) con-
taining either empty control vector or ubr-5 RNAi until day 3. Day 3 adult worms
were immobilized following the protocol described in ref.70. Brieﬂy, worms were
placed on 5% agarose-containing pads on a suspension of polystyrene beads
(Polyscience, 2.5% by volume). For imaging, we used a Meta 710 confocal
microscope (Zeiss) at the CECAD Imaging Facility.
Quantitative ﬂuorescence recovery after photobleaching. Q67-YFP day 3 adult
worms were immobilized on 5% agarose pads using 0.1% sodium azide. After three
prebleaching scans, a constant region of interest (ROI) (44.29 × 30.09 µm) was
bleached for 20 scans (860 ms per iteration) in a SP8 Confocal Microscope (Leica).
Directly after bleaching, the ﬂuorescence recovery was sampled once every 2 s for
90 times. Average ﬂuorescence intensities within ROIs were measured under the
same condition for empty vector and ubr-5 RNAi-treated worms using ImageJ
software. The half-life of ﬂuorescence recovery (t1/2) was determined by curve
ﬁtting of experimental data using the following exponential equation: I(t)= a(1−
e^(tau × t).
Motility assay. Animals were grown on E. coli (OP50) bacteria at 20 °C until
L4 stage and then transferred to 25 °C and fed with E. coli (HT115) bacteria
containing empty control vector or ubr-5 RNAi for the rest of the experiment. At
day 3 of adulthood, worms were transferred to a drop of M9 buffer and after 30 s of
adaptation the number of body bends was counted for 30 s. A body bend was
deﬁned as change in direction of the bend at the mid-body58.
Filter trap. AM716, AM23, DVG144 and DVG145 C. elegans strains were grown at
20 °C until L4 stage and then grown at 25 °C on E. coli (HT115) bacteria containing
either empty control vector or ubr-5 RNAi for the rest of the experiment. Day 3
adult worms were collected with M9 buffer and worm pellets were frozen with
liquid N2. Frozen worm pellets were thawed on ice and worm extracts were
generated by glass bead disruption on ice in non-denaturing lysis buffer (50 mM
Hepes pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with
EDTA-free protease inhibitor cocktail (Roche). Worm and cellular debris was
removed with 8000 × g spin for 5 min. Approximately 100 µg of protein extract was
supplemented with SDS at a ﬁnal concentration of 0.5% and loaded onto a cellulose
acetate membrane assembled in a slot blot apparatus (Bio-Rad). The membrane
was washed with 0.2% SDS and retained Q67-GFP was assessed by immunoblot-
ting for green ﬂuorescent protein (GFP; ImmunoKontakt, 210-PS-1GFP, 1:5000).
Extracts were also analyzed by SDS–PAGE with GFP antibody to determine pro-
tein expression levels.
iPSCs were collected in non-denaturing lysis buffer supplemented with EDTA-
free protease inhibitor cocktail and lysed by passing 10 times through a 27 G needle
attached to a 1 ml syringe. Then, we followed the ﬁlter trap protocol described
above. Cell pellet lysates were loaded after solubilization with 2% SDS. The
membrane was washed with 0.2% SDS and retained polyQ proteins were assessed
by immunoblotting for anti-polyQ-expansion diseases marker antibody (Millipore,
MAB1574, 1:5000). Extracts were also analyzed by SDS–PAGE to determine HTT
protein expression levels.
Data availability. Proteomics data of HTT ubiquitination sites have been depos-
ited to the ProteomeXchange Consortium via the PRIDE partner repository with
the dataset identiﬁer PXD009803. To deﬁne E3 enzymes signiﬁcantly increased in
hESC, we analyzed available quantitative proteomics data from PRIDE:
PXD007738 35. All the other data are also available from the corresponding author
upon reasonable request.
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Supplementary Figure 1. Proteasome inhibition induces aggregation of polyQ-expanded 
HTT in distinct HD-iPSC lines. a, Immunocytochemistry with antibody against polyQ-
expanded proteins of HD Q71-iPSC line #2 treated with 5 µM MG-132 for 12 h. Cell nuclei were 
stained with Hoechst 33342. The images are representative of four independent experiments. b, 
Graph represents the percentage of polyQ aggregate-positive cells/total nuclei in HD Q71-iPSC 
line #2 (mean ± s.e.m., 4 independent experiments, 300-350 total cells per treatment). c, 
Immunocytochemistry with antibody against polyQ-expanded proteins of HD Q57-iPSCs treated 
with 5 µM MG-132 (12 h). The images are representative of four independent experiments. d, 
Graph represents the percentage of polyQ aggregate-positive cells/total nuclei in HD Q57-iPSCs 
(mean ± s.e.m., 4 independent experiments, 250-300 total cells per treatment). e, 
Immunocytochemistry of control iPSC line #3 with antibody against polyQ-expanded proteins. 
The images are representative of two independent experiments. In a, c and e, scale bar represents 
10 µm. All the statistical comparisons were made by Student’s t-test for unpaired samples. P-
value: *** (P<0.001), **** (P<0.0001). 
 
 
  
Supplementary Figure 2. Proteasome inhibition does not induce HTT aggregation in two 
corrected isogenic counterparts of Q180-iPSCs. a, Immunocytochemistry of Q180-iPSCs and 
two isogenic counterparts (i.e., HD-C#1 and HD-C#2), in which the 180 CAG expansion was 
corrected to a nonpathological repeat length. Proteasome inhibition treatment: 5 µM MG-132 for 
12 h. We used an antibody against polyQ-expanded protein to detect mutant HTT aggregates. 
Cell nuclei were stained with Hoechst 33342. Scale bar represents 10 µm. The images are 
representative of three independent experiments. b, Graph represents the percentage of polyQ 
aggregate-positive cells/total nuclei in Q180-iPSCs and their corrected isogenic counterparts 
(mean ± s.e.m., 3 independent experiments, 250-300 total cells per treatment for each line).    
  
Supplementary Figure 3. Filter trap assay detects aggregation of endogenous polyQ-
expanded HTT in HD iPSCs treated with proteasome inhibitor. a, Filter trap analysis of 
control iPSCs #2 (Q33) treated with MG-132 for 12 h using anti-polyQ-expansion diseases 
marker antibody. We did not observe differences when we loaded higher amounts of total protein 
from the cell lysate, indicating that the weak signal detected in this assay corresponds to 
background signal. b, Filter trap analysis of HD Q180-iPSCs treated with MG-132 for 12 h using 
anti-polyQ-expansion diseases marker. In MG-132-treated samples, the levels of detected polyQ-
expanded aggregates correlate with the amount of total protein loaded. However, the background 
signal does not change in DMSO-treated cells regardless the total amount of protein loaded. The 
images are representative of two independent experiments. 
  
 
 
 
Supplementary Figure 4. Validation of antibodies to total HTT and anti-polyQ-expansion 
diseases marker. a, Western blot analysis of control iPSCs #3 and HD Q71-iPSCs #1 with 
antibodies to total HTT, polyQ-expanded proteins and β-actin. Arrow indicates mutant HTT 
detected with total HTT antibody in the HD Q71-iPSC line. The images are representative of 
three independent experiments. b, Western blot analysis of HD Q71-iPSCs #1 upon HTT 
knockdown. The images are representative of two independent experiments. c, Western blot 
analysis of HD Q180-iPSCs upon HTT knockdown. The images are representative of two 
independent experiments. d, Western blot analysis of Q23-HTT and Q100-HTT overexpressing 
(OE)-HEK293 cells with antibodies to total HTT, polyQ-expanded proteins, GFP and β-actin. 
The images are representative of two independent experiments. 
  
 
 
Supplementary Figure 5. Proteasome inhibition increases HTT protein levels in distinct 
iPSC lines. a, Western blot analysis with antibodies to total HTT and polyQ-expanded proteins of 
control iPSC line #1 treated with different concentrations of MG-132 (12 h). The graph represents 
the HTT relative percentage values to DMSO-treated iPSCs corrected for β-actin loading control 
(mean ± s.e.m. of three independent experiments). b, Western blot analysis of control iPSC line 
#3 treated with 1 µM MG-132 (12 h). The graph represents the HTT relative percentage values 
(corrected for β-actin) to DMSO-treated iPSCs (mean ± s.e.m. of three independent experiments). 
c, Western blot analysis of HD Q57-iPSC line treated with 1 µM MG-132 for 12 h. The graph 
represents the relative percentage value to DMSO-treated iPSCs (corrected for β-actin) of total 
HTT levels detected with anti-HTT antibody (mean ± s.e.m. of three independent experiments). d, 
Western blot analysis of HD Q71-iPSC line #2 treated with 1 µM MG-132 for 12 h. The graphs 
represent the relative percentage values to DMSO-treated iPSCs (corrected for β-actin) of normal 
(nHTT) and mutant HTT (mHTT) detected with antibodies to total HTT and polyQ-expanded 
proteins (mean ± s.e.m. of three independent experiments). All the statistical comparisons were 
made by Student’s t-test for unpaired samples. P-value: *(P<0.05), **(P<0.05). 
  
 
 
 
Supplementary Figure 6. Higher exposure time of the membrane presented in Fig. 2e for a 
better comparison of mutant HTT (mHTT) levels detected with total HTT antibody in HD Q180-
iPSCs. 
  
 
 
 
Supplementary Figure 7. Autophagy inhibition triggers accumulation of polyQ-expanded 
HTT aggregates to a lesser extent when compared to proteasome inhibition. a, 
Immunocytochemistry of control iPSC line #1 (Q21) and HD Q71-iPSC line #2 treated with 0.5 
µM MG-132 or 0.25 µM bafilomycin for 12 h. We used an antibody against polyQ-expanded 
protein to detect mutant HTT aggregates. Cell nuclei were stained with Hoechst 33342. Scale bar 
represents 10 µm. The images are representative of three independent experiments. b, Graph 
represents the percentage of polyQ aggregate-positive cells/total nuclei in the indicated iPSC lines 
with 0.5 µM MG-132 or 0.25 µM bafilomycin for 12 h (mean ± s.e.m., 3 independent 
experiments, 200-250 total cells per treatment for each line). 
  
 
 
Supplementary Figure 8. Autophagy inhibition does not increase HTT protein levels in iPSCs. a, 
Western blot analysis of control iPSC line #2 treated with bafilomycin (12 h) using antibodies to total HTT, 
polyQ-expanded proteins, LC3 and P62. β-actin is the loading control. The graph represents the relative 
percentage values to DMSO-treated iPSCs of nHTT detected with total HTT antibody and corrected for β-
actin loading control (mean ± s.e.m. of three independent experiments). b, Western blot analysis of HD 
Q71-iPSC line #2 treated with bafilomycin (12 h) The graphs represent the relative percentage values to 
DMSO-treated iPSCs (corrected for β-actin) of normal (nHTT) and mutant (mHTT) huntingtin detected 
with antibodies to total HTT and polyQ-expanded proteins (mean ± s.e.m. of three independent 
experiments). c, Western blot analysis of HD Q180-iPSCs treated with bafilomycin (12 h). The graphs 
represent the relative percentage values to DMSO-treated iPSCs (corrected for β-actin) of nHTT and 
mHTT detected with antibodies to total HTT and polyQ-expanded proteins, respectively (mean ± s.e.m. of 
three independent experiments). d, Graph represents the percentage of propidium iodide-positive cells/total 
nuclei in the indicated iPSC lines treated with bafilomycin (12 h) (mean ± s.e.m., 3 independent 
experiments, 200-300 total cells for each line). e, Chymotrypsin-like proteasome activity in the indicated 
iPSC lines treated with bafilomycin for 12 h (relative slope to the respective DMSO-iPSCs). Graph 
represents the mean ± s.e.m. of three independent experiments. All the statistical comparisons were made 
by Student’s t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), ***(P<0.001), **** (P<0.0001). 
  
 
 
 
Supplementary Figure 9. UBR5 levels decrease during differentiation of H9 hESCs. a, 
Western blot analysis of UBR5 levels in H9 hESCs compared with their neural progenitor cell 
(NPC) and terminally differentiated neuronal counterparts. β-actin is the loading control. The 
graph represents the UBR5 relative percentage values (corrected for β-actin loading control) to 
H9 hESCs (mean ± s.e.m. of five independent experiments). b, qPCR of UBR5 mRNA levels. 
Graph represents the mean ± s.e.m. (relative expression to H9 hESCs) of three independent 
experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. 
P-value: ***(P<0.001), ****(P<0.0001). 
  
  
 
 
 
Supplementary Figure 10. UBR5 levels decrease during differentiation of control and HD-
iPSC lines. a, Western blot of UBR5 levels in control #2 iPSCs (Q33) compared with their neural 
progenitor cell (NPC) and striatal neuron counterparts. The graph represents the UBR5 relative 
percentage values to iPSCs corrected for β-actin loading control (mean ± s.e.m. of three 
independent experiments). b, Western blot of UBR5 levels in HD Q71 iPSCs #1 compared with 
their NPC and striatal neuronal counterparts. The graph represents the UBR5 relative percentage 
values to iPSCs corrected for β-actin loading control (mean ± s.e.m. of three independent 
experiments). All the statistical comparisons were made by Student’s t-test for unpaired samples. 
P-value: *(P<0.05), ** (P<0.01). 
  
 
 
 
Supplementary Figure 11. Analysis of HTT mRNA levels in iPSCs and their differentiated 
counterparts.  qPCR of HTT mRNA levels in (a) control #1 (Q21), (b) HD 71 #2 and (c) HD 
180. Graphs represents the mean ± s.e.m. (relative expression to iPSCs) of three independent 
experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. 
P-value: *(P<0.05), **(P<0.01), ***(P<0.001). 
  
  
 
 
Supplementary Figure 12. Loss of intrinsic high levels of UBR5 does not change HTT 
mRNA levels in human pluripotent stem cells. a, qPCR analysis of UBR5 and HTT mRNA 
levels in H9 hESCs. Graph (relative expression to non-targeting (NT) shRNA) represents the 
mean ± s.e.m. of four independent experiments. b, qPCR analysis in H1 hESCs (mean ± s.e.m, n= 
3 independent experiments). c, qPCR analysis in control iPSCs #2 (mean ± s.e.m, n= 4 
independent experiments). d, qPCR analysis in control iPSCs #3 (mean ± s.e.m, n= 3 independent 
experiments). e, qPCR analysis in HD Q57-iPSCs (mean ± s.e.m, n= 3 independent experiments). 
f, qPCR analysis in HD Q71-iPSCs #1 (mean ± s.e.m, n= 5 independent experiments).  All the 
statistical comparisons were made by Student’s t-test for unpaired samples. P-value: *(P<0.05), 
**(P<0.01), ***(P<0.001), **** (P<0.0001). 
 
 
Supplementary Figure 13. Knockdown of UBR5 results in increased levels of HTT in 
hESCs, control iPSCs and HD iPSCs. a, Western blot analysis of HTT levels in H9 hESCs 
upon UBR5 knockdown. The graph represents the HTT relative percentage values to NT shRNA-
H9 hESCs corrected for β-actin loading control (mean ± s.e.m. of three independent experiments). 
b, Western blot analysis of H1 hESCs. The graph represents the HTT relative percentage values 
to NT shRNA-H1 hESCs corrected for β-actin loading control (mean ± s.e.m. of two independent 
experiments). c, Western blot analysis of control iPSCs #3. The graph represents the HTT relative 
percentage values to NT shRNA-control iPSCs #3 corrected for β-actin loading control 
(mean ± s.e.m. of two independent experiments). d, Western blot analysis of HD Q71-iPSC line 
#1 upon UBR5 knockdown. The graphs represent the relative percentage values to NT shRNA-
iPSCs (corrected for β-actin) of nHTT and mHTT detected with antibodies to total HTT and 
polyQ-expanded proteins (mean ± s.e.m. of three independent experiments). e, Western blot 
analysis of HD Q57-iPSCs. The graph represents the relative percentage value to NT shRNA-
iPSCs (corrected for β-actin) of total HTT levels detected with anti-HTT antibody (mean ± s.e.m. 
of two independent experiments). All the statistical comparisons were made by Student’s t-test 
for unpaired samples. P-value: * (P<0.05), **(P<0.01), **** (P<0.0001). 
 
 
 
 
 
 
Supplementary Figure 14. Knockdown of UBR5 does not change proteasome activities in 
iPSCs. Proteasome activities in control iPSC line #2 (Q33) upon UBR5 knockdown (relative 
slope to NT shRNA iPSCs). Graphs represent the mean ± s.e.m. of three independent 
experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. 
 
 
  
  
Supplementary Figure 15. Besides UBR5, knockdown of other up-regulated E3 enzymes in iPSCs 
does not increase HTT protein levels. a, Western blot analysis of HD Q180-iPSC lysates with antibodies 
to UBR5, UBE3A, RNF181 and UBR7 E3 enzymes. β-actin is the loading control. The images are 
representative of two independent experiments. b, qPCR analysis of UBE3A and UBR7 mRNA levels in 
HD Q71-iPSC line #3. Graph (relative expression to non-targeting (NT) shRNA) represents the mean ± 
s.e.m. of three independent experiments. c, Western blot analysis of HD Q71-iPSC line #1 upon 
knockdown of either UBE3A or UBR7. The graph represents the relative percentage values to NT shRNA 
iPSCs (corrected for β-actin) of nHTT and mHTT detected with antibody to total HTT (mean ± s.e.m. of 
two independent experiments). d, qPCR analysis of RNF181 mRNA levels in HD Q71-iPSC line #1. Graph 
(relative expression to NT shRNA) represents the mean ± s.e.m. of two independent experiments. e, 
Western blot analysis of HTT levels in HD Q71-iPSC line #1 upon knockdown of RNF181. The graph 
represents the relative percentage values to NT shRNA iPSCs (corrected for β-actin) of nHTT and mHTT 
detected with antibody to total HTT (mean ± s.e.m. of two independent experiments). f, qPCR analysis of 
TRIM71 mRNA levels in HD Q180-iPSCs. Graph (relative expression to NT shRNA) represents the mean 
± s.e.m. of two independent experiments. g, Western blot analysis of HD Q180-iPSCs upon knockdown of 
TRIM71 with antibodies to total HTT, polyQ-expanded proteins and β-actin. The graphs represent the 
relative percentage values to NT shRNA iPSCs (corrected for β-actin) of nHTT and mHTT detected with 
antibodies to total HTT and polyQ-expanded proteins, respectively (mean ± s.e.m. of three independent 
experiments). All the statistical comparisons were made by Student’s t-test for unpaired samples. P-value: 
*(P<0.05), **(P<0.01), ***(P<0.001). 
 
 
  
Supplementary Figure 16. UBR5 binds HTT protein in iPSCs. a, Co-immunoprecipitation 
with UBR5 and FLAG antibodies in control iPSC line #1 (Q21) followed by western blot with 
HTT and UBR5 antibodies. The images are representative of two independent experiments. b, 
Co-immunoprecipitation with UBR5 and FLAG antibodies in control iPSC line #2 (Q33). The 
images are representative of two independent experiments. c, Co-immunoprecipitation with 
UBR5 and FLAG antibodies in HD Q180-iPSCs followed by western blot with HTT, polyQ-
expanded and UBR5 antibodies. The images are representative of two independent experiments. 
  
 
 
 
Supplementary Figure 17. UBR5 prevents accumulation of mutant HTT aggregates in HD-
iPSCs. a, Immunocytochemistry of HD Q57-iPSCs upon UBR5 knockdown. PolyQ-expanded 
and Hoechst 33342 staining were used as markers of aggregates and nuclei, respectively. Scale 
bar represents 10 µm. The images are representative of three independent experiments. b, 
Immunocytochemistry of control iPSC line #3 upon UBR5 knockdown. Scale bar represents 10 
µm. The images are representative of two independent experiments.  
 
  
 
 
 
Supplementary Figure 18. Knockdown of UBR5 induces accumulation of normal HTT in 
corrected isogenic counterparts of Q180-iPSCs. Western blot of Q180-iPSCs and two isogenic 
counterparts (i.e., HD-C#1 and HD-C#2), in which the 180 CAG expansion was corrected to a 
nonpathological repeat length. The graphs represent the relative percentage values to the 
respective NT shRNA-iPSCs (corrected for β-actin) of nHTT and mHTT detected with antibodies 
to total HTT and polyQ-expanded proteins, respectively (mean ± s.e.m. of three independent 
experiments). 
 
  
 
 
Supplementary Figure 19. Proteasome inhibition does not further increase the 
accumulation of polyQ-aggregates induced by loss of UBR5. Graph represents the percentage 
of polyQ aggregate-positive cells/total nuclei in HD Q71-iPSC line #1 (mean ± s.e.m., 3 
independent experiments, 300-400 total cells per condition). Proteasome inhibitor treatment: 5 
µM MG-132 for 12 h. PolyQ-expanded and Hoechst 33342 staining were used as markers of 
aggregates and nuclei, respectively. All the statistical comparisons were made by Student’s t-test 
for unpaired samples. P-value: *** (P<0.001), **** (P<0.0001). 
  
 
 
 
Supplementary Figure 20. Knockdown of distinct proteostasis components in HD-iPSCs 
does not impair HTT mRNA levels. qPCR analysis of HD Q71-iPSC line #1 upon knockdown 
of distinct proteostasis components. Graph (relative expression to non-targeting (NT) shRNA) 
represents the mean ± s.e.m. of three independent experiments.  All the statistical comparisons 
were made by Student’s t-test for unpaired samples. P-value: * (P<0.05), ** (P<0.01). 
 
  
 
 
Supplementary Figure 21. Percentage of cell death in MJD-iPSC lines. a, Graph represents 
the percentage of propidium iodide-positive cells/total nuclei in MJD-iPSC line #1 (mean ± 
s.e.m., 2 independent experiments, 400-500 total cells). b, Percentage of propidium iodide-
positive cells/total nuclei in MJD-iPSC line #2 (mean ± s.e.m., 2 independent experiments, 400-
500 total cells). Proteasome inhibitor treatment: 5 µM MG-132 for 6 h. All the statistical 
comparisons were made by Student’s t-test for unpaired samples. P-value: ** (P<0.01). 
 
  
  
 
Supplementary Figure 22. UBR5 does not interact with ATXN3 and FUS proteins in iPSCs. 
a, Co-immunoprecipitation with UBR5 and FLAG antibodies in MJD Q74-iPSC line #2 followed 
by western blot with HTT, ATXN3 and UBR5 antibodies. * indicates IgG. The images are 
representative of two independent experiments. b, Co-immunoprecipitation with UBR5 and 
FLAG antibodies in control iPSCs #4 (FUSwt/wt), followed by western blot with HTT, FUS and 
UBR5 antibodies. The images are representative of two independent experiments. c, Co-
immunoprecipitation with UBR5 and FLAG antibodies in ALS-iPSCs #2 (FUSP525L/P525L), 
followed by western blot with HTT, FUS and UBR5 antibodies. The images are representative of 
two independent experiments. 
 
 
  
 
 
Supplementary Figure 23. Loss of UBR5 does not affect expression of pluripotency and 
germ layer markers in control pluripotent stem cells. a, qPCR analysis in control iPSC line #1 
(Q21). The graph represents the relative expression to NT shRNA (mean ± s.e.m., n= 3 
independent experiments). b, Control iPSC line #2 (Q33) (mean ± s.e.m., n= 3 independent 
experiments). c, H9 hESCs (mean ± s.e.m., n= 4 independent experiments). All the statistical 
comparisons were made by Student’s t-test for unpaired samples. P-value: * (P<0.05). 
 
  
 
 
Supplementary Figure 24. Accumulation of polyQ-expanded HTT aggregates upon UBR5 
knockdown does not affect pluripotency expression levels. qPCR analysis of pluripotency 
markers in (a) HD Q71-iPSC line #2 and (b) HD Q180-iPSC line. The graphs represent the 
relative expression to NT shRNA HD-iPSCs (mean ± s.e.m. (n= 3 independent experiments for 
each line)).  All the statistical comparisons were made by Student’s t-test for unpaired samples. P-
value: * (P<0.05), ** (P<0.01). 
 
  
 
 
Supplementary Figure 25. UBR5 knockdown does not induce loss of OCT4 expression. 
Immunocytochemistry of control iPSCs #1, control iPSCs #2 and HD Q180-iPSCs. OCT4 and 
Hoechst 33342 staining were used as markers of pluripotency and nuclei, respectively. Scale bar 
represents 20 µm. The images are representative of three independent experiments. 
 
 
Supplementary Figure 26. Loss of UBR5 does not impair neural differentiation of control 
and HD-iPSCs. After neural induction of the indicated iPSCs lines with down-regulated levels of 
UBR5, we did not observe differences in their ability to differentiate into PAX6-positive cells 
compared with their respective NT shRNA controls. Scale bar represents 20 µm. The images are 
representative of three independent experiments. 
 
 
 
Supplementary Figure 27. HD-iPSCs with downregulated levels of UBR5 differentiate into 
NPCs with aggregates. Upon neural induction of HD Q71-iPSC line #2 with down-regulated 
levels of UBR5, NPCs accumulate polyQ-expanded HTT aggregates. PolyQ-expanded and 
Hoechst 33342 staining were used as markers of aggregates and nuclei, respectively. Scale bar 
represents 10 µm. The images are representative of three independent experiments.  
  
  
 
 
Supplementary Figure 28. Filter trap of HD Q71-NPCs #2 derived from iPSCs with 
downregulated levels of UBR5. Upon neural induction of HD Q71-iPSC line #2 with 
downregulated levels of UBR5, NPCs accumulate mutant HTT aggregates as assessed by filter 
trap experiments with anti-polyQ-expansion diseases marker antibody. The images are 
representative of three independent experiments.  
 
  
 
 
Supplementary Figure 29. iPSCs with downregulated levels of UBR5 differentiate into 
NPCs with high expression of HTT upon neural induction. a, Control iPSCs #1 with 
downregulated levels of UBR5 were differentiated into NPCs and analyzed by western blot. The 
graph represents the HTT relative percentage values to NT shRNA NPCs (corrected for β-actin) 
detected with antibody to total HTT (mean ± s.e.m. of three independent experiments). b, Western 
blot analysis of NPCs derived from control iPSCs #2 with downregulated levels of UBR5. The 
graph represents the HTT relative percentage values to NT shRNA NPCs (corrected for β-actin) 
detected with antibody to total HTT (mean ± s.e.m. of three independent experiments). c, Western 
blot analysis of NPCs derived from HD Q71-iPSCs #2 with downregulated levels of UBR5. The 
graph represents the HTT relative percentage values to NT shRNA NPCs (corrected for β-actin) 
detected with antibody to total HTT (mean ± s.e.m. of two independent experiments). All the 
statistical comparisons were made by Student’s t-test for unpaired samples. P-value: *(P<0.05), 
**(P<0.01), ***(P<0.001).  
 
 
Supplementary Figure 30. iPSCs with downregulated levels of UBR5 can differentiate into striatal 
neurons. a, Striatal neuronal differentiation of HD Q180-iPSCs with downregulated levels of UBR5. 
GABA staining was used as a marker of striatal neurons. MAP2 and Hoechst 33342 staining were used as 
markers of neurons and nuclei, respectively. Scale bar represents 20 µm. The images are representative of 
three independent experiments. b, Quantification of GABA cell populations among MAP2-positive neurons 
upon striatal neuronal differentiation (mean ± s.e.m., three independent experiments, 1500-2000 cells per 
condition for each line). Knockdown of UBR5 was performed at the iPSC stage. c, qPCR analysis of 
striatal neuronal markers (DARPP32, CALB1, CALB2, GAD1, GAD2) and pan-neuronal markers (MAP2, 
TUBB3) in neurons derived from control iPSCs #1 with downregulated levels of UBR5. The graph 
represents the relative expression to NT shRNA neurons (mean ± s.e.m. (n= 4 independent experiments)). 
d, Control neurons #2 (n= 3 independent experiments). e, HD Q71-Neurons #1 (n= 3 independent 
experiments). f, HD Q71-Neurons #2 (n= 2 independent experiments). g, HD Q180-Neurons (n= 3 
independent experiments). All the statistical comparisons were made by Student’s t-test for unpaired 
samples. P-value: *(P<0.05).  
  
 
 
Supplementary Figure 31. Lack of polyQ-expanded HTT aggregates in terminally 
differentiated neurons derived from HD-iPSCs with downregulated levels of UBR5. 
Striatal neuronal differentiation of distinct control and HD-iPSCs with downregulated levels of 
UBR5. PolyQ-expanded and MAP2 staining were used as markers of polyQ-expanded aggregates 
and neurons, respectively. Scale bar represents 20 µm. The images are representative of three 
independent experiments.  
  
 
 
Supplementary Figure 32. Proteasome inhibition does not trigger aggregation of polyQ-
expanded HTT in MSNs derived from HD-iPSCs. a, b, Immunocytochemistry with antibody 
against polyQ-expanded proteins of HD Q71-neurons lines #1 (a) and #2 (b) treated with 1 µM 
MG-132 for 16 h. MAP2 was used as a pan-neuronal marker whereas DARPP32 was used as a 
marker of striatal neurons. Cell nuclei were stained with Hoechst 33342. Scale bar represents 10 
µm. The images are representative of two independent experiments. c, d, Western blot analysis of 
HD Q71-neurons lines #1 (c) and #2 (d) treated with 1 µM MG-132 for 16 h. The graphs 
represent the relative percentage values to the respective DMSO-treated neurons (corrected for β-
actin) of normal (nHTT) and mutant HTT (mHTT) detected with antibodies to total HTT and 
polyQ-expanded proteins (mean ± s.e.m. of two independent experiments). No significant 
differences were found. All the statistical comparisons were made by Student’s t-test for unpaired 
samples. 
 
 
Supplementary Figure 33. Loss of UBR5 does not induce aggregation of mutant HTT in 
MSNs derived from HD-iPSCs. Immunocytochemistry with antibody against polyQ-expanded 
proteins in the indicated neurons. MAP2 was used as a pan-neuronal marker whereas DARPP32 
was used as a marker of striatal neurons. Cell nuclei were stained with Hoechst 33342. Scale bar 
represents 10 µm. The images are representative of three independent experiments.  
 
 
 
 
Supplementary Figure 34. Knockdown of UBR5 in MSN cultures derived from iPSCs does 
not increase HTT levels. a, b, Western blot analysis of the indicated control neuronal cultures 
with antibodies to HTT and DARPP32. The graphs represent the HTT relative percentage values 
to the respective NT shRNA neurons corrected for β-actin loading control (mean ± s.e.m. of three 
independent experiments). c, Western blot analysis of HD Q57-neurons. The graph represents the 
relative percentage value to NT shRNA neurons (corrected for β-actin) of total HTT levels 
detected with anti-HTT antibody (mean ± s.e.m. of three independent experiments). d, Western 
blot analysis of HD Q71-neurons #2. The graph represents the relative percentage values to NT 
shRNA neurons (corrected for β-actin) of nHTT and mHTT detected with anti-HTT antibody 
(mean ± s.e.m. of four independent experiments). e, Western blot analysis of HD Q180-neurons. 
The graphs represent the relative percentage values to NT shRNA neurons (corrected for β-actin) 
of nHTT and mHTT detected with antibodies to HTT and polyQ-expanded proteins, respectively 
(mean ± s.e.m. of three independent experiments). 
 
 
 
 
 
Supplementary Figure 35. Loss of UBR5 does not induce apoptosis in MSN cultures derived 
from iPSCs. Percentage of TUNEL-positive nuclei in the indicated MSN cultures: a, Control 
Neurons #1, b, Control Neurons #2, c, HD Q57-Neurons, d, HD Q71-Neurons #1, e, HD Q71-
Neurons #2, f, HD Q180-Neurons. In a-f, total number of cells was evidenced after staining of 
nuclei with Hoechst 33342. Each graph represents the mean ± s.e.m. of the percentage observed 
in 3 independent neuronal differentiation experiments (we assessed approximately 200-300 total 
nuclei in each independent experiment for each line). All the statistical comparisons were made 
by Student’s t-test for unpaired samples. P-value: *(P<0.05). 
 
  
 
Supplementary Figure 36. Higher magnification of C. elegans mid-body of the images 
presented in Figure 9c. 
 
  
 
 
 
 
Supplementary Figure 37. FRAP analysis of Q67-YFP-expressing worms. Worms fed with 
empty vector or ubr-5 RNAi were immobilized and regions containing polyQ-YFP foci in the 
head neurons were bleached. Subsequently, pictures were taken once every 2 seconds for 90 
times. a, Graph represents percentage of immobile fraction. b, Graph represents the half-life of 
fluorescence recovery. In (a, b) data represents the mean ± s.e.m. of 9 worms from two 
independent experiments. All the statistical comparisons were made by Student’s t-test for 
unpaired samples. P-value: *(P<0.05). 
 
 
 
 
 
 
 
 
Supplementary Figure 38. Ectopic expression of UBR5 does not reduce aggregation of ß-
amyloid fibrils. Upon cell fractionation of HEK293 cells, ß23 polypeptide with N-terminal c-
Myc-epitope is largely recovered in the insoluble fraction. Overexpression of UBR5 does not 
increase the solubility of ß23 fibrils, as we did not detect the protein in the soluble fraction under 
this condition. Anti-Myc antibody was used to detect ß23 protein in the distinct cell fractions. T, 
total lysate; S, soluble fraction; P, pellet fraction. The images are representative of four 
independent experiments. 
 
  
 
 
 
Supplementary Figure 39. Identification of HTT ubiquitination sites. a, Immunoprecipitation 
with anti-HTT antibody in Q100-HTT(OE) HEK293 cells treated with 0.5 µM MG-132 for 16 h. 
Immunoprecipitation was followed by western blot with antibodies to HTT and polyubiquitinated 
proteins (polyUb) to detect immunoprecipitated total HTT protein and polyUb-HTT, respectively. 
These data validate increased polyubiquitination of HTT upon wild-type UBR5 overexpression 
when compared to catalytic inactive UBR5 mutant of the samples analyzed by proteomics for 
identification of ubiquitination sites. b, Relative ubiquitination levels of Lys2097 and Lys631 of 
HTT in Q100-HTT(OE) HEK293 cells upon overexpression of catalytic inactive mutant or wild-
type UBR5. HTT was immunoprecipitated with anti-HTT antibody and analyzed by mass 
spectrometry. Lys631 and 2097 of HTT were found to be ubiquitinated. The ubiquitination 
intensity of each lysine was normalized by the total HTT level in every condition. The graphs 
show ubiquitination levels normalized to the levels of ubiquitination in samples overexpressing 
UBR5 catalytically catalytic inactive UBR5 mutant (mean ± s.e.m. of three independent 
experiments). All the statistical comparisons were made by Student’s t-test for unpaired samples. 
P-value: *(P<0.05). 
 
 
 
 
 
  
 
 
Supplementary Figure 40. SNP genotyping of hESCs and iPSCs used in this study. 
  
 
 
Supplementary Figure 40 (continuation). SNP genotyping of hESCs and iPSCs used in this 
study. 
  
 
 
 
 
 
Supplementary Figure 41. Uncropped images are presented with molecular weight ladders. 
 
 
  
 
 
 
 
Supplementary Figure 41 (continuation). Uncropped images are presented with molecular 
weight ladders. 
  
 
 
 
 
Supplementary Figure 41 (continuation). Uncropped images are presented with molecular 
weight ladders. 
 
  
 
 
 
Supplementary Table 1. Patient information for disease-iPSC lines.  
 
 
 
 
 
  
iPSC line Age at sampling Age of onset Sex Relevant gene for disease Clinical information
HD Q71 lines #1/#2 20 14 Female Q71HTT/
Q19HTT
Rigid form of HD, 
hypokinetic variant of 
HD with dystonia 
and marked tremor, 
ataxic wide-based 
gait, symptomatic
HD Q180 6 <6 Male Q180HTT/
Q18HTT
Juvenile HD, 
symptomatic
HD Q57 29 Female Q57HTT/
Q17HTT
Post-juvenile HD,
pre-symptomatic
MJD Q74 line #1 40 30 Male Q74ATXN3/
Q21ATXN3
Scale for the 
Assessment and 
Rating of Ataxia 
(SARA): 23,0.
Additional 
symptoms: parkinso
nism, restless legs,
spasticity,
neuropathy
MJD Q74 line #2 38 31 Male Q74ATXN3/
Q22ATXN3
SARA: 22,5.
Additional 
symptoms: parkinso
nism, restless legs,
spasticity,
neuropathy
ALS line #1 39 Mid-late age Male FUSR521C/WT Affected by ALS in 
mid-late age
ALS line #2 Generated from 
control iPSCs #4 by 
TALEN-directed 
mutagenesis 
Male FUSP525L/P525L Patient carrying this 
mutation displayed 
severe and
juvenile onset of ALS
 
 
Supplementary Table 2. List of E3 enzymes significantly increased in hESCs compared with 
their neuronal counterparts. Tandem mass tag (TMT) quantitative proteomics comparing H9 
hESCs with neurons. Statistical comparisons were made by Student’s t-test (n= 3). False 
Discovery Rate (FDR) adjusted p-value (q-value) <0.05 was considered significant. 
 
  
E3 ubiquitin ligases 
increased in hESCs
hESC vs neuron 
ratio q-value
TRIM71 17.26 0.029
TRIM28 2.61 0.015
UBR5 2.49 0.007
RGPD1 2.46 0.010
RGPD2 2.41 0.010
RGPD8 2.36 0.013
UBR7 2.35 0.007
RGPD4 2.26 0.011
SART1 2.26 0.011
RGPD5 2.26 0.011
TRIM33 2.24 0.009
RGPD3 2.19 0.012
UBE4B 1.95 0.011
RNF20 1.94 0.017
ARIH2 1.80 0.037
RNF181 1.69 0.004
UBR4 1.61 0.021
PRPF19 1.48 0.019
HECTD1 1.46 0.010
KCMF1 1.43 0.012
UBE3A 1.30 0.007
TRIP12 1.30 0.014
RNF40 1.27 0.034
TRAF2 1.21 0.008
HERC1 1.17 0.011
HUWE1 1.09 0.028
a) 
 
 
 
b) 
 
 
 
 
 
 
Supplementary Table 3. STR profiles of hESC and MJD-iPSC lines. a, The H9 and H1 
hESCs used in our study matches exactly the published STR profile of these cells across the 8 
STR loci analysed. b, The MJD-iPSCs used in our study matches exactly the STR profile of 
their parental fibroblasts provided by the depositor of the lines. The STR profile is not 
presented in full to protect the donor’s identity as requested by the provider of the cells 
(EBiSC consortium). 
 
  
Locus ID
Alleles
H9 hESCs H1 hESCs
vWA 17, 17 15, 17
TH01 9.3, 9.3 9.3, 9.3
TP0X 10, 11 8,11
CSF1P0 11, 11 12, 13
D5S818 11, 12 9, 11
D13S317 9, 9 8, 11
D7S820 9, 11 8, 12
D16S539 12, 13 9,13
Locus ID
Alleles
MJD-iPSC line #1 MJD iPSC line #2
TH01 6, 10 9, 9.3
CSF1P0 10, 11 9, 10
D5S818 12, 13 10, 12
D13S317 8, 10 11, 11
D7S820 10, 12 9, 11
D16S539 11, 14 9, 12
  
 
 
Supplementary Table 4. Confirmation of genetic identity of HD-iPSCs lines with the 
corresponding parental fibroblasts by STR analysis. Since ALS-iPSCs #2 were raised from 
control iPSCs #4 by TALEN-directed mutagenesis, we confirmed that the STR profile of the 
ALS-iPSCs #2 used in our experiments matches with the profile of control iPSCs #4. 
 
 
 
  
Allele size in base pairs
TPOX CSFIPO THO1 vWA D17S1303 D16S539
Allele1, Allele2 Allele1, Allele2 Allele1, Allele2 Allele1, Allele2 Allele1, Allele2
ND30014 242, 242 306, 318 169, 172 146, 151 223, 227 154, 159
Control iPSCs #1 242, 242 306, 318 169, 172 146, 151 223, 227 154, 159
GMO2183 231, 231 315, 315 169, 172 146, 159 231, 235 150, 154
Control iPSCs #2 231, 231 315, 315 169, 172 146, 159 231, 235 150, 154
GMO4281 231, 242 306, 310 165, 169 146, 154 223, 223 154, 159
HD Q71-iPSCs #1 231, 242 306, 310 165, 169 146, 154 223, 223 154, 159
HD Q71-iPSCs #2 231, 242 306, 310 165, 169 146, 154 223, 223 154, 159
GMO9197 231, 234 306, 310 155, 172 135, 145 231, 235 142, 159
HD Q180-iPSCs 231, 234 306, 310 155, 172 135, 145 231, 235 142, 159
HD-C#1 (isogenic corrected line) 231, 234 306, 310 155, 172 135, 145 231, 235 142, 159
HD-C#2 (isogenic corrected line) 231, 234 306, 310 155, 172 135, 145 231, 235 142, 159
ND33392 237, 241 309, 314 164, 171 140, 145 223, 235 154, 159
HD Q57-iPSCs 237, 241 309, 314 164, 171 140, 145 223, 235 154, 159
Control iPSCs #4 231, 231 306, 311 169, 172 140, 155 223, 235 159, 168
ALS-iPSCs #2 231, 231 306, 311 169, 172 140, 155 223, 235 159, 168
 
 
 
 
Supplementary Table 5. List of primers used for qPCR experiments. 
 
Gene Forward (5' → 3') Reverse (5' → 3')
ACTB CTGGCACCCAGCACAATG CCGATCCACACGGAGTACTTG
GAPDH GCACCGTCAAGGCTGAGAAC GGATCTCGCTCCTGGAAGATG
UBR5 TGGAGTGAATCTGAGCCTTACAGA AATGTTGCTCGTGGATGATGTAAT
HTT GATTGGATGGGCACCATTAGA GATTGGATGGGCACCATTAGA
0CT4 GGAGGAAGCTGACAACAATGAAA GGCCTGCACGAGGGTTT
NANOG AAATCTAAGAGGTGGCAGAAAAACA GCCTTCTGCGTCACACCATT
SOX2 TGCGAGCGCTGCACAT TCATGAGCGTCTTGGTTTTCC
DPPA4 CTGGTGCCAACAATTGAAGCT AGGCACACAGGCGCTTATATG
GATA6 AGCGCGTGCCTTCATCA GTGGTAGTTGTGGTGTGACAGTTG
AFP GAGGGAGCGGCTGACATTATT ACCAGGGTTTACTGGAGTCATTTC
MSX1 CTCCGCAAACACAAGACGAAC CACATGGGCCGTGTAGAGTC
NES TGAAGGGCAATCACAACAGG TGACCCCAACATGACCTCTG
PAX6 CATACCAAGCGTGTCATCAATAAAC TGCGCCCATCTGTTGCT
UBE3A GACTCAAAGTTAGACGTGACCATATCA CTTCAAGTCTGCAGGATTTTCCA
UBR7 TGCCGGCTCTAGTTCTGAATC TTCTGCGTTGAGGCTTTCATT
RNF181 CCTTGCCATCACCTTTTCCA GGACAGGAATTTGTCTTGCTTAG
TRIM71 CGGCGAGGCATAAGAAAGC GCTTTCACCTGGCGGATCT
DARPP32 CCTGAAGGTCATCAGGCAGT GGTCTTCCACTTGGTCCTCA
CALB1 TCAGGACGGCAATGGATACA AAGAGCAAGATCCGTTCGGT
CALB2 TGGCGGAAGTACGACACAGA GGAATCCCTTGAGCTCATTGG
GAD1 CCAAGGTGCTGGACTTTCAT AAATCGAGGATGACCTGTGC
GAD2 CGAGCCTGGTGCCAAGTG CAGGGCGCACAGTTTGTTT
MAP2 AAAGAAGCTCAACATAAAGACCAGACT GTGGAGAAGGAGGCAGATTAGC
TUBB3 GGCCAAGTTCTGGGAAGTCA CGAGTCGCCCACGTAGTTG
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T
he survival of an organism is linked to its ability to
maintain the integrity of the cellular proteome. Oxidative
or thermal stress, misfolding-prone mutations and aging
challenge the structure of proteins. Damaged proteins form toxic
aggregates and disrupt cellular membranes, overwhelming the
cellular machinery required for their degradation and causing cell
malfunction and death1. The quality of the proteome is controlled
by proteostasis, a complex network of competing and integrated
cellular pathways that regulate the synthesis, folding, aggre-
gation, trafﬁcking, interaction and degradation of proteins2.
With age, post-mitotic cells lose extensive control of proteo-
stasis: widespread, aberrant changes in translation, a gener-
alized downregulation of chaperones and a loss of function in
protein degradation machineries often appear in differentiated
cells across time3,4. This demise in proteostasis is considered
one of the hallmarks of aging and contributes to the func-
tional loss characteristic of old organisms2,3. Proteostasis
dysfunction is associated with multiple age-related disorders
such as Huntington’s disease (HD), Alzheimer’s or Parkinson’s
disease2,3. In contrast, preservation or enhancement of
proteostasis surveillance systems until late in life improves
resistance to proteotoxic stress and slows down the aging
process4,5.
Embryonic stem cells (ESCs) demonstrate a striking capacity to
proliferate indeﬁnitely while maintaining their pluripotency6—a
capacity that necessarily demands avoidance of any imbalance in
proteostasis that would otherwise compromise their function and
immortality. Furthermore, ESCs require high global translational
rates to maintain their pluripotency7. These observations raise an
intriguing question: how do ESCs maintain the quality of their
proteome under enhanced protein synthesis and proliferation
rates? Thus, we hypothesize that ESCs can provide a novel
paradigm to study proteostasis and its demise with age. Human
ESCs (hESCs) and induced pluripotent stem cells (iPSCs) exhibit
high proteasome activity compared with their differentiated
counterparts8. However, pluripotent stem cells are remarkably
more sensitive (100 ) to proteasome inhibitors than progenitor
or terminally differentiated cells8,9. Increased proteasome activity
of human pluripotent stem cells is induced by enhanced levels of
the proteasome subunit PSMD11/RPN-6 (ref. 8). Interestingly,
RPN-6 overexpression (OE) in somatic tissues is sufﬁcient to
induce proteotoxic resistance and extend healtshpan in the
organismal model Caenorhabditis elegans10. Besides increased
proteasome activity, we hypothesize that other proteostasis
components are also enhanced in hESCs/iPSCs to maintain
their pluripotency and immortality.
In this study, we focused on the chaperome network, a key
node of proteostasis. The human chaperome is formed by 332
chaperones and co-chaperones that regulate the folding and
function of proteins11. The binding of chaperones to nascent
proteins assists their folding into the correct structure.
Furthermore, chaperones assure the proper folding and cellular
localization of proteins throughout their life cycle12. Gene
expression analysis of human brain aging shows a striking
repression of 32% of the chaperome, including ATP-dependent
chaperone machines such as cytosolic HSP90, HSP70 family
members (for example, HSPA8 and HSPA14) and subunits of the
T-complex protein-1 ring complex/chaperonin containing TCP1
(TRiC/CCT) complex. In contrast, 19.5% of the chaperome is
induced during human brain aging11. In addition, these
repression and induction are enhanced in the brains of those
with HD, Alzheimer’s or Parkinson’s disease compared with their
age-matched controls11. Notably, knockdown of speciﬁc
chaperome components that are repressed during aging such as
CCT subunits, HSPA14 or HSPA8 induces proteotoxicity in HD
C. elegans and mammalian cell models11. Therefore, deﬁning
differences in the levels and regulation of chaperone machines
between immortal hESCs and their differentiated counterparts
could be of central importance not only for understanding hESC
identity but also the aging process.
Here we show that human pluripotent stem cells exhibit
increased assembly of the chaperonin TRiC/CCT complex, a
mechanism induced by high levels of speciﬁc CCT subunits. By
studying proteostasis of pluripotent stem cells, we ﬁnd that CCT8
is sufﬁcient to increase TRiC/CCT assembly. Furthermore,
enhanced TRiC/CCT assembly is required for the striking ability
of pluripotent stem cells to maintain proteostasis of aggregation-
prone huntingtin (HTT), the mutant protein underlying HD. Our
results indicate that the differentiation process correlates with a
decline in the expression of CCT subunits and TRiC/CCT
assembly. Since the levels of CCT subunits are further decreased
in somatic tissues during organismal aging11, we examined
whether modulation of CCT8 can delay the aging process and
proteostasis dysfunction by using C. elegans as a model organism.
Notably, upregulation of CCT8 levels in somatic tissues triggers
TRiC/CCT assembly and extends organismal lifespan particularly
under proteotoxic conditions. Thus, we deﬁne CCT8 as a key
modulator of TRiC/CCT assembly and establish a link between
TRiC/CCT chaperonin, hESC identity and youthfulness.
Results
CCT subunits decrease during hESC differentiation. To
examine changes in the chaperome network during differentiation,
we performed quantitative analysis of both the transcriptome and
proteome comparing hESCs with their neural progenitor cell
(NPC) and neuronal counterparts (Supplementary Figs 1 and 2
and Supplementary Data 1 and 2). In our transcriptome analysis,
we identiﬁed 279 chaperome components. Among them, 119 genes
were downregulated and 44 genes were upregulated during dif-
ferentiation into NPCs (Supplementary Fig. 1 and Supplementary
Data 1). At the protein level, we found that 36 out of 122 identiﬁed
chaperome components decrease during differentiation into NPCs
(Supplementary Fig. 2 and Supplementary Data 2). In contrast, 27
chaperome components were increased during neural differentia-
tion. Among the 44 chaperome components decreased in
terminally differentiated neurons compared with hESCs, 28
proteins were already downregulated during differentiation into
NPCs (Supplementary Data 2).
Notably, several subunits of the chaperonin TRiC/CCT
complex decreased at both transcript and protein levels during
neural differentiation of hESCs (Supplementary Fig. 3 and
Supplementary Table 1). TRiC/CCT is required for cell viability
as a key component of the proteostasis network that facilitates the
folding ofB10% of the eukaryotic proteome13,14. TRiC/CCT not
only assists the folding of newly synthesized proteins15 but also
binds to misfolded proteins regulating their aggregation16. In
eukaryotes, the hetero-oligomeric TRiC/CCT complex consists of
two stacked rings of eight paralogous subunits each17. In our
quantitative proteomics assay, we found that CCT3, CCT4 and
CCT8 subunits are signiﬁcantly increased in hESC compared
with NPCs (Supplementary Table 1). We conﬁrmed these
results by western blot analysis and found that other subunits
also decrease during neural and neuronal differentiation
(that is, CCT2, CCT6A and CCT7; Fig. 1a). The decrease in the
protein amount of CCT subunits correlated with a reduction of
the mRNA levels during differentiation (Fig. 1b). This down-
regulation of CCT subunits was not a speciﬁc phenomenon
associated with the neural lineage as differentiation into either
endoderm or mesoderm induced a similar decrease (Fig. 1c–f).
Because hESC lines can vary in their characteristics, we
differentiated a distinct hESC line as well as two iPSC lines,
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and obtained similar results (Supplementary Figs 4 and 5).
Consistent with the ability of pluripotent stem cells to self-renew
indeﬁnitely while maintaining their undifferentiated state6, the
expression of CCT subunits and pluripotency markers did
not decline with passage (Fig. 1g,h). Taken together, our
results indicate that human pluripotent stem cells are able to
maintain enhanced expression of CCT subunits under unlimited
proliferation in their undifferentiated state. However, the levels of
subunits such as CCT8 or CCT2 decrease when hESCs/iPSCs
differentiate into distinct cell lineages. Thus, increased levels of
CCT subunits could be an intrinsic characteristic of human
pluripotent stem cells linked to their immortality and identity.
Increased expression of CCT8 induces TRiC/CCT assembly.
Prompted by these ﬁndings, we asked whether increased levels
of CCT subunits resulted into more assembled TRiC/CCT
complexes in human pluripotent stem cells. Although both hESCs
and NPCs have similar levels of total CCT1 subunits (Figs 1a
and 2a, Supplementary Fig. 4 and Supplementary Table 1), hESCs
lines exhibited a dramatic increase in the assembly of TRiC/CCT
in the form of two stacked rings (Fig. 2a and Supplementary
Fig. 4). Similarly, iPSCs also had increased TRiC/CCT assembly
compared with differentiated cells (Supplementary Fig. 5). Since
all the subunits are required for TRiC/CCT function18, down-
regulated CCT subunits could become structural limiting factors
during differentiation and modulate the decrease of TRiC/CCT
assembly. An intriguing possibility is that speciﬁc subunits can
also function as assembly activators. A comparison between the
levels (relative to CCT1) of the different subunits in hESCs and
NPCs showed that CCT8 is the most abundant subunit in both
cell types despite decreasing during differentiation (Fig. 2b).
These ﬁndings indicate that CCT8 is not stoichiometric limiting
for TRiC/CCT assembly. Thus, we asked whether an increase in
the total protein levels of CCT8 could trigger TRiC/CCT
assembly. Strikingly, ectopic expression of CCT8 induced an
increase in TRiC/CCT assembly whereas the total protein levels
of CCT1 remained similar (Fig. 2c). In contrast, we found a
decrease in the levels of CCT1 in its monomeric form on CCT8
OE (Fig. 2c). Collectively, our results suggest that human
pluripotent stem cells have an intrinsic proteostasis network
characterized by high levels of TRiC/CCT complex. However, the
levels of several CCT subunits decrease during differentiation
resulting in diminished assembly of TRiC/CCT chaperonin.
In addition, we identiﬁed CCT8 as a potential activator of
TRiC/CCT assembly by using hESCs/iPSCs as a model to study
proteostasis.
Loss of CCT subunits affects hESC identity. With the strong
connection between hESC/iPSC identity, CCT8 expression and
enhanced assembly of TRiC/CCT complex, we asked whether
increased levels of CCT8 contribute to maintain pluripotency.
Given that TRiC/CCT is essential for cell viability13, loss of
CCT subunits induced cell death and detachment of hESCs
(Supplementary Fig. 6a). To avoid these effects, we induced a
mild knockdown ofB30–50% (Fig. 3a). Notably, downregulation
of CCT8 resulted in decreased levels of pluripotency markers
(Fig. 3a). We hypothesized that high CCT8 expression impinges
on hESC function via enhanced assembly of TRiC/CCT complex.
Since mutation or loss of a single subunit is sufﬁcient to impair
the activity of the complex18, we knocked down other subunits
a
CCT7
β-actin
CCT2
CCT6A
β-actin
CCT8
β-actin
CCT1
CCT7
β-actin
CCT2
CCT6A
β-actin
CCT8
0.0
0.5
1.0
hESCs
NPCs
Neurons
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
**
**
*
***
***
**
**
*****
*
b
hESCs
Endoderm
0.0
0.5
1.0
1.5
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
**** ****
** ***
f g
c d
0.0
0.5
1.0
1.5
Cardiac progenitors
Cardiomyocytes
hESCs
Cardiac mesoderm
*
***
****
*
*
**
*
**
*
***
***
**
**
R
el
at
iv
e 
m
R
N
A 
le
ve
lsCCT7
β-actin
CCT2
CCT6A
CCT8
h
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
hESCs passage 31–33
hESCs passage 67–69
hESCs passage 83–85
0.0
0.5
1.0
1.5
* *
*
β-actin
CCT8
CCT7
CCT2
CCT1
OCT4
hESC 
passage
31 67 83
50
37
37
50
50
50
50
37
50
37
37
50
50
50
50
50
50
50
37
50
50
50
50
37
50
kDa  kDa  
kDa  kDa  
CC
T8
CC
T7
CC
T6
A
CC
T5
CC
T2
CC
T8
CC
T7
CC
T6
A
CC
T5
CC
T2
CC
T2
CC
T5
CC
T6
A
CC
T7
CC
T8
CC
T1
CC
T2
CC
T3
CC
T4
CC
T5
CC
T6
A
CC
T7
CC
T8
OC
T4
NA
NO
G
DP
PA
4
En
do
de
rm
hE
SC
s
hE
SC
s
NP
Cs
Ne
uro
ns
hE
SC
s
Me
so
de
rm
Ca
rdi
ac 
me
sod
erm
Ca
rdi
ac 
pro
ge
nito
rs
Ca
rdi
om
yoc
yte
s
e
Figure 1 | The expression of CCT subunits decreases during differentiation. (a,c,e) Western blot analysis with antibodies to CCT8, CCT7, CCT6A, CCT2
and CCT1. b-actin is the loading control. The images are representative of two independent experiments. In a,c the differentiation was performed with the
H9 hESC line whereas in e we used H1 hESCs. (b) CCT subunits relative expression to H9 hESCs represents the mean±s.e.m. of three independent
experiments. (d) CCT subunits relative expression to H9 hESCs represents the mean±s.e.m. (n¼ 7 independent experiments). (f) CCT subunits relative
expression to H1 hESCs represents the mean±s.e.m. of three independent experiments. (g) The protein levels of CCTsubunits do not differ with passage in
H9 hESCs. b-actin is the loading control. The images are representative of two independent experiments. (h) Data represent the mean±s.e.m. of the
relative expression levels to H9 hESCs passage 31–33 (n¼ 3 independent experiments). All the statistical comparisons were made by Student’s t test for
unpaired samples. P value: *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13649 ARTICLE
NATURE COMMUNICATIONS | 7:13649 | DOI: 10.1038/ncomms13649 | www.nature.com/naturecommunications 3
(that is, CCT2, CCT6A and CCT7) to determine whether
increased TRiC/CCT is required for hESC function. As with
CCT8 knockdown, decreased levels of other subunits affected the
expression of pluripotency markers (Fig. 3a,b). We performed
these experiments in an independent hESC line as well
as two iPSC lines and obtained similar results (Supplementary
Fig. 6b–d). In addition, loss of CCT levels induced the expression
of markers of the distinct germ layers (Fig. 3c and Supplementary
Fig. 7). Since we observed an upregulation in speciﬁc markers of
the three germ layers (Fig. 3c and Supplementary Fig. 7), our data
suggest that hESCs/iPSCs undergo a decline of pluripotency on
knockdown of CCT subunits but they do not differentiate into a
particular cell lineage. Although we cannot discard a role of free
monomeric CCT subunits, our results indicate that increased
levels of the TRiC/CCT complex are required for human
pluripotent stem cell identity.
TRiC determines proteostasis of pluripotent stem cells. Because
the TRiC/CCT complex modulates aggregation of damaged and
misfolded proteins16, we asked whether this chaperonin is
required for increased proteostasis of pluripotent stem cells. To
examine this hypothesis, we used iPSCs derived from HD. HD is
an autosomal dominant neurodegenerative disorder caused by the
expansion of a CAG triplet repeat region in the huntingtin gene
(HTT), which translates into a polyglutamine stretch (polyQ) in
the protein resulting in proteotoxicity and aggregation19. In its
wild-type form, HTT contains 6–35 glutamine residues. However,
in individuals affected by HD, it contains435 glutamine residues
and longer repeats predict younger disease onset19. Here we used
three different control iPSC lines and HD-iPSCs from four
donors with different allelic series (that is, polyQ57, polyQ60,
polyQ71 and polyQ180). These HD-iPSC lines possess one
mutant copy of huntingtin gene but also one normal allele
(Fig. 4a,b). Although the levels of mutant HTT were lower
compared with the normal protein, HD-iPSCs exhibited
signiﬁcant amounts of mutant polyQ-expanded HTT protein
(Fig. 4a,b). In iPSCs that express longer CAG repeat expansions
(polyQ180), the differences between the levels of mutant and
normal HTT were more dramatic (Fig. 4b). Nevertheless, we
conﬁrmed the expression of mutant HTT in these iPSCs by using
an antibody that detects remarkably better polyQ-expanded HTT
than wild-type HTT (refs 20,21; Fig. 4b,e). To examine the
aggregation of mutant HTT in HD-iPSCs, we performed ﬁlter
trap analysis that allows for quantiﬁcation of polyQ aggregates10.
Although HD-iPSCs expressed signiﬁcant levels of polyQ-
expanded HTT, these cells did not exhibit accumulation of
detectable polyQ aggregates compared with control iPSCs as
assessed by both ﬁlter trap and immunohistochemistry analyses
(Fig. 4c,e and Supplementary Fig. 8). In HD organismal models
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and mammalian cells, the inhibition of HSP90 induces heat-shock
response (HSR) and reduces polyQ-expanded protein
aggregation22. We found that the treatment with an inhibitor of
HSP90 did not further decrease the signal observed in HD-iPSCs
by ﬁlter trap, reinforcing that these cells do not accumulate
detectable aggregates of mutant HTT (Supplementary Fig. 8a).
However, a collapse in proteostasis induced by proteasome
inhibition triggered the accumulation of polyQ aggregates in HD-
iPSCs (ref. 23; Supplementary Fig. 8b–c).
Loss of CCT subunits enhances aggregation of mutant HTT
and worsens HD-related changes in yeast, C. elegans and
mammalian neuronal models24–26. Thus, increased TRiC/CCT
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assembly induced by high levels of CCT subunits could
contribute to maintain the proteostasis of mutant HTT in
iPSCs. We found that knockdown of CCT8 and other CCT
subunits trigger the accumulation of polyQ aggregates without
affecting the mutant HTT total protein levels in HD-iPSCs
(Fig. 4d,e and Supplementary Fig. 9). These results were observed
in all the HD-iPSC lines tested whereas knockdown of CCT
subunits did not induce accumulation of polyQ aggregates in
control iPSCs (Fig. 4c–e and Supplementary Fig. 10). Remarkably,
loss of different CCT subunits (that is, CCT2, CCT6A, CCT7 and
CCT8) had similar effects (Fig. 4d and Supplementary Fig. 9),
indicating that the TRiC/CCT complex modulates polyQ
aggregation in HD-iPSCs.
HD-iPSCs represent a valuable resource to gain mechanistic
insights into HD (ref. 20). Neuronal dysfunction and death occurs
in many brain regions in HD, but striatal neurons expressing
cyclic AMP-regulated phosphoprotein (DARPP32) undergo
the greatest neurodegeneration27. HD-iPSCs can be terminally
differentiated into neurons (including DARPP32-positive cells)
that exhibit HD-associated phenotypes such as cumulative risk of
death over time and increased vulnerability to excitotoxic
stressors20. Furthermore, proteotoxicity induced via autophagy
inhibition or oxidative stress results in higher neurodegeneration
of HD cells compared with controls20. Despite these phenotypes,
mutant HTT-expressing neurons present important limitations
for disease modelling such as lack of robust neurodegeneration,
polyQ aggregates and gene expression changes resembling HD
(refs 20,23). Despite the efforts to detect polyQ aggregates under
different conditions (for example, adding cellular stressors), the
presence of inclusions has not been observed in neurons derived
from HD-iPSCs (refs 20,23). The lack of inclusions in these
cells could reﬂect the long period of time before aggregates accu-
mulate in HD (ref. 20). Consistently, HD human neurons
do not accumulate detectable polyQ aggregates at 12 weeks after
transplantation into HD rat models whereas these inclusions are
observed after 33 weeks of transplantation23. To assess whether
loss of CCT subunits triggers neurodegeneration and polyQ
aggregation in these cells, we differentiated three HD-iPSC lines
(Q57, Q71 and Q180) into striatal neurons28. Among those cells
expressing the neuronal marker MAP2, B50% also expressed
DARPP32 (Supplementary Fig. 11a). As with proteasome
inhibitor treatment, we could not detect polyQ aggregates in
mutant HTT-expressing neurons on knockdown of different CCT
subunits (that is, CCT2, CCT6, CCT7 and CCT8) by either
immunohistochemistry (Supplementary Fig. 11b) or ﬁlter trap
(Supplementary Fig. 11c). However, knockdown of CCTs resulted
in increased cell death of HD neuronal cultures as assessed by
activation of caspase-3 whereas it did not induce neurode-
generation of control cells (Supplementary Fig. 11d). In contrast,
proteasome inhibition triggered cell death at the same extent in
both control and HD neurons (Supplementary Fig. 11d). These
results indicate that mutant HTT-expressing neurons are more
susceptible to TRiC/CCT dysfunction than controls, providing
a link between downregulation of CCTs with onset of neuro-
degeneration in HD during aging.
Somatic overexpression of CCT8 extends organismal lifespan.
Our results indicate that increased TRiC/CCT complex is a key
determinant of proteostasis of immortal hESCs/iPSCs. However,
c
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the levels of CCT subunits decreased on differentiation. During
human brain aging, the expression of CCTs is further repressed11.
With the strong correlation between cct levels, differentiation and
aging, we asked whether inducing TRiC/CCT assembly in somatic
post-mitotic cells could have a positive role in longevity. To
examine the impact of TRiC/CCT on organismal aging and
proteotoxic resistance, we used the nematode C. elegans. In this
organism, CCT transcripts are detected in most tissues and
developmental stages29. The role of TRiC/CCT complex in
proliferating cells during C. elegans development has been
extensively studied30. Disruption of TRiC/CCT assembly by
knockdown of different CCT subunits causes a variety of defects
in cell division and results in embryonic lethality30–32. These
effects are partially mediated by a collapse in microtubule
function as a consequence of diminished folding of tubulin by
TRiC/CCT (ref. 30). In addition, loss of different cct subunits
during post-embryonic developmental stages results in larval
arrest, body morphology alterations as well as defects in
developing gonads and sterility, indicating a key role of the
TRiC/CCT complex in C. elegans development30. In adult worms,
the only proliferating cells are found in the germline whereas
somatic tissues are formed exclusively by post-mitotic cells33. To
examine the expression of CCTs in germ cells, we dissected the
germline and intestine from adult C. elegans and compared the
levels of CCT subunits by immunohistochemistry. We found that
CCT1 subunit is enhanced in germ cells compared with the
intestine (Supplementary Fig. 12a), suggesting that CCTs are
highly expressed in the germline. Notably, knockdown of cct
subunits during adulthood dramatically decreased the number of
germ cells destabilizing the germline (Supplementary Fig. 12b).
Accordingly, we observed a dramatic decrease in the number of
laid eggs after 1 day of cct RNA interference (RNAi) treatment
during adulthood (Supplementary Fig. 12c). Overall, these data
suggest that high levels of TRiC/CCT complex are essential for
proliferating cells and germline stability. However, knockdown of
cct subunits during adulthood did not decrease lifespan in
wild-type worms (Supplementary Fig. 13 and Supplementary
Data 3).
To assess the expression of CCT subunits in somatic tissues of
adult C. elegans, we generated a green ﬂuorescent protein (GFP)
transcriptional reporter construct for cct-8 gene. Although we did
not observe GFP expression in germ cells as a result of germline
silencing of transgenes34,35, these experiments conﬁrmed wide
expression of cct-8 in somatic cells including neurons or body
wall muscle cells (Supplementary Fig. 14). Somatic expression
pattern of cct-8 resembled other cct subunits (for example, cct-1,
cct-2 and cct-7) showing a high expression in pharynx and
tail30,35 (Supplementary Fig. 14). In aging organisms, post-mitotic
somatic tissues undergo a gradual deterioration and become
particularly susceptible to age-associated protein aggregation
diseases. Thus, we asked whether increasing the levels of the
TRiC/CCT complex in somatic tissues could delay the aging of
post-reproductive organisms. To examine this hypothesis we
overexpressed CCT8, a subunit that promotes TRiC/CCT
assembly in mammalian cells (Fig. 2c). For this purpose, we
induced ectopic expression of cct-8 under sur-5 promoter
(Fig. 5a), which is expressed ubiquitously in somatic tissues but
not in the germline10,36. Notably, somatic OE of cct-8 was
sufﬁcient to extend the lifespan of C. elegans under normal
conditions (20 C; Fig. 5b and Supplementary Data 3). These
worms exhibited up to 20% increased median lifespan compared
with the control strain and other cct-overexpressing worms
(Fig. 5b). We observed similar results in two independent OE
lines of the different cct subunits tested (Supplementary Data 3).
Since OE of a single cct subunit did not change the levels of other
subunits, the longevity phenotype can be attributed speciﬁcally to
cct-8 (Fig. 5a). Interestingly, the lifespan extension induced by
ectopic expression of cct-8 was more dramatic at 25 C, a
condition that results in mild heat stress (Fig. 5c). Under this
temperature, cct-8(OE) C. elegans lived up to 40% longer than the
control strain. Overexpression of cct-2 also increased lifespan
signiﬁcantly at 25 C, although to a lesser extent than cct-8
(Fig. 5c). Since heat stress challenges the structure of proteins and
triggers the accumulation of misfolded proteins, our results
indicate that both cct-8 and cct-2 extend longevity by sustaining
the integrity of the proteome during adulthood.
To examine whether these pro-longevity effects are induced
through modulation of the TRiC/CCT complex, we knocked
down the expression of a different subunit. Given that cct
subunits are required during larval development, we initiated
RNAi treatment during adulthood. Interestingly, knockdown of
cct-6 partially reduces the longevity phenotype of both cct-8(OE)
and cct-2(OE) worms whereas it did not affect the lifespan of the
control strain (Fig. 5d and Supplementary Fig. 15). By native gel
electrophoresis analysis, we conﬁrmed that OE of cct-8 in somatic
tissues increases TRiC/CCT assembly in the form of two stacked
rings (Fig. 5e). Collectively, these results suggest that somatic OE
of cct-8 induces longevity via modulation of TRiC/CCT assembly,
particularly under proteotoxic conditions.
CCT8 determines proteotoxic stress resistance. During aging,
organisms lose their ability to maintain proteostasis and respond
to proteotoxic stress3,5. With age, the expression of several cct
subunits signiﬁcantly decreased in C. elegans whereas the levels of
cct-1 remained similar (Fig. 6a and Supplementary Fig. 16). At
day 5 of adulthood, several cct subunits (for example, cct-2, cct-5
and cct-8) were already downregulated (Fig. 6a and
Supplementary Fig. 16). To examine whether somatic cct-8(OE)
ameliorates the age-associated demise in proteotoxic stress
responses, we induced acute heat stress (34 C) at different ages
(that is, days 1 and 5). Severe heat stress dramatically affects
survival and activates the HSR, an essential mechanism to ensure
proper cytosolic protein folding and alleviate proteotoxic stress37.
Under heat stress (34 C), cct-8(OE) worms did not survive
signiﬁcantly longer compared with control strain at day 1 of
adulthood (Fig. 6b and Supplementary Data 3). However,
cct-8(OE) worms were markedly more resistant to proteo-
toxicity than control strains when subjected to heat stress at
day 5 of adulthood (Fig. 6c). Although to a lesser extent, cct-2(OE)
also conferred resistance to heat stress (Fig. 6c). As a more formal
test, we asked whether animals with reduced HSR had increased
survival when cct-8 was overexpressed (Fig. 6d). Heat-shock
transcription factor activates the HSR and is required for
proteotoxicity resistance and adult lifespan38. Thus, we induced
downregulation of HSR via silencing hsf-1 expression. Notably,
hsf-1-RNAi-treated cct-8(OE) worms lived markedly longer
compared with control worms under the same treatment
(Fig. 6d). These results indicate that cct-8(OE) C. elegans can
signiﬁcantly overcome the loss of a key transcription factor such
as hsf-1, which is not only required for HSR but also lifespan.
Growing evidence suggest that the TRiC/CCT complex could
be a therapeutic target in HD (refs 24,26). For instance,
simultaneous OE of all eight CCT subunits ameliorates polyQ-
expanded HTT aggregation and neuronal death24. Intrigued by
the protection that cct-8 could confer, we tested whether
increased levels of this subunit are sufﬁcient to protect from
polyQ-expanded aggregation. For this purpose, we used a
C. elegans model that expresses polyQ peptides throughout the
nervous system. In these worms, neurotoxicity correlates with
increased length of the polyQ repeat and age8,39. The neurotoxic
effects can be monitored by worm motility, which is markedly
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13649 ARTICLE
NATURE COMMUNICATIONS | 7:13649 | DOI: 10.1038/ncomms13649 | www.nature.com/naturecommunications 7
reduced by the aggregation of polyQ peptides with a pathogenic
threshold at a length of 35–40 glutamines39. We found that
ectopic expression of cct-8 reduced toxicity and improve motility
of worms expressing polyQ67 either at 20 C or 25 C (Fig. 6e and
Supplementary Fig. 17). Similarly, cct-2(OE) also ameliorated the
neurotoxic effects of polyQ67 aggregation although the impact of
cct-8 is more dramatic (Fig. 6e and Supplementary Fig. 17).
Moreover, ﬁlter trap analysis showed that cct-8(OE) reduced
polyQ67 aggregates without decreasing the total protein levels
of polyQ67 (Fig. 6f). In fact, we observed higher expression of
total polyQ67 protein in cct-8(OE) worms probably because they
are in a healthier state than controls. Taken together, these results
indicate CCT8 as a novel candidate to sustain proteostasis during
aging.
Longevity promoting pathways such as reduced insulin–
insulin-like growth factor signalling (IIS) and dietary restriction
(DR) delay the onset of age-related diseases associated with
proteostasis dysfunction4. These pathways confer increased
proteome integrity and resistance to proteotoxic stress during
aging4,5, mechanisms that contribute to lifespan extension. Thus,
we hypothesized that the TRiC/CCT complex could be required
for the longevity phenotype induced by DR and reduced IIS.
Notably, loss of function of TRiC/CCT complex signiﬁcantly
decreased longevity of long-lived IIS and DR genetic models
whereas it did not affect the lifespan of wild-type worms (Fig. 7a).
In C. elegans, the aging of somatic tissues is regulated by signals
from the germline40. Concomitantly, ablation of germ cells
extends lifespan and induces heightened resistance to proteotoxic
stress in post-mitotic tissues10,40. We found that TRiC/CCT
dysfunction reduces the lifespan of germline-lacking genetic
worm models (Fig. 7b). We have previously reported that
removal of germ cells induces increased expression of key
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Figure 5 | Somatic increased expression of cct-8 induces TRiC/CCTassembly and extends longevity. (a) Data represent the mean±s.e.m. of the relative
expression levels to GFP(OE) worms (n¼4 independent experiments). Statistical comparisons were made by Student’s t test for unpaired samples.
P value: **Po0.01, ****Po0.001. (b,c,d) Each lifespan graph shows a Kaplan–Meier survival plot of a single representative experiment. In each graph,
experimental and control animals were grown in parallel. n¼ total number of uncensored animals/total number (uncensoredþ censored) of animals
observed in each experiment. P values refer to experimental and control animals in a single lifespan experiment. See Supplementary Data 3 for statistical
analysis, replicate data and independent OE lines results of lifespan experiments. (b) cct-8(OE) extends lifespan at 20 C (log rank, Po0.0001). GFP(OE):
median¼ 14, n¼ 73/96; cct-2, GFP(OE): median¼ 14, n¼ 65/96; cct-7, GFP(OE): median¼ 13, n¼46/74; cct-8, GFP(OE): median¼ 16,
n¼ 70/96. (c) Both cct-8(OE) and cct-2(OE) worms live longer compared with control GFP(OE) strain at 25 C (log rank, Po0.0001). cct-8(OE) worms live
longer compared with cct-2(OE) and other cct(OE) strains (log rank, Po0.0001). GFP(OE): median¼ 10, n¼89/96; cct-2, GFP(OE): median¼ 11, n¼ 79/96;
cct-5, GFP(OE): median¼ 11, n¼42/50; cct-7, GFP(OE): median¼9, n¼ 56/77; cct-8, GFP(OE): median¼ 14, n¼ 82/96. (d) Knockdown of cct-6 reduces
the long lifespan induced by cct-8(OE) (log rank, P¼0.0001). In contrast, loss of cct-6 does not decrease the lifespan of GFP(OE) worms. RNAi was initiated
at day 1 of adulthood. GFP(OE) fed empty vector RNAi bacteria: median¼ 10, n¼ 74/96; GFP(OE) fed cct-6 RNAi bacteria: median¼ 11, n¼ 73/96; cct-8,
GFP(OE) fed empty vector bacteria: median¼ 13, n¼ 77/96; cct-8, GFP(OE) fed cct-6 RNAi bacteria: median¼ 12, n¼ 79/96. (e) Native gel electrophoresis
of GFP(OE) and cct-8,GFP(OE) worm extracts followed by immunoblotting with CCT-1 antibody (two different exposure times of the same membrane are
shown). Overexpression of cct-8 induces an increase in the assembly of TRiC/CCT in the form of two stacked rings. *indicates a complex of B475 kDa
which is strongly detected in worm lysates. The molecular weight suggests that this signal corresponds to single ring TRiC/CCT assembled forms. The
images are representative of two independent experiments.
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proteasome subunits in somatic tissues10. An intriguing
possibility is that the germline also modulates the levels of CCT
subunits in somatic tissues. Indeed, germline-lacking C. elegans
showed upregulation of CCT expression in somatic tissues
(Fig. 7c,d). Altogether, our data suggest that the TRiC/CCT
complex could be a key determinant of proteotoxic resistance and
longevity.
Discussion
Our ﬁndings establish enhanced assembly of the TRiC/CCT
complex as an intrinsic characteristic of pluripotent stem cells.
This increased assembly correlates with an upregulation of several
CCT subunits. Notably, human pluripotent stem cells are able to
maintain high expression of CCT subunits during unlimited
proliferation. However, pluripotent stem cells lose their high
levels of CCT subunits on differentiation and this decline is
already signiﬁcant in multipotent cells (for example, NPCs)
before terminal differentiation. Therefore, enhanced TRiC/CCT
assembly could be linked to the immortal and pluripotent
characteristics of hESCs/iPSCs. Indeed, we found that slight
dysfunctions of the TRiC/CCT complex induce a decrease in
pluripotency markers and, concomitantly, an increase in
differentiation markers. Deﬁning the mechanisms by which
increased TRiC/CCT regulates hESC/iPSC identity could open a
new door to a better understanding of pluripotency and
differentiation. Although the exact mechanisms are still
unknown, the TRiC/CCT complex could impinge on hESC/iPSC
function in several (and non-exclusive) manners. TRiC/CCT
assists the folding of a signiﬁcant percentage of nascent proteins
such as actin and tubulin14,41. Thus, one possibility is that
enhanced TRiC/CCT assembly is required for the proper folding
of speciﬁc regulatory or structural proteins involved either
in maintenance of hESC/iPSC identity or generation of
healthy differentiated cells. Interestingly, a study performed in
calreticulin / mouse ESCs showed a downregulation in the
expression of Cct2, Cct3 and Cct7 (ref. 42) in these cells. Calreti-
culin, a chaperone that binds to misfolded proteins preventing
their export from the endoplasmic reticulum, is essential for
cardiac development in mice43 and required for proper myoﬁbril
formation during cardiomyocyte differentiation of mouse ESCs
in vitro44. Since the TRiC/CCT complex regulates folding
and actin dynamics, the downregulation of Cct subunits in
calreticulin / mouse ESCs could forecast the myoﬁbrillar
disarray observed in their cardiomyocytes counterparts42. As
TRiC/CCT also regulates the aggregation of misfolded and
damaged proteins, increased TRiC/CCT levels could be linked to
the biological purpose of pluripotent stem cells and their intrinsic
properties such as high global protein synthesis rates and
immortality. Given the ability of hESCs to replicate indeﬁnitely
0.0
0.5
1.0
1.5 Day 5
Day 1
Day 10
Day 15
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
**
** *** *** ** **
**
***
***
*** *
**
****
**
*
**
a 34 °C (day 1 adulthood) 34 °C (day 5 adulthood)b
0 5 10 15 20
0
50
100
GFP(OE) 
cct-8, GFP(OE)
cct-2, GFP(OE)Pe
rc
en
ta
ge
 a
liv
e
Time (h) Time (h)
0 10 20 30
0
50
100
GFP(OE) 
cct-8, GFP(OE)
cct-2, GFP(OE)
c
25 °C
d
0 2 4 6 8 10
0
50
100
GFP(OE) + hsf-1 RNAi
cct-8, GFP(OE) + hsf-1 RNAi
cct-2, GFP(OE) + hsf-1 RNAi
Time (days)
Pe
rc
en
ta
ge
 a
liv
e
e f
Be
nd
s/
30
s
25 °C 
Be
nd
s/
30
s
0
10
20
30
40
50
****
***
***
SDS–PAGE
SDS-resistant
polyQ aggregates
Filter trap
Q67
GFP(OE),
Q67
cct-8, GFP(OE),
Q67
Total Q67-YFP
GFP
0
20
40
60
80
25
50
Q6
7
 
G
FP
(O
E)
,Q
67
cc
t-8
, G
FP
(O
E)
,Q
67
α-tubulin
cc
t-8
, G
FP
(OE
), Q
67
cc
t-2
, G
FP
(OE
), Q
67
GF
P(O
E), 
Q6
7
cc
t-8
, G
FP
(OE
), Q
67
cc
t-2
, G
FP
(OE
), Q
67
GF
P(O
E), 
Q6
7
en
pl-
1
cc
t-8
cc
t-7
cc
t-6
cc
t-5
cc
t-4
cc
t-3
cc
t-2
cc
t-1
kDa
Figure 6 | cct-8 determines proteotoxic stress resistance during aging and protects from polyQ aggregation. (a) The expression of several cct subunits
decreases with age. In contrast, we did not ﬁnd signiﬁcant differences in cct-1 and enpl-1, the C. elegans orthologue to the human chaperone HSP90B1. Data
represent the mean±s.e.m. of the relative expression levels to day 1 adult worms grown at 20 C (n¼4 independent experiments). These experiments
were performed with the sterile control strain fer-15(b26)II;fem-1(hc17). (b) When subjected to heat stress (34 C) at day 1 of adulthood, both cct-8(OE) and
cct-2(OE) worms show similar survival rates compared with the control strain (GFP(OE): median¼ 11, n¼ 70/72; cct-2, GFP(OE): median¼ 10, n¼ 71/72;
cct-8, GFP(OE): median¼9, n¼ 70/72). (c) In contrast, cct-8(OE) (log rank, Po0.0001) and cct-2(OE) (log rank, P¼0.0036) worms survive longer than
control strain when subjected to heat stress at day 5 of adulthood (GFP(OE): median¼ 14, n¼ 57/58; cct-2, GFP(OE): median¼ 16, n¼ 57/57; cct-8,
GFP(OE): median¼ 17, n¼ 57/57). (d) hsf-1-RNAi-treated cct(OE) worms were long-lived compared with control strain under the same treatment (log rank,
Po0.0001). RNAi was initiated at day 1 of adulthood. GFP(OE) fed hsf-1 RNAi bacteria: median¼ 7, n¼90/96; cct-2, GFP(OE) fed hsf-1 RNAi bacteria:
median¼ 8, n¼82/96; cct-8, GFP(OE) fed hsf-1 RNAi bacteria: median¼9, n¼ 72/96. (e) Ectopic expression of cct-8 and cct-2 improve motility in
polyQ67 worms grown at 25 C. In the left panel, each point represents the average thrashing rate of a single 3 day-adult animal over a period of 30 s. In the
right panel, bar graphs represent average±s.e.m. of these data (GFP(OE);Q67 (n¼ 37), cct-2,GFP(OE);Q67 (n¼ 38), cct-8,GFP(OE);Q67 (n¼ 38)). All the
statistical comparisons were made by Student’s t test for unpaired samples. P value: ***Po0.001, ****Po0.0001. (f) Filter trap indicates that cct-8 OE
results in decreased polyQ aggregates (detected by anti-GFP antibody). Right panel: SDS–PAGE analysis with antibodies to GFP and a-tubulin loading
control. The images are representative of two independent experiments. See Supplementary Data 3 for statistical analysis and replicate data of lifespan and
stress assays experiments.
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and generate every other cell type in the body, the TRiC/CCT
complex could be a key quality control mechanism to maintain a
global intact proteome for either self-renewal or the generation of
progenitor cells. In this context, the accumulation of damaged
and misfolded proteins caused by proteostasis defects may affect
hESC/iPSC function and immortality. With the asymmetric
divisions invoked by these cells, the passage of damaged proteins
to progenitor cells could also compromise development and
organismal aging. In support of this hypothesis, we found that the
TRiC/CCT complex determines the ability of pluripotent stem
cells to maintain proteostasis of mutant huntingtin.
Another important question is how pluripotent stem cells
achieve their high TRiC/CCT levels. Interestingly, speciﬁc
subunits such as CCT4 are relatively more abundant compared
to CCT1 in hESCs whereas this proportion is reversed in NPCs
(Fig. 2b). Therefore, these subunits could become limiting
assembly factors during differentiation. Despite decreasing during
neural differentiation, other CCT subunits (that is, CCT8 and
CCT2) were more abundant relatively to the rest of subunits in
both hESCs and NPCs suggesting that they could be activators
of TRiC/CCT assembly rather than limiting factors. Indeed,
increasing the expression of CCT8, the most abundant subunit,
triggers TRiC/CCT assembly regardless the levels of other
subunits such as CCT1 in both mammalian cells and C. elegans.
Further studies will be required to understand how CCT8
promotes TRiC/CCT assembly. A fascinating hypothesis is that
CCT8 could act as a scaffold protein that triggers the interaction
between the different subunits.
Our ﬁndings in human pluripotent stem cells led us to identify
CCT8 as a powerful candidate to sustain proteostasis during
organismal aging. The somatic induction of TRiC/CCT assembly
via CCT8 OE extends lifespan and protects from proteotoxic
stress in C. elegans. Notably, somatic CCT8 OE can partially
protect this nematode from knockdown of hsf-1, a transcription
factor that coordinates cellular protein-misfolding responses. The
precise mechanism by which the TRiC/CCT complex ameliorates
the detrimental effects triggered by loss HSF1 is not yet
understood. In response to proteotoxic stress, HSF1 binds heat-
shock elements in the promoters of target genes and triggers their
expression45. In mammalian cells, all the CCT subunits contain
heat-shock elements and are transcriptionally activated by HSF1
(ref. 46). Thus, ectopic expression of CCT8 could ameliorate
the effects induced by a decrease of CCT subunits on HSF1
knockdown. In addition, a direct regulatory interaction between
TRiC/CCT activity and induction of proteotoxic stress response
by HSF1 has been recently reported47,48. HSF1A, a chemical
activator of HSF1, binds to the TRiC/CCT complex and inhibits
its folding activity47,48. Both the inactivation of TRiC/CCT
complex by HSF1A or its depletion by loss of CCT subunits
induce HSF1 activity47. Since TRiC/CCT chaperonin interacts
with HSF1 (ref. 47), TRiC/CCT could have a direct repressor role
in regulating HSF1 (ref. 47). However, a decrease in TRiC/CCT
activity mediated by either HSF1A or knockdown of CCT
subunits can also lead to the accumulation of misfolded proteins
that trigger the HSF1-induced proteotoxic response47. In support
of this hypothesis, our results suggest that increased TRiC/CCT
assembly induced by CCT8 reduces the accumulation of
misfolded proteins and, therefore, ameliorates the deleterious
impact of reduced HSF1-mediated signalling.
During organismal aging, loss of proteostasis in somatic tissues
could contribute to the late onset of age-related diseases such as
HD (refs 3,11). Hence, the decrease in the levels of several CCT
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increased levels of CCT-1 in the intestine compared with wild-type worms. Cell nuclei were stained with DAPI. White arrow indicates gonad and red arrow
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subunits during human brain aging11 may induce TRiC/CCT
dysfunction, proteotoxic stress and neurodegeneration. In
support of this hypothesis, knockdown of CCT subunits hastens
aggregation of mutant HTT and worsens HD-related changes in
HD models11,24–26. Previous studies have shown that
simultaneous OE of all eight CCT subunits ameliorates polyQ-
expanded HTT aggregation and neuronal death24. Furthermore,
OE of CCT1 remodels the morphology of HTT aggregates and
reduces neurotoxicity26. Although CCT1 OE does not increase
TRiC/CCT assembly, this subunit modulates the interaction
between HTT and TRiC/CCT complex26. Since CCT8 is
sufﬁcient to increase TRiC/CCT assembly, this subunit could be
a candidate to correct deﬁciencies in age-related diseases
associated with proteostasis dysfunction. Indeed, we found that
OE of CCT8 can protect from the accumulation of polyQ-
expanded proteins. Recently, a link between CCT8 and mutant
HTT expression was observed in an integrated genomics and
proteomics study of knock-in HD mouse models expressing the
human HTT exon1 carrying different CAG lengths (polyQ20,
Q80, Q92, Q111, Q140 or Q175)49. Notably, highly expanded-
polyQ HTT exon1 (Q175) induces a signiﬁcant increase of CCT8
at both transcript and protein levels in the striatum of young mice
(6 months) whereas other subunits were not altered49. In
contrast, CCT8 induction was not observed in knock-in mice
expressing mutant HTT with lower than 175 polyQ repeats.
These ﬁndings suggest that upregulation of CCT8 could be a
compensatory mechanism to protect from polyQ aggregation.
While expression of CCT subunits decrease during both
differentiation and biological aging, our results indicate that
mimicking proteostasis of pluripotent stem cells by modifying
either the chaperome or proteasome network8 delays the aging of
somatic cells and extends organismal lifespan. Given the link
between sustained proteostasis in somatic cells and healthy aging,
our ﬁndings raise an intriguing question: why the levels of CCT8
decrease during differentiation if this subunit could have
beneﬁcial effects on organismal longevity and proteotoxic stress
resistance? In this regard, it is important not to diminish potential
detrimental effects of mimicking proteostasis of pluripotent stem
cells in somatic tissues. For instance, cancer cells and pluripotent
stem cells not only share their immortality features but also
increased proteostasis nodes such as proteasome activity and
speciﬁc chaperones50–52. Proteasome and chaperone levels in
cancer cells are consistent with the special requirements of these
cells, such as elimination of aberrant proteins. Interestingly, the
expression of CCT8 is increased in gliomas and hepatocellular
carcinoma whereas its knockdown induces a decrease in the
proliferation and invasion capacity of these cells53,54. Similarly,
other CCT subunits have been linked to cancer55. Whereas
proteasome inhibitors and interventions of the chaperome
network have been suggested as potential strategies for anti-
cancer therapy52,56, an abnormal activation of these mechanisms
in somatic dividing cells could have the opposite effect inducing
their abnormal proliferation. However, although the TRiC/CCT
complex is important for the proliferation of cancer cells, this
chaperonin is also required for the proper folding of p53 and,
therefore, promotes tumour suppressor responses57. Thus, the
TRiC/CCT complex could be an important factor to avoid
misfolding of tumour suppressors and the increase incidence of
cancer during the aging process. Besides its link with cancer,
other factors could explain the decline of CCT subunits during
differentiation. In support of the disposable soma theory of
aging58, a fascinating hypothesis is that downregulation of the
TRiC/CCT complex during differentiation is part of an
organismal genetic programme that ensures a healthy progeny
whereas somatic tissues undergo a progressive demise in their
homeostasis and function. Due to the limitation of nutrients in
nature, organisms divide the available metabolic resources
between reproduction and maintenance of the non-reproductive
soma. Evolutionary pressure has been theorized to force a
re-allocation of the resources to prevent or eliminate damage to
the germline and progeny, while little resources are placed on the
maintenance of somatic cells58. In support of this hypothesis,
signals from the germline modulate the aging of somatic tissues
and removal of the germline extends lifespan40. Interestingly, our
results indicate that germline-lacking worms exhibit increased
levels of TRiC/CCT in post-mitotic cells.
Collectively, we underscore the importance of deﬁning
proteostasis of pluripotent stem cells to uncover novel mechan-
isms of organismal healthspan extension. Besides CCT subunits,
other chaperome components also decrease during differentiation
and, therefore, could be interesting targets to be studied in the
context of aging. In addition, it will be fascinating to explore
whether other proteostasis components are also divergent
in pluripotent stem cells and if mimicking these mechanisms in
somatic cells extends organismal healthspan.
Methods
hESCs/iPSCs culture. The human H9 (WA09) and H1 (WA01) hESC lines
were obtained from WiCell Research Institute. The human control iPSC line #1
(hFIB2-iPS4 (ref. 59)) and HD Q71-iPSC line #1 (ref. 60) were a gift from G.Q.
Daley. These iPSC lines were derived and fully characterized for pluripotency
in refs 59,60. ND42242 (control iPSC line #2, Q21), ND36997 (control iPSC
line #3, Q33), ND41656 (HD Q57-iPSC), ND36998 (HD Q60-iPSC), ND42229
(HD Q71-iPSC line #2) and ND36999 (HD Q180-iPSC) were obtained from
NINDS Human Cell and Data Repository (NHCDR) through Coriell Institute.
Parental ﬁbroblasts GM02183 (control Q33), GM03621 (HD Q60), GM04281
(HD Q71) and GM09197 (HD Q180) were obtained from Coriell Institute whereas
ND30014 (control Q21) and ND33392 (HD Q57) ﬁbroblasts were obtained from
NHCDR through RUCDR Inﬁnite Biologics at Rutgers University. hESCs and
iPSCs were maintained on Geltrex (ThermoFisher Scientiﬁc) using mTeSR1
(Stem Cell Technologies). hESCs and iPSCs colonies were passaged using a
solution of dispase (2mgml 1), and scraping the colonies with a glass pipette. The
hESC and iPSC lines used in our experiments had a normal diploid karyotype as
indicated by single nucleotide polymorphism (SNP) genotyping (Supplementary
Fig. 18). Genetic identity of hESCs was assessed by short tandem repeat (STR)
analysis. The H9 and H1 hESC lines used in our study matches exactly the known
STR proﬁle of these cells across the 8 STR loci analysed (Supplementary Table 2).
No STR polymorphisms other than those corresponding to H9 and H1 were found
in the respective cell lines, indicating correct hESC identity and no contamination
with any other human cell line. By STR analysis, we also conﬁrmed correct genetic
identity of the iPSCs used in our study with the corresponding parental ﬁbroblast
lines when ﬁbroblasts were available (that is, ND42242, ND36997, ND41656,
ND36998, ND42229, ND36999 and HD Q71-iPSC line #1; Supplementary
Table 3). All the cell lines used in this study were tested for mycoplasma
contamination at least once every 3 weeks. No mycoplasma contamination
was detected. Research involving hESC lines was performed with approval
of the German Federal competent authority (Robert Koch Institute).
Pan-neuronal differentiation. Neural differentiation of H9 hESCs, H1 hESCs and
iPSCs was performed using the monolayer culture protocol following the STEMdiff
Neural Induction Medium (Stem Cell Technologies) method based on ref. 61.
Undifferentiated pluripotent stem cells were rinsed once with PBS and then we
added 1ml of Gentle Dissociation Reagent (Stem Cell Technologies) for 10min.
After the incubation period, we gently dislodged pluripotent cells and add 2ml
of Dulbecco’s Modiﬁed Eagle Medium (DMEM)-F12þ 10mM ROCK inhibitor
(Abcam). Then, we centrifuged cells at 300g for 10min. Cells were resuspended
on STEMdiff Neural Induction Mediumþ 10mM ROCK inhibitor and plated
on polyornithine (15mgml 1)/laminin (10mgml 1)-coated plates (200,000
cells cm 2). For neuronal differentiation, NPCs were dissociated with Accutase
(Stem Cell Technologies) and plated into neuronal differentiation medium (DMEM/
F12, N2, B27 (ThermoFisher Scientiﬁc), 1mgml 1 laminin (ThermoFisher
Scientiﬁc), 20 ngml 1 brain-derived neurotrophic factor (BDNF) (Peprotech),
20 ngml 1 glial cell-derived neurotrophic factor (GDNF) (Peprotech), 1mM
dibutyryl-cyclic AMP (Sigma) and 200 nM ascorbic acid (Sigma)) onto
polyornithine/laminin-coated plates as described in ref. 8. Cells were differentiated
for 1–2 months, with weekly feeding of neuronal differentiation medium.
Striatal neuron differentiation. iPSCs were differentiated into striatal neuron by
induction with sonic hedgehog in a deﬁned medium as reported in ref. 28. Brieﬂy,
iPSCs were detached by incubating with dispase (1mgml 1) for 20min. The
detached colonies were cultured in suspension as free-ﬂoating embryoid bodies
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(EBs) in the differentiation medium consisting of DMEM/F12, 20% knockout
serum replacement, 1MEM non-essential amino acids, 2mM L-glutamine, and
100mM b-Mercaptoethanol. On day 4, the medium was replaced with a neural
induction medium consisting of DMEM/F12, N2 supplement, 1MEM non-
essential amino acids, 2mM glutamine and 2 mgml 1 heparin. On day 7, the EBs
were attached to laminin-coated substrate in a 35-mm culture petri dish and
cultured in the neural induction medium. In the next week, the EBs ﬂattened and
columnar neuroepithelia organized into rosette appeared in the centre of individual
colonies. On day 12, sonic hedgehog (200 ngml 1) was added for 14 days
(until day 25). From day 26, neuroepithelial spheres were dissociated with Accutase
(1 unit ml 1, Invitrogen) at 37 C for 5min and placed onto polyornithine/
laminin-coated coverslips in the neurobasal medium in the presence of valproic
acid (VPA, 10 mM, Sigma) for 1 week, followed by a set of trophic factors, including
brain derived neurotrophic factor (BDNF, 20 ngml 1), glial-derived neurotrophic
factor (10 ngml 1), insulin-like growth factor 1 (10 ngml 1) and cyclic AMP
(1mM) (all from R&D Systems). DARPP32-expressing neurons appeared by day
35.
Endoderm differentiation. Endoderm differentiation of H9 hESCs was performed
using STEMdiff Deﬁnitive Endoderm Kit (Stem Cell Technologies).
Cardiomyocyte differentiation. Cardiomyocyte differentiation was performed as
described in ref. 62. Conﬂuent H1 hESCs were dissociated into single cells with
Accutase at 37 C for 10min followed by inactivation using two volumes of
F12/DMEM. Cells were counted and 230,000 cells cm 2 where plated in ITS
medium (Corning), containing 1.25 mM CHIR 99021 (AxonMedchem) and
1.25 ngml 1 BMP4 (R&D), and seeded on Matrigel-coated 24-well plates. After
24 h, medium was changed to TS (transferrin/selenium) medium. After 48 h,
medium was changed to TS medium supplemented with 10 mM canonical
Wnt-Inhibitor IWP-2 (Santa Cruz) for 48 h. Then, medium was changed to fresh
TS until beating cells were observed at days 8–10. Finally, medium was changed
to Knockout DMEM (ThermoFisher Scientiﬁc) supplemented with 2% FCS,
L-Glutamine and Penicillin/Streptomycin until cells were used for downstream
analysis.
SNP genotyping. The molecular karyotype was analysed by SNP genotyping using
Illumina’s HumanOmniExpressExome-8-v1.2 BeadArray (Illumina, Inc., San
Diego, CA, USA) at the Institute for Human Genetics (Department of Genomics,
Life & Brain Center, University of Bonn, Germany). Processing was performed on
genomic DNA following the manufacturer’s procedures. Copy number regions
were detected using the cnvPartition version 3.1.6.
STR typing. STR analysis of H9 and H1 hESC lines was conducted using the
Promega PowerPlex 21 system (Promega Corporation) by Euroﬁns Genomics
(Germany). We analysed loci D5S818, D13S317, D7S820, D16S539, vWA, TH01,
TP0X and CSF1P0 to compare with the known STR proﬁle of these hESC lines63.
Genotype analysis of iPSCs lines and their parental ﬁbroblasts was performed using
the following microsatellite markers: D17S1303, D16S539, D10S526, vWA, THO1,
D5S818, CSF1PO and TPOX. Fluorescently labelled PCR products were
electrophoresed and detected on an automated 3730 DNA Analyzer and data were
analysed using Genemapper software version 3.0 to compare allele sizes between
iPSCs and their parental ﬁbroblasts (Applied Biosystems).
Lentiviral infection of human stem cells. Lentivirus (LV)-non targeting shRNA
control, LV-shCCT2#1 (clone number TRCN0000029499), LV-shCCT2#2
(TRCN0000029500), LV-shCCT6A#1 (TRCN0000062514), LV-shCCT6A#2
(TRCN0000062515), LV-shCCT7#1 (TRCN0000147373), LV-shCCT7#2
(TRCN0000149108), LV-shCCT8#1 (TRCN0000442235) and LV-shCCT8#2
(TRCN0000438803) in pLKO.1-puro vector were obtained from Mission shRNA
(Sigma). Transient infection experiments were performed as follows. hESC/iPSC
colonies growing on Geltrex were incubated with mTesR1 medium containing
10mM ROCK inhibitor (Abcam) for 2 h and individualized using Accutase.
Hundred thousand cells were plated on Geltrex plates and incubated with mTesR1
medium containing 10 mM ROCK inhibitor for 1 day. Cells were infected with 5 ml
of concentrated lentivirus. Plates were centrifuged at 800g for 1 h at 30 C. Cells
were fed with fresh media the day after to remove virus. After 1 day, cells were
selected for lentiviral integration using 1 mgml 1 puromycin (ThermoFisher
Scientiﬁc). Cells were collected for experimental assays after 4–6 days of infection.
Alternatively, we generated stable transfected hESCs. In this case, hESC colonies
growing on Geltrex were incubated with mTesR1 medium containing 10 mM
ROCK inhibitor for 1 h and individualized using Accutase. Fifty thousand cells
were infected with 20 ml of concentrated lentivirus in the presence of 10 mM ROCK
inhibitor for 1 h. Cell suspension was centrifuged to remove virus, passed though a
mesh of 40 mM to obtain individual cells, and plated back on a feeder layer of fresh
mitotically inactive mouse embryonic ﬁbroblasts in hESC media (DMEM/F12, 20%
knockout serum replacement (ThermoFisher Scientiﬁc), 1mM L-glutamine,
0.1mM non-essential amino acids, b-mercaptoethanol and 10 ngml 1 bFGF
(Joint Protein Central)) supplemented with 10 mM ROCK inhibitor. After a few
days in culture, small hESC colonies arose. Then, we performed 1 mgml 1
puromycin selection during 2 days and colonies were manually passaged onto
fresh mouse embryonic ﬁbroblasts to establish new hESC lines.
Transfection of HEK293T cells. HEK293T cells (ATCC) were plated on 0.1%
gelatin-coated plates and grown in DMEM supplemented with 10% FCS and 1%
non-essential amino acids (ThermoFisher Scientiﬁc) at 37 C, 5% CO2 conditions.
Cells were transfected once they reached 80–90% conﬂuency. 1 mg CCT8 OE
plasmid (Sino Biological HG11492-UT) or pCDNA3.1 empty vector plasmid
(Life Technologies V870–20) were used for transfection, using Fugene HD
(Promega) following manufacturer’s instructions. 24 h after transfection, the cells
were treated with 500 mgml 1 Hygromycin B gold (Invivogen) during 16 h to
select for transfected cells. After 24 h incubation in normal medium, the cells were
harvested for TRiC/CCT assembly experiments.
Immunohistochemistry. Cells were ﬁxed with paraformaldehyde (4% in PBS) for
20min, followed by permeabilization (0.2% Triton X-100 in PBS for 10min) and
blocking (3% BSA in 0.2% Triton X-100 in PBS for 10min). Cells were incubated in
primary antibody overnight at 4 C (Mouse anti-Polyglutamine-Expansion Dis-
eases Marker Antibody (Merck Millipore, MAB1574, 1:50), Rabbit anti-Cleaved
Caspase-3 (Cell Signaling, 9661, 1:400), Rabbit anti-DARPP32 (Abcam, ab40801,
1:100), Chicken anti-MAP2 (Abcam, ab5392, 1:1,000). After washing with PBS,
cells were incubated in secondary antibody (Alexa Fluor 488 goat anti-mouse
(ThermoFisher Scientiﬁc, A-11029, 1:1,000), Alexa Fluor 647 donkey anti-chicken
(Jackson ImmunoResearch, 703-605-155, 1:1,000), Alexa Fluor 568 goat anti-
Rabbit (ThermoFisher Scientiﬁc A-21067, 1:1,000)) and co-stained with 2 mgml 1
Hoechst 33342 (Life technologies). Finally, coverslips were covered with Mowiol
(Sigma).
mRNA sequencing. For hESCs, NPCs and neurons (1, 2 and 4 weeks of differ-
entiation) total RNA was extracted using RNAbee (Tel-Test Inc.). Total RNA was
rRNA-depleted and libraries were prepared using TruSeq Stranded Total RNA
Library Prep Kit (Illumina). RNA-seq libraries were then sequenced 100 bp single
end with HiSeq 2500 System. 100 bp short reads were trimmed and quality clipped
with Flexbar64. All remaining reads (418 bp in length) were mapped against the
human 45S rRNA precursor sequence (NR_046235) to remove rRNA contaminant
reads. We used the human genome sequence and annotation (EnsEMBL 79)
together with the splice-aware STAR read aligner65 (release 2.5.1b) to map and
assemble our reference transcriptome. Subsequent transcriptome analyses on
differential gene and transcript abundance were carried out with the cufﬂinks
package66. Supplementary Data 4 provides the statistical analysis of the
transcriptome data.
Sample preparation for label-free quantitative proteomics and analysis. Cells
were scratched in urea buffer (containing 8M urea, 50mM ammonium bicarbo-
nate and 1 complete protease inhibitor mix with EDTA (Roche)), homogenized
with a syringe and cleared using centrifugation (16,000g, 20min). Supernatants
were reduced (1mM DTT, 30min), alkylated (5mM IAA, 45min) and digested
with trypsin at a 1:100 w/w ratio after diluting urea concentration to 2M. The day
after, samples were cleared (16,000g, 20min) and supernatant was acidiﬁed.
Peptides were cleaned up using stage tip extraction67. In short, peptides were eluted
from C18 tips with 30ml of 0.1% formic acid in 80% acetonitrile, concentrated in a
speed vac to complete dryness and resuspended in 10 ml buffer A (0.1% formic
acid). The liquid chromatography tandem mass spectrometry (LC-MS/MS)
equipment consisted out of an EASY nLC 1000 coupled to the quadrupole based
QExactive instrument (Thermo Scientiﬁc) via a nano-spray electroionization
source. Peptides were separated on an in-house packed 50 cm column (1.9 mm C18
beads, Dr Maisch) using a binary buffer system: A) 0.1% formic acid and B) 0.1%
formic acid in acetonitrile. The content of buffer B was raised from 7 to 23% within
120min and followed by an increase to 45% within 10min. Then, within 5min
buffer B fraction was raised to 80% and held for further 5min after which it was
decreased to 5% within 2min and held there for further 3min before the next
sample was loaded on the column. Eluting peptides were ionized by an applied
voltage of 2.2 kV. The capillary temperature was 275 C and the S-lens RF level was
set to 60. MS1 spectra were acquired using a resolution of 70,000 (at 200m/z), an
Automatic Gain Control target of 3e6 and a maximum injection time of 20ms in a
scan range of 300–1,750 Th. In a data dependent mode, the 10 most intense peaks
were selected for isolation and fragmentation in the higher-energy collisional
dissociation (HCD) cell using a normalized collision energy of 25 at an isolation
window of 2.1 Th. Dynamic exclusion was enabled and set to 20 s. The MS/MS
scan properties were: 17,500 resolution at 200m/z, an Automatic Gain Control
target of 5e5 and a maximum injection time of 60ms. All proteomics data sets (at
least 5 biological replicates per condition) were analysed with the MaxQuant
software68 (release 1.5.3.30). Spectra were searched against the ‘all peptides’
database from EnsEMBL release 79 (Homo_sapiens.GRCh38.pep.all.fasta). We
employed the label-free quantitation mode69 and used MaxQuant default settings
for protein identiﬁcation and LFQ quantiﬁcation. All downstream analyses were
carried out on LFQ values, which have been subjected to the variance stabilization
transformation method (limma)70. We identiﬁed differentially abundant protein
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groups by linear modelling including cell type and experimental batch as variable
using limma’s moderated t-statistics framework. We retain all protein groups with an
adjusted P value (q-value) of o0.05. For the characterization of protein level
differences in the chaperome network, we extracted the annotated human chaperome
from Brehme et al.11 and intersected this dataset with our computed protein
abundance fold changes and test for differential abundance. All tables and ﬁgures
were generated with custom R scripts71. Supplementary Data 5 provides the statistical
analysis of the quantitative proteomics data comparing neurons versus hESCs and
NPCs versus hESCs.
C. elegans. strains and generation of transgenic lines. Wild-type (N2), CF512
(fer-15(b26)II;fem-1(hc17)IV), CB4037 (glp-1(e2141)III), DA1116 (eat-2(ad1116)II)
C. elegans strains were obtained from the Caenorhabditis Genetic Center, which is
funded by NIH Ofﬁce of Research Infrastructure Programs (P40OD010440).
CF1041 (daf-2(e1370)III) was a gift from C. Kenyon. C. elegans were handled using
standard methods72.
For the generation of worm strains DVG48–DVG49 (N2, ocbEx48[psur5::cct-8,
pmyo3::GFP] and N2, ocbEx49[psur5::cct-8, pmyo3::GFP]), a DNA plasmid mixture
containing 70 ng ml 1 of the plasmid psur5::cct-8 and 20 ng ml 1 pPD93_97
(pmyo3::GFP) was injected into the gonads of adult N2 hermaphrodite animals,
using standard methods73. GFP-positive F1 progeny were selected. Individual F2
worms were isolated to establish independent lines. Following this method we
generated the worm strains DVG47 (N2, ocbEx47[psur5::cct-2, pmyo3::GFP]),
DVG50 (N2, ocbEx50[psur5::cct-2, pmyo3::GFP]), DVG41 (N2, ocbEx41[psur5::cct-
5, pmyo3::GFP]), DVG58 (N2, ocbEx55[psur5::cct-5, pmyo3::GFP]) and
DVG44 (N2, ocbEx44[psur5::cct-7, pmyo3::GFP]). Control worms DVG9
(N2, ocbEx9[myo3p::GFP]) were generated by microinjecting N2 worms with
20 ng ml 1 pPD93_97.
AM716 (rmIs284[pF25B3.3::Q67::YFP]) was a gift from R. I. Morimoto.
For the generation of worm strains DVG59 ([rmIs284[pF25B3.3::Q67::YFP;ocbEx9
[myo3p::GFP]), DVG55 ([rmIs284[pF25B3.3::Q67::YFP;ocbEx49[psur5::cct-8,
pmyo3::GFP]) and DVG57 ([rmIs284[pF25B3.3::Q67::YFP;ocbEx50[psur5::cct-2,
pmyo3::GFP]), AM716 was crossed to DVG9, DVG49 and DVG50, respectively.
Lifespan studies. Synchronized animals were raised and fed OP50 E. coli at 20 C
until day 1 of adulthood. Then, worms were transferred onto plates with RNAi
clones. 96 animals were used per condition and scored every day or every other day74.
From the initial worm population, the worms that are lost or burrow into the
medium as well as those that exhibit ‘protruding vulva’ or undergo bagging were
censored. n¼ total number of uncensored animals/total number (uncensoredþ
censored) of animals observed in each experiment. Lifespans were conducted at either
20 C or 25 C as stated in the ﬁgure legends. For non-integrated lines DVG9,
DVG41, DVG44, DVG47-50 and DVG58, GFP-positive worms were selected for
lifespan studies. PRISM 6 software was used for statistical analysis to determine
median and percentiles. In all cases, P values were calculated using the log-rank
(Mantel–Cox) method. The P values refer to experimental and control animals in a
single experiment. In the main text, each graph shows a representative experiment.
See Supplementary Data 3 for statistical analysis and replicate data.
Construction of cct C. elegans expression plasmids. To construct the cct
C. elegans expression plasmids, pPD95.77 from the Fire Lab kit was digested with
SphI and XmaI to insert 3.6KB of the sur5 promoter. The resultant vector was then
digested with KpnI and EcoRI to excise GFP and insert a multi-cloning site
containing KpnI, NheI, NotI, XbaI and EcoRI. T21B10.7.1 (cct-2), C07G2.3a.1
(cct-5), F01F1.8a.1 (cct-6) and T10B5.5a (cct-7) were PCR ampliﬁed from cDNA to
include 50 NheI and 30 NotI restriction sites then cloned into the aforementioned
vector. Y55F3AR.3a (cct-8) was ampliﬁed with 50 NheI and 30 EcoRI. All constructs
were sequence veriﬁed.
Construction of cct-8 expression construct. To construct pDV077, pPD95.77
from the Fire Lab kit was digested with XbaI and XmaI. The promoter region and
part of the ﬁrst intron of Y55F3AR.3a (cct-8) was PCR ampliﬁed from N2 gDNA to
include  600 to 100 and then cloned into the aforementioned vector using the
same enzymes.
RNAi constructs. RNAi-treated strains were fed E. coli (HT115) containing an
empty control vector (L4440) or expressing double-stranded RNAi. cct-2, cct-6,
cct-7 and cct-8 RNAi constructs were obtained from the Vidal RNAi library. cct-5
and hsf-1 RNAi constructs were obtained from the Ahringer RNAi library.
All constructs were sequence veriﬁed.
C. elegans germline and gut immunostaining. N2 and CB4037 strains were
grown at 25 C from hatching on OP50. Worms were dissected in dissection buffer
(0.2% Tween 20, 1 Egg buffer, 20mM Sodium Azide) on a coverslip. Fixation
was performed by adding formaldehyde buffer (1 Egg buffer, 0.2% Tween 20 and
3.7% formaldehyde) and animals were frozen on dry ice between the coverslip and
a poly-lysine coated slide (Thermo Scientiﬁc). The coverslips were removed and the
slides were placed for 1min at  20oC in methanol, then washed twice with PBS
0.1% Tween 20. After blocking for 30min in PBST 10% donkey serum, anti-TCP1
alpha (Abcam, ab90357) antibody was added (1:1,000) followed by overnight
incubation in a humid chamber. Anti Rat secondary antibody (Alexa Fluor 546)
was added (1:400) for 2 h at room temperature. Finally, slides were mounted with
Precision coverslip (Roth) using DAPI Fluoromount-G (Southern Biotech).
Anti-TCP1 alpha is proﬁled for use in C. elegans by Abcam. We validated by
western blot analysis that anti-TCP1 alpha recognizes this subunit in worms at the
correct molecular weight. Native gel experiments conﬁrmed that anti-TCP1 alpha
recognizes CCT1 in its monomeric form as well as part of the TRiC/CCT complex.
Nuclear staining in RNAi-treated C. elegans. N2 wild-type worms were grown
on E. coli (HT115) containing an empty control vector (L4440) from hatching until
adulthood. The animals were then either kept on empty vector bacteria or fed with
RNAi bacteria to cct-2 or cct-8 until day 4 of adulthood. Animals were then
harvested and washed three times in M9 buffer. After 1 h incubation in methanol,
worms were washed again three times with M9 buffer and mounted on a slide
using DAPI Fluoromount-G (Southern Biotech).
Heat stress assays. For day 1 adulthood heat-shock assays, eggs were transferred
to plates seeded with E. coli (OP50) bacteria and grown to day 1 of adulthood at
20 C. Worms were then transferred to fresh plates with E. coli (HT115) containing
L4440 and heat shocked at 34 C. Worms were checked every hour for viability. For
day 5 adulthood heat-shock assays, adult worms were transferred to fresh plates
with E. coli (HT115) containing L4440 every day and then heat shocked at 34 C at
day 5. PRISM 6 software was used for statistical analysis and P values were
calculated using the log-rank (Mantel–Cox) method.
Motility assay. Thrashing rates were determined as described in ref. 39. Animals
were grown at 20 C until L4 stage and then grown at 20 C or 25 C for the rest of
the experiment. Worms were fed with E. coli (OP50) bacteria. Worms were
transferred at day 3 of adulthood to a drop of M9 buffer and after 30 s of
adaptation the number of body bends was counted for 30 s. A body bend was
deﬁned as change in direction of the bend at the midbody.
Western blot. Cells were collected from tissue culture plates by cell scraping and
lysed in protein cell lysis buffer (10mM Tris-HCl, pH 7.4, 10mM EDTA, 50mM
NaCl, 50mM NaF, 1% Triton X-100, 0.1% SDS supplemented with 2mM sodium
orthovanadate, 1mM phenylmethylsulphonyl ﬂuoride and complete mini protease)
for 1 h at 1,000 r.p.m. and 4 C in a Thermomixer. Samples were centrifuged at
10,000g for 15min at 4 C and the supernatant was collected. Protein concentra-
tions were determined with a standard BCA protein assay (Thermo Scientiﬁc).
Approximately 20–30 mg of total protein was separated by SDS–polyacrylamide gel
electrophoresis (SDS–PAGE), transferred to nitrocellulose membranes (Whatman)
and subjected to immunoblotting. Western blot analysis was performed with anti-
TCP1 alpha (Abcam, ab90357, 1:1,000), anti-CCT2 (Abcam, ab92746, 1:10,000),
anti-CCT6A (Abcam, ab140142, 1:1,000), anti-CCT7 (Abcam, ab170861, 1:10,000),
anti-CCT8 (Proteintech, 12263-1-AP, 1:1,000), anti-OCT4 (Stem Cell Technolo-
gies, #60093, 1:5,000), anti-HTT (Cell Signaling, ab#5656, 1:1,000), anti-polyQ-
expansion diseases marker antibody (Millipore, MAB1574, 1:1,000), anti-GFP
(ImmunoKontact, 210-PS-1GFP, 1:5,000), anti-a-tubulin (Sigma, T6199, 1:5,000),
anti-GAPDH (Abcam, ab9484, 1:5,000) and anti--actin (Abcam, ab8226, 1:5,000).
In C. elegans, we tested all the CCT subunit antibodies indicated above but only
anti-TCP1 alpha (Abcam, ab90357) was positive (as already proﬁled for use in this
organism by Abcam). Uncropped versions of all important western blots are
presented in Supplementary Fig. 19.
RNA isolation and quantitative RT–PCR. For human cell samples, total RNA was
extracted using RNAbee (Tel-Test Inc.). cDNA was generated using qScript Flex
cDNA synthesis kit (Quantabio). SybrGreen real-time qPCR experiments were
performed with a 1:20 dilution of cDNA using a CFC384 Real-Time System
(Bio-Rad) following the manufacturer’s instructions. Data were analysed with the
comparative 2DDCt method using the geometric mean of ACTB and GAPDH as
housekeeping genes. For C. elegans samples, total RNA was isolated from syn-
chronized populations ofB2,000 adults using QIAzol lysis reagent (Qiagen). Data
were analysed with the comparative 2DDCt method using the geometric mean of
cdc-42 and pmp-3 as endogenous control75. See Supplementary Tables 4 and 5 for
details about the primers used for this assay.
Filter trap. Worms were grown at 20 C until L4 stage and then grown at 25 C for
the rest of the experiment. Day 3 adult worms were collected with M9 buffer and
worm pellets were frozen with liquid N2. Frozen worm pellets were thawed on ice
and worm extracts were generated by glass bead disruption on ice in non-dena-
turing lysis buffer (50mM Hepes pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton
X-100) supplemented with EDTA-free protease inhibitor cocktail (Roche). Worm
and cellular debris was removed with 8,000g spin for 5min. Approximately 100 mg
of protein extract was supplemented with SDS at a ﬁnal concentration of 0.5%
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and loaded onto a cellulose acetate membrane assembled in a slot blot apparatus
(Bio-Rad). The membrane was washed with 0.1% SDS and retained Q67-GFP was
assessed by immunoblotting for GFP (ImmunoKontakt, 210-PS-1GFP, 1:5,000).
Extracts were also analysed by SDS–PAGE to determine protein expression levels.
iPSCs were collected in non-denaturing lysis buffer supplemented with EDTA-
free protease inhibitor cocktail and lysed by passing 10 times through a 27 gauge
needle attached to a 1ml syringe. Then, we followed the ﬁlter trap protocol
described above. The membrane was washed with 0.1% SDS and retained polyQ
proteins were assessed by immunoblotting for anti-polyQ-expansion diseases
marker antibody (Millipore, MAB1574, 1:5,000). This antibody recognizes polyQ-
containing proteins like HTT and detects remarkably better polyQ-expanded HTT
than wild-type HTT (refs 20,21). Extracts were also analysed by SDS–PAGE to
determine HTT protein expression levels.
Blue native gel immunoblotting of TRiC/CCT complex. For experiments with
hESCs (H9 and H1) and their NPC counterparts, cells were collected in lysis buffer
(50mM Tris-HCl (pH 7.5), 1mM dithiothreitol and 10% glycerol supplemented
with protease inhibitor cocktail (Roche)) and lysed by passing 10 times through a
27 gauge needle attached to a 1ml syringe. Lysate was centrifuged at 16,000g for
10min at 4 C. 50mg of total protein was run on a 3–13% gel in deep blue cathode
buffer (50mM Tricine, 7.5mM Imidazole and 0.02% Coomassie G250) at 4 C for
3 h at 100V and then exchange deep blue cathode buffer to slightly blue cathode
buffer (50mM Tricine, 7.5mM Imidazole, and 0.002% Coomassie G250) and run
at 100V overnight. Proteins were then transferred to a polyvinylidene diﬂuoride
membrane at 400mV for 3 h by semi-dry blotting. Western blot analysis was
performed with anti-TCP1 alpha (Abcam, ab90357, 1:1,000), anti-CCT2 (Abcam,
ab92746, 1:10,000) and anti-CCT8 (Proteintech, 12263-1-AP, 1:1,000). Extracts
were also analysed by SDS–PAGE to determine CCT subunit expression levels and
loading control. Uncropped versions of all important native and SDS–PAGE gels
are presented in Supplementary Fig. 19.
Data availability. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository under
accession code PXD005123. Transcriptome data have been deposited in the
Sequence Read Archive (SRA) under the accession code SRP091319. All the other
data are also available from the corresponding author upon request.
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4) DISCUSSION 
 
1)   Analysis of the role of E3 ligases in pluripotency 
 
      Proteostasis is essential for organismal development and cell function (van Oosten-Hawle 
and Morimoto 2014). ESCs have unlimited self-renewal capacity in cell culture and do not 
undergo senescence (Miura, Mattson et al. 2004). This unlimited self-renewal capacity needs a 
specialized high level of quality control mechanisms to maintain the integrity of the genome 
and cell function (Nagaria, Robert et al. 2013). Recent studies have shown that pluripotent stem 
cells have enhanced proteasome activity which is critical to maintain their proteostasis (Vilchez, 
Boyer et al. 2012, Vilchez, Morantte et al. 2012, Noormohammadi, Khodakarami et al. 2016). 
This increased proteasome activity is mediated by PSMD11/RPN6 which is a subunit required 
for the proteasome assembly (Vilchez, Boyer et al. 2012). However, the mechanisms by which 
proteasome activity regulates hESC function remain unknown. Therefore, we proposed that 
elucidating the regulation of the proteostasis network in hESCs may shed light on hESC identity 
and the aging process. In this study, we elucidated the mechanisms by which increased 
proteasome activity regulates hESC identity by focusing on the E3 ubiquitin ligases which 
promote ubiquitin transfer to a specific substrate. For this aim, we analyzed proteomics data in 
which hESCs were compared with their neuronal differential counterparts. We identified 44 E3 
ligases differentially regulated, from which 35 were upregulated in hESC. Three E3 (HUWE1, 
TRIM33 and RNF40) which were upregulated in our proteomics data have been shown to have 
a role in stem cell identity, thus supporting our approach (Zhao, Heng et al. 2008, Dupont, 
Mamidi et al. 2009, Fuchs, Shema et al. 2012). First, we validated our proteomics results 
through Western blot and also analyzed the change of these E3 ligases at the mRNA level. Since 
we did not observe a decrease in their mRNA levels during neuronal differentiation, these E3s 
probably are regulated on the post-transcriptional or post-translational level. To delineate 
whether the downregulation of these E3 ligases also occurred during differentiation into other 
germ layers, we also compared hESC with endoderm precursors. This comparison revealed that 
this downregulation is not specific to neuronal differentiation. Furthermore, to assess the 
possible substrate of these E3 ligases which could participate in stem cell identity, we 
investigated the interactome of these up-regulated E3 ligases. We combined these data with a 
shot label free proteomic experiment in E3 knockdown hESCs as well as proteasome-inhibitor 
experiments. Unexpectedly, we found relatively low numbers of potential targets of the E3 
ligases which is also upregulated when inhibiting the proteasome. Although we only identified 
a low number of potential substrates of the E3 ligases, our data contributes to discover potential 
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proteasomal targets in hESCs. Among the identified possible targets, we validated the 
interaction of HECTD1 with EXOC5 (Exocyst complex component 5) and RNF181 with 
PSMD3 (26S proteasome non-ATPase regulatory subunit 3). It has been previously reported 
that the identification of E3 ligase substrates is difficult due to several technical challenges 
(Iconomou and Saunders 2016). First, ubiquitylation is a dynamic process and it is under control 
of both E3 ligases and DUBs which can remove ubiquitin chains (Komander, Reyes-Turcu et 
al. 2009). Secondly, the weak interaction and the fast dissociation rate between E3 ligases and 
their substrate results in difficulties for the identification using immunoprecipitation techniques 
(Pierce, Kleiger et al. 2009). Furthermore, the low abundancy of substrate also challenges the 
identification of interactors. Finally, some substrates can be ubiquitylated by multiple E3s 
ligases at different sites or a E3 ligases ubiquitylate multiple substrate in response to different 
conditions (Jain and Barton 2009). Therefore, we cannot rule out that the interactor partners of 
the E3 ligase identified could still be targets of the proteasome, their activity/function could be 
modified by ubiquitylation or they could be part of a E3-containing protein complex. In addition 
to the challenge for the identification of the substrates of the E3 ligases, we need to consider 
the effect of inhibiting the proteasome. Proteasome inhibition promotes the accumulation of 
polyubiquitylated proteins and severe shortage of monoubiquitin at the cellular level. This can 
promote the activation of other degradation pathways such as autophagy (Bustamante, 
Gonzalez et al. 2018). Therefore, the exposure time and the amount of inhibitor can alter the 
experimental results and activating other degradative pathways can also impair substrate 
identification. To evaluate whether these E3 ligases have role in hESCs identity, we performed 
loss-of-function experiments and then analyzed the pluripotency level and differentiation 
capacities of the hESCs. However, we did not observe a significant change in stem cell markers 
or their differentiation capacity upon silencing these E3 ligases. Potential functional 
redundancies between E3 ligases could explain these results (Rubenstein and Hochstrasser 
2010).  For instance, the tumor suppressor p53 can be degraded through multiple E3 ligases 
such as E4F1, WWP1 and COP1 (Lee and Gu 2010). Another example is the yeast α cell-
specific transcriptional repressor α2, which can be targeted to the proteasome through 
ubiquitination by the E3 enzymes Doa10 and Slx5/Slx8 (Xie, Rubenstein et al. 2010). These 
redundant mechanisms could be important to ensure tightly regulated, proper degradation of a 
particular substrate when one of the E3s is not functioning or saturated by the number of targets 
for ubiquitination. Besides, some E3s can show subtle differences in terms of ubiquitination of 
the same substrate based on their different subcellular localizations and lead to ubiquitination 
of the same substrate in an intracellular dependent manner. As an example, Doa10 and 
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Slx5/Slx8, which are involved in ubiquitylation of α2, have different subcellular localization 
(Rubenstein and Hochstrasser 2010). Therefore, both the redundant and compensatory 
mechanisms of the E3s could be essential for the maintenance of the proteome of pluripotent 
stem cells and this could hinder the study of the impact of one single E3 ligase. Moreover, to 
compensate the effect of the knockdown of these E3 ligases, E3-depleted hESCs could activate 
other proteostatic pathways such as autophagy (Bustamante, Gonzalez et al. 2018).  
      As mentioned previously, we also inhibited the proteasome using MG132 and performed 
quantitative proteomics. Analyses of quantitative proteomics of MG132- treated hESCs 
revealed that the proteasome is coupled to other important biological processes of hESCs 
identity in addition to its role in proteostasis of hESCs. For example, impairment in proteasome 
activity increases the levels of activators of ribosome biogenesis and translation. This could be 
an adaptation mechanism to compensate the decrease in proteolytic activity. On the other hand, 
it could affect stem cell pluripotency and differentiation capacity due to the need of enhanced 
expression of ribosomal subunits and global translational rates in hESCs (Ingolia, Lareau et al. 
2011, You, Park et al. 2015). Furthermore, we observed a down-regulation of proteins involved 
in mRNA transport such as the nuclear pore complex protein NUP153, which has been shown 
to be important for ESC pluripotency (Jacinto, Benner et al. 2015). Interestingly, proteasome 
dysfunction also caused the down-regulation of proteins involved in telomere maintenance, 
such as NOP10, and which are essential to sustain hESCs function (Zeng, Liu et al. 2014). In 
addition, proteasome dysfunction promoted a decrease in the levels of multiple proteins, which 
are key metabolic regulators. Specifically, hexokinase II (HK2), which sustains high levels of 
glycolysis in hESCs, was downregulated. These alterations in the metabolic enzymes are 
important since hESC have distinct metabolic characteristics that are required for their energetic 
needs (Varum, Rodrigues et al. 2011). 
      In summary, although we did not observe a strong phenotype of our target E3s on 
pluripotency and differentiation in the loss-of-function experiments, our results are important 
for the identification of the potential candidates of these E3 ligases in hESCs. In addition, we 
cannot discard the possibility that these E3 ligases could be involved in stem cell identity under 
different stress conditions and their high levels would be necessary in these situations. Under 
different stress conditions, these E3 ligases could be involved in the rapid modification of the 
cell cycle, removal of damaged protein and regulation of transcription to sustain their stemness. 
Moreover, our proteomics data from the proteasome inhibited experiments indicated that in 
hESCs, the proteasome is involved in other biological processes such as telomere maintenance, 
RNA biogenesis and metabolism as well as sustaining proteostasis. Taken together, this study 
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is important for the characterization of the UPS in hESCs and provide valuable data for a further 
understanding of hESCs. 
2) The investigation of the role of UBR5 in the proteostasis of HTT 
 
      Pluripotent stem cells have enhanced cellular quality control mechanisms to maintain their 
pluripotency and stemness. Several studies suggested that, in addition to a tight regulation of 
gene expression, epigenetic and signaling networks, pluripotent stem cells have enhanced 
proteasome activity to maintain their proteostasis, which is essential for the proper cellular 
function and organismal development (Buckley, Aranda-Orgilles et al. 2012, Vilchez, Boyer et 
al. 2012, Noormohammadi, Khodakarami et al. 2016, Garcia-Prat, Sousa-Victor et al. 2017). 
Impairment in proteostasis results in the accumulation of misfolded, damaged and aggregated 
proteins that might affect the stemness and pluripotency of ESCs. Moreover, defects in 
proteostasis are also associated with the early onset of age-related diseases such as AD, PD and 
HD.  Notably, human pluripotent stem cells, especially iPSC, are an invaluable source to 
investigate the mechanisms and pathologies of neurodegenerative diseases by recapitulating 
diseases and allow to screen drug candidates for potential therapeutic treatments. Therefore, the 
analysis of the mechanisms of enhanced proteostasis capacities in pluripotent stem cells derived 
from patients could provide valuable information to understand the disease pathology and 
regulation. This mechanism, which is required for this super-vigilant proteostasis, could also 
be mimicked in somatic tissues as a therapeutic approach. 
     Remarkably, although HD-iPSCs express mHTT, they do not accumulate polyQ-expanded 
aggregates (Consortium 2012, Jeon, Lee et al. 2012, Noormohammadi, Khodakarami et al. 
2016). Moreover, the length of expansion of polyQ does not influence pluripotency, self-
renewal and survival of HD-iPSCs. However, they show HD- associated phenotypes such as 
increased vulnerability to stress and variations in gene expression when they are differentiated 
into neural progenitor cells and neurons (Park, Arora et al. 2008, Consortium 2012). In this part 
of the study, we investigated the underlying mechanisms to suppress the aggregation of polyQ-
expanded HTT in HD-iPSCs mediated by enhanced proteasome activity by focusing on the E3 
ubiquitin ligase network. First, we analyzed how proteasome dysfunction affected polyQ-
expanded HTT aggregate formation in HD-iPSCs. We observed that enhanced proteasome 
activity in HD-iPSCs regulates the levels of both normal and mutant HTT and ameliorates 
polyQ-expanded HTT aggregation. To study whether the effect of the proteasome on mHTT 
aggregation was associated with a reduction in the cell viability, we also examined how 
proteasome inhibition affected cell viability. We observed the accumulation of polyQ-expanded 
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HTT even with short proteasome inhibition which in turn did not promote any cell death. 
Moreover, higher concentrations of the proteasome inhibitor triggered only a mild increase 
(~8%) in cell death. This data excluded the possibility that the impact of declined proteasome 
activity on polyQ-expanded HTT aggregation was related with a decrease in cell viability. 
Although our data suggest a direct link between proteasome activity and HTT regulation, we 
cannot rule out that proteasome inhibition could trigger global proteostasis collapse. To 
elucidate this, we inhibited the autophagy-lysosome system, which is also involved in 
proteostasis of HTT (Koyuncu, Fatima et al. 2017). Although autophagy impairment triggered 
the formation of aggregates, these aggregates were less compact and the amount of aggregate- 
containing cells was also lower than the ones with proteasome inhibition. Moreover, autophagy 
inhibition caused a decline in the amount of HTT protein. We showed that this decrease in HTT 
protein was not associated with cell viability or induced a compensatory upregulation of the 
proteasome. These results highlighted the direct link between the proteasome activity with HTT 
protein levels and polyQ-expanded HTT aggregation. Remarkably, we found that intrinsic high 
expression of UBR5 E3 ligases was a key component of the UPS to control of HTT level in 
iPSCs. UBR5 is a highly conserved HECT ligase in metazoans and is involved in several 
distinct biological processes such as DNA damage response, development, metabolism and 
transcription (Shearer, Iconomou et al. 2015). We observed that UBR5 interacts with both 
normal and mutant HTT and mediates its proteasomal degradation. The depletion of UBR5 lead 
to dysregulation in HTT levels and the accumulation of polyQ-expanded HTT in HD-iPSCs. 
Therefore, our data showed that UBR5 is a key regulator of HTT and polyQ-expanded HTT 
aggregation in HD-iPSCs. Moreover, we also found that the HECT domain-containing the E3 
ligase activity of UBR5 is needed for the degradation of HTT, revealing a further link between 
enhanced proteasome activity and modulation of mHTT levels. To investigate whether the other 
E3 ligases upregulated in pluripotent stem cells were involved in the regulation of HTT level, 
we downregulated several of them (TRIM71, UBR7, UBE3A, RNF181) and we did not observe 
any direct role in the modulation of HTT levels or accumulation of polyQ-expanded HTT 
aggregation. On the other hand, the study of the impact of the other upregulated E3s could 
provide a further understanding in the regulation of HTT and polyQ-expanded HTT aggregation 
in pluripotent stem cells. Since our findings demonstrated a role of UBR5 in the regulation of 
HTT, we also examined whether this regulation caused an alteration in pluripotency. 
Previously, a study had reported that Ubr5 knockdown lead to significant loss of pluripotency 
markers in murine ESCs whereas another study suggested that Ubr5 RNAi treatment did not 
cause change in stem cell identity (Buckley, Aranda-Orgilles et al. 2012, Kinsella, Dora et al. 
162
2016). In iPSCs, we did not observe any change in pluripotency and germ layer markers upon 
loss of function of UBR5. This suggested that the accumulation of aggregates upon UBR5 
knockdown is not associated with an impairment in the pluripotency markers. In addition, these 
data showed that the formation of aggregates upon UBR5 knockdown did not impaired 
pluripotency markers. Furthermore, we also analyzed whether UBR5 is required for the 
generation of GABAergic medium spiny neurons (MSNs) from iPSCs via a method based on 
the induction of hedgehog signaling. We also did not observe any variation in the differentiation 
efficiency between the control and UBR5 knock down cells. This finding was also surprising 
because knockdown of Ubr5 in murine pluripotent stem cells decreases the induction of Sonic 
hedgehog upon retinoic-acid treatment (Kinsella, Dora et al. 2016). Although the loss of Ubr5 
leaded to on average shorter limbs than control limbs, the effects were not statistically 
significant. Moreover, in these lines, a conditional Ubr5 mutant mouse showed a perturbation 
in hedgehog signaling in the developing limb while the mutants did not have obvious 
morphological defects (Kinsella, Dora et al. 2016). These differences in pluripotency and 
differentiation could be related with genetic differences between mice and humans. Hence, it 
has been reported that human and mouse ESCs differ enormously in the transcriptional 
networks and signaling pathways that regulate pluripotency and lineage development 
(Schnerch, Cerdan et al. 2010). Furthermore, mouse ESCs require leukemia inhibitory factor 
(LIF)/STAT3 for their maintenance in an undifferentiated state and show a naive state that is 
similar to the pluripotent state in the inner cell mass of the pre-implantation embryo. However, 
hESCs and iPSCs do not require LIF signaling and also show a more primed state that is similar 
to post-implantation embryonic configurations (Weinberger, Ayyash et al. 2016). Since HD-
iPSCs did not show any change in stem cell identity and were able to differentiate after 
knocking down UBR5, we speculate that enhanced proteasome activity may be necessary to 
eliminate the generation of precursor cells that accumulate protein aggregates at early 
developmental stages of organism. To support this hypothesis, in vivo experiments might be 
necessary. Interestingly, in contrast to what happens at the iPSCs state, we couldn’t find any 
aggregates in HD-iPSCs differentiated into MSNs upon UBR5 knockdown. There could be 
several reasons for this. Firstly, although the knockdown levels of UBR5 were very strong, it 
could have been lost during differentiation into MSNs. Secondly, during terminal neuronal 
differentiation, additional proteostatic mechanisms could have been activated in order to avoid 
the accumulation of aggregates. Moreover, the differentiation protocol could be also crucial to 
define the role of UBR5 in the regulation of HTT protein and polyQ-expanded HTT aggregation 
in the neuronal level. It is important to note that recent studies have suggested that modeling 
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HD by using neurons differentiated from HD-iPSCs is challenging because neurons 
differentiated from HD-iPSC do not exhibit aggregates or a strong cell death phenotype 
(Consortium 2012, Jeon, Lee et al. 2012, Victor, Richner et al. 2018). Therefore, a different 
neuronal differentiation protocol could be required to study the impact of UBR5 knock down 
in the regulation of polyQ-expanded HTT aggregation in neuronal level. For instance, recent 
studies have shown the direct reprogramming of fibroblast into neural stem cells (Son, Ichida 
et al. 2011, Victor, Richner et al. 2018, Xiao, Liu et al. 2018). It has been revealed that MSNs 
derived from HD patient fibroblasts by using microRNA-based neuronal conversion maintain 
age signatures of original fibroblasts. These MSNs showed polyQ-expanded HTT aggregates 
as well as mitochondrial dysfunction and mHTT-dependent DNA damage during culturing 
(Victor, Richner et al. 2018). This method could be helpful to study of the role of UBR5 in the 
HTT regulation in neurons. Moreover, identifying the mechanisms which are responsible for 
the lack of aggregates in neurons differentiated from HD-iPSCs would be key for their 
implications for organismal aging and development. 
      Remarkably, genome-wide association (GWA) study has shown that genetic variations in a 
region of chromosome 8 - the one which contains UBR5- are associated with the age of 
neurological onset of HD (Genetic Modifiers of Huntington's Disease 2015). Our results 
highlight that impairment in UBR5 function could be one of the regulators in the onset of HD. 
To further investigate the impact of UBR5 in the regulation of aggregates, we analyzed whether 
ectopic expression of UBR5 is sufficient to hasten the accumulation of polyQ-expanded HTT 
aggregation and polyQ-expanded HTT protein levels. We found that ectopic expression of 
UBR5 diminished accumulation of aggregates and increases the degradation of HTT by 
mediating proteasomal degradation. Moreover, the ectopic expression of a catalytic inactive 
UBR5 mutant protein (Gudjonsson, Altmeyer et al. 2012) did not ameliorate the aggregates nor 
polyQ-expanded HTT protein levels. These findings also supported that UBR5 controlled HTT 
levels via proteasome and for this the E3 ligase activity was required. Our immunoprecipitation 
experiment confirmed an interaction between HTT and UBR5. The overexpression of UBR5 
caused an increase in polyubiquitination of mHTT. Since we observed a dramatic increase in 
polyubiquitination of mHTT upon ectopic expression of UBR5, we performed proteomics 
analyses to determine potential lysine sites modified by UBR5. Our findings are supported by 
a recent study that suggested that UBR5 knockdown caused a modification of HTT protein with 
K11/K48 in HeLa cells. They also showed that this modification happened at Lys337 of HTT 
(Yau, Doerner et al. 2017). In our proteomic analyses, we found two other ubiquitinated lysine 
sites: Lys631 and Lys2097. Nevertheless, only levels of Lys2097 showed significant 
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differences between overexpression of wild-type and catalytically dead UBR5. On the other 
hand, it will be fascinating to investigate more putative ubiqitinated lysine sites by applying 
different methods. For instance, ubiquitome proteomic approaches could be applied to 
investigate novel potential ubiquitinated lysine sites. In this method, identification of possible 
ubiquitin sites is based on pull-down of diglycine peptides which result from the cleavage of 
the isopeptide-linked ubiquitin by trypsin (Jadhav and Wooten 2009). Moreover, 
characterization of these ubiquitination sites could be interesting to further understand the 
regulation of HTT protein by UBR5 which in turn could be used as a target for a potential 
therapeutic approach.  
      Due to the challenges, we faced while using MSNs derived from HD- iPSC, we used the C. 
elegans model to further investigate the impact of UBR5 on polyQ-expanded aggregation with 
age. We also observed that UBR5 hastens polyQ- expanded aggregation and ameliorates 
neurotoxicity in a C. elegans model of HD. It is important to remark that in this C. elegans 
model of HD, only the polyQ-expanded peptide and not the whole HTT protein is 
overexpressed. Therefore, our findings do not rule out that UBR5 could also be involved in the 
regulation of other polyQ-expanded aggregates. To examine this hypothesis, we analyzed the 
impact of UBR5 on different polyQ-containing protein such as ATAXIN-3 (ATXN3). An 
abnormal CAG expansion (>52) in ATXN3 causes Machado-Joseph disease (MJD), a 
neurodegenerative disease characterized by progressive cerebellar dysfunction (Kawaguchi, 
Okamoto et al. 1994). We performed UBR5 loss of function experiments in MJD-iPSCs and 
found that UBR5 does not regulate ATXN3 proteostasis. These data revealed that UBR5 does 
not modulate all polyQ-containing proteins, but the effect on HTT would be more specific. In 
addition, to confirm this hypothesis, we also use two other models in which proteins aggregate. 
First, we used iPSCs derived from amyotrophic lateral sclerosis (ALS) patients and which carry 
a diseases-mimicking mutation in the RNA-binding protein FUS (Lenzi, De Santis et al. 2015). 
ALS is a fatal neurodegenerative disorder characterized by loss of motor neurons in the spinal 
cord and brain and progressive decline in muscles. FUS is one of the RNA-binding proteins 
involved in ALS and it is part of stress granules (SG) and control SG assembly (Bentmann, 
Haass et al. 2013). Normally, FUS is mostly localized in the nucleus but it can shuttle between 
the nucleus and cytoplasm. In ALS, the mutations in FUS disrupt the nuclear import of the 
protein, causing aggregation of FUS in the cytoplasm (Lenzi, De Santis et al. 2015). UBR5 
knock down experiments performed in ALS-iPSC revealed that UBR5 does not regulate FUS 
protein or stress granules formation. In addition, we also analyzed the effect of UBR5 on 
solubility of aggregation-prone β-amyloid protein. In several neurodegenerative diseases such 
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as AD and PD, specific proteins have tendency to structural rearrangements leading to 
misfolded proteins. This causes the formation of amyloid-like fibrils with cross-β structure and 
these amyloid-like fibrils formation is responsible for the protetoxicity (Stroo, Koopman et al. 
2017). We found that the overexpression of UBR5 does not decrease the insolubility of 
aggregation-prone β-amyloid protein (Olzscha, Schermann et al. 2011). Taken together, these 
results point to a specific role of UBR5 in HTT regulation. However, we cannot exclude the 
possibility that UBR5 could be involved in the control of other aggregation-prone proteins 
associated with different disease. Finally, we also asked whether UBR5 controlled the global 
proteostasis capacity of human pluripotent stem cells. Notably, we found that depletion of 
UBR5 induced the accumulation of aggresomes in pluripotent stem cells. Overwhelming the 
proteolytic system can lead to the accumulation of misfolded and damaged proteins into 
aggresomes. This remarkable result suggested that UBR5 is also essential for the degradation 
of misfolded proteins ensued from normal metabolism. Further investigations in the role of 
UBR5 in the global capacity of human pluripotent stem cells will offer valuable insights into 
understanding the balance between normal protein homeostasis and an alteration in several 
disease conditions. 
      In summary, our results in pluripotent stem cells uncovered UBR5 as a novel modulator of 
the super-vigilant proteostasis and suggest that UBR5 could be used as a potential therapeutic 
target in HD.  
5) CONCLUSIONS 
 
      Although growing evidence indicates that the UPS regulates stem cell identity, there are 
still numerous questions which remain unanswered regarding the underlying mechanisms. 
Therefore, our studies shed light on the characterization of UPS in hESCs and provide valuable 
implications for understanding how proteostasis regulates stemness and pluripotency. In 
addition, in the second part of our studies, by working with HD-iPSCs, we highlight the role of 
UBR5, a member of the UPS network, as a mediator of HD progression and pathology. Our 
findings provide a better understanding of the role of the proteasome in HD. Furthermore, our 
results evidence the importance of enhanced proteasome activity after reprogramming for 
properly maintaining proteostasis in iPSCs. Taken together, our studies provide a strong link 
between UBR5 and the progression of HD and highlight its role in the modulation of the super-
vigilant proteostasis in pluripotent stem cells, which makes UBR5 a putative candidate for 
therapeutic approach. The characterization and understanding of proteostasis in pluripotent 
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stem cells has also shown to have potential implications for organismal aging and aging-related 
disorders. 
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published in Scientific Reports and Nature Communications, respectively. The first paper is 
“Insights into the ubiquitin- proteasome system of human embryonic stem cells” and the second 
paper is entitled “The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent 
stem cells from Huntington’s disease patients “. In addition to these two projects, I also 
contributed in another publication of our laboratory which appeared in Nature Communications 
in 2016 and has the title “Somatic increase of CCT8 mimics proteostasis of human pluripotent 
stem cells and extends C. elegans lifespan”. I was involved in performing the experiments on 
inducible pluripotent stem cells from Huntington’s Disease and was therefore placed as the 5th 
author of the manuscript. I contributed majorly or equally in the following experiments and 
processes in these studies listed in below: 
•   Study design 
•   Cell culture experiments (maintaining and culturing of iPSCs, hESCs, HEK293, 
differentiated cells such as NPC, transfection and infection of cells, differentiation from 
pluripotent to differentiated counterparts) 
•   Western blots experiment 
•   Immunoprecipitation experiments 
•   Immunocytochemistry experiments 
•   Filter trap assay 
•   Molecular cloning 
•   Quantitative real time polymerase chain reaction(qRT-PCR) 
•   C. elegans experiments (analysis of the aggregates using biochemical as well as imaging 
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•   Flurosence recovery after photobleaching (FRAP) experiments 
•   Proteomics and analysis of data by using computational tools 
•   Data interpretation 
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